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5Foreword
The mobility provided by road transport, particularly the passenger car, allows many
modern Europeans to enjoy a lifestyle characterised by ﬂexibility and independence.
However, if we count up the lives lost and injuries inﬂicted in road trafﬁc accidents, it
is clear that this comes at a price, with the most recent statistics revealing that more
than 40 000 people die on European roads each year, while a further 1.7 million are
injured. No less than a quarter of these deaths, some 10 000 per year, are estimated
to be caused by drink-driving. And although alcohol is by far the most prevalent
and well-documented psychoactive substance affecting drivers, concerns have been
mounting about increasing reports of road deaths linked to illicit or medicinal drugs.
Public awareness of the role of psychoactive substances other than alcohol in road
trafﬁc accidents has increased, due to attention given to this issue by the media, and
policymakers are increasingly called upon to respond to this problem.
In the European road safety programme tabled in 2003, the European Union set
itself the ambitious target of halving the number of road deaths by the end of the
decade, thereby saving up to 20 000 lives in 2010. In recognition of the growing
problem of driving under the inﬂuence of psychoactive substances, including illicit
drugs and medicines, and the urgent need to establish a ﬁrm understanding of this
issue, the programme proposed a range of measures designed to improve and share
information on driving under the inﬂuence of drugs as a cause of road accidents.
Also in 2003, the European Council called on the Commission to ensure that the
current programme on road safety is followed up by a set of actions to combat
the impact of psychoactive substance use on road accidents. An essential step in
this direction is currently being taken under the DRUID project, reporting in 2010,
which aims to ﬁll gaps in the knowledge base, thereby enabling the development of
harmonised, EU-wide regulations for driving under the inﬂuence of alcohol, drugs
and medicine. Driving under the inﬂuence of drink, drugs and medicines is also
targeted in the EU drugs strategy 2005–12 and the EU drugs action plan 2005–08.
As part of its aim to provide factual, objective, reliable and comparable information on
the drug situation and responses to drug use in Europe, the EMCDDA has undertaken
to update its 1999 literature review on drugs and driving. This edition of the Insights
series is the result of that update. Together with the EMCDDA’s 2007 Selected issue
on the use of cannabis and benzodiazepines by drivers, the present report provides
a comprehensive picture of the European situation on illicit drugs and medicines
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6
in connection with driving. Both the policymaker and the general reader will ﬁnd
summarised here the large number of studies that have been published on the topic
since 1999, allowing an objective appraisal of the known effects of psychoactive
substances on the ability to drive, and an assessment of the extent to which drivers
impaired by such drugs are present on the roads.
Though this edition of the EMCDDA Insights series does not intend to be deﬁnitive,
I am pleased to present what I hope will be seen as an important signpost towards
more effective solutions to the problem of driving under the inﬂuence of drugs.
I wish to thank the following people: Elke Raes, T. Van den Neste and A.G. Verstraete,
who conducted the literature survey and prepared the text; Dominique Lopez and
Brendan Hughes, who managed the project under the direction of Paul Grifﬁths;
Shazia Qureshi for editing the text; and Fiona Brown and Peter Fay, who coordinated
its publication.
Wolfgang Götz
Director of the EMCDDA
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7Introduction
In the EU Member States, concern about the role of drugs in driver impairment
and trafﬁc accidents has continuously increased. In 1999, a study of drug use
among drivers in different European countries concluded that, in the general driver
population, the prevalence of illicit drug use was probably in the range 1–5%,
whereas licit drug use was in the range 5–15% (Verstraete, 2003).
The ﬁrst report by the EMCDDA (1999) on drugs and driving reviewed the available
studies evaluating the relationship between drug use, impaired driving and trafﬁc
accidents for a large range of psychoactive substances. It also reviewed Member
States’ drug testing procedures and associated legislation on drug-impaired driving,
as well as the issues raised by such testing. Among the report’s conclusions was
that more research — both experimental and epidemiological — was needed for
a better understanding of the effects of drugs on the ability to drive. It was also
suggested that psychomotor tests and roadside screening devices needed to be
further developed in order to improve procedures for detecting impaired drivers.
The European action plan on drugs 2000–04 reﬂected this need, calling for
research into the effects of driving under the inﬂuence of illicit drugs and certain
psychoactive medicines (1). Meanwhile, countries have tightened laws, increased
penalties or altered national road safety or drug strategies to address the problem
(EMCDDA, 2007). However, individual countries’ legal responses to drug-impaired
driving vary greatly, from zero-tolerance laws (sanctioning detection of the
substance per se) to impairment laws (sanctioning if the person is deemed unﬁt to
drive). Possible penalties are also markedly different between countries (2).
By 2007, a wealth of European and world research had addressed the issue and
an update of the EMCDDA (1999) report was justiﬁed. The main objectives of the
present report are to review the current knowledge on driver impairment due to
drug use from experimental and epidemiological studies published since 1999, to
underline the strengths and limitations of the different types of studies and to report
on current levels of prevalence found in various subsets of drivers on EU roads.
(1) Action 3.1.2.5.
(2) See ELDD Topic overviews (http://emcdda.europa.eu/publications/legal-reports).
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The coverage of the initial European literature review has been widened to include
studies from Australia, Canada and the United States. The scope of substances
discussed has also been widened because of concern about the increasing use
of stimulants in Europe, as well as the problem use of benzodiazepines. Cocaine,
opiates and substances used in substitution treatment (methadone, buprenorphine)
have been added, and the distinction between long-, medium- and short-acting
benzodiazepines is now acknowledged. Thus, this report encompasses the main
psychoactive substances found in Europe.
Chapter 1 addresses methodological issues pertaining to experimental and
epidemiological studies on drugs and driving. Chapter 2 reviews surveys carried
out in different parts of the world (since 1999) according to the type of drivers
surveyed and provides an overview of the differences found depending on the
sample, screening, design of the study, etc. Finally, Chapter 3 discusses the effects
and risks in terms of driving for each substance considered. When available, results
on polydrug use and association with alcohol are reported. The report concludes by
outlining the various responses available to national authorities.
Despite the current focus in EU Member States and by researchers on rapid roadside
testing devices, their efﬁcacy and effectiveness are not addressed here. Several
countries have passed laws to allow such drug testing; however, the EU’s roadside
testing assessment projects considered no device reliable enough for roadside
screening. For an overview of the different issues at stake, the reader can refer to
the Rosita project (3). For the legal aspects, which are also not addressed in this
publication, the ELDD provides a comprehensive overview of the wide variety of
legal mechanisms used to sanction drugs and driving in the EU and Norway.
Although the focus of the present report is drugs and driving, it should be kept
in mind that the data from European studies clearly demonstrate that the main
psychoactive substance endangering lives on the roads today is alcohol
(EMCDDA, 2007).
(3) http://www.rosita.org/
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How studies were selected for this report
This report is the result of an inventory of the existing literature published in Europe,
the United States, Canada and Australia, mainly in the English language.
A database was created consisting of relevant articles from ISI Web of Science,
PubMed (Medline), Psychinfo and Transport, relevant reports, relevant conference
proceedings of ICADTS, TIAFT etc., relevant books, reference lists of relevant reviews
and other sources of information. The following terms or combinations of these terms
were used in the search strategy: ‘drug*’, ‘narcotic*’, ‘medicin*’, ‘alcohol’, ‘marihuana’,
‘marijuana’, ‘cannabis’, ‘cannabinoids’, ‘THC’, ‘opiates’, ‘morphine’, ‘methadone’,
‘heroin’, ‘benzo*’, ‘amphetamine*’, ‘MDMA’, ‘MDA’, MDEA’, ‘MBDB’, ‘cocaine’,
‘benzoylecgonine’, ‘antidepressants’, ‘antihistamines’, ‘GHB’, ‘ketamine’, ‘fentanyl’,
‘ephedrine’, ‘phentermine’, ‘epidemiological’, ‘experimental’, ‘driving*’, ‘driver*’,
‘accident’, ‘psychomotor*’, ‘cognitive’, ‘impairment’, ‘test battery’, ‘roadside’, ‘inﬂuence’,
‘alcolock’, ‘alcohol ignition interlock’, ‘BAC’.
Only the references published since the writing of Literature review on the relation
between drug use, impaired driving and trafﬁc accidents (EMCDDA, 1999) and those
relevant for the update of the report, were taken into consideration.
For meta-analyses, odds ratios and relative risks were calculated using the statistical
programme MedCalc.
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Executive summary
This literature review provides a comprehensive report on the relationship between
drug use, impaired driving and trafﬁc accidents. It covers methodological issues
(Chapter 1), presents results of prevalence surveys among drivers and provides an
overview of ﬁndings from major international epidemiological surveys published
since 1999 (Chapter 2), and also gathers evidence from experimental and ﬁeld
studies of the relationship between drug use, driving impairment and trafﬁc
accidents (Chapter 3).
The research here can be broadly separated into experimental and epidemiological
studies. Every approach has its inherent advantages and disadvantages. Experimental
studies may be set in a laboratory, in a driving simulator, or on the public road,
and the drug is administered in measured doses to volunteers. They can result in an
interpretation by single cause, but can only identify potential risks, and the results can
in some cases be of limited value because of the use of non-realistic doses, or because
of the drug use history or inter-individual differences of the volunteers. Epidemiological
studies examine the prevalence of drugs in various populations. They include roadside
surveys, studies assessing the prevalence of drugs in a subset of drivers, accident
risk studies, responsibility analyses, surveys among the general population and
pharmacoepidemiological studies. However, they may contain risk factors that cannot
be eliminated by study design, and that may be indistinguishable from factors that are
highly correlated with the risk factor. Between studies, results may be incomparable
due to testing different populations, different kinds of samples, etc.
The results of experimental studies indicated that several illicit drugs can have
an inﬂuence on driving performance; some drugs, but not all, show effects that
are dose-dependent. Cannabis can impair some cognitive and psychomotor skills
that are necessary to drive. MDMA exhibits both negative and positive effects on
performance, while studies investigating the effects of a combination of alcohol and
illicit drugs found that, in such cases, some illicit drugs (for example, cannabis) can
cause additional, synergistic impairment, while others (for example, cocaine) can
partially reverse the impairment. MDMA can diminish some, but not all, deleterious
effects of alcohol, while other negative effects of alcohol can be reinforced. The
chronic use of all illicit drugs is associated with some cognitive and/or psychomotor
impairment, and can lead to a decrease in driving performance even when the
subject is no longer intoxicated.
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The results of experimental studies also show obvious impairment for some
therapeutic drugs. Benzodiazepines generally have impairing effects, but some types
(whether long-, medium- or short-acting) cause severe impairment while others are
unlikely to have residual effects in the morning. First-generation antihistamines are
generally more sedating than second-generation ones, though there are exceptions
in both groups. Tricyclic antidepressants show more impairment than the more recent
types, though the results of experimental tests after consuming SSRIs are not always
consistent. In every therapeutic class, however, some substances are associated with
little or no impairment. These therapeutic drugs should preferably be prescribed to
those wishing to drive.
Epidemiological studies have conﬁrmed many of the ﬁndings from experimental
studies. About 1% to 2% of drivers stopped during roadside surveys test positive
for drugs in saliva, though one outlier returned a ﬁgure of 11%. Driving under the
inﬂuence of a combination of alcohol and drugs is not uncommon. Studies assessing
the prevalence of drugs, medicines and/or alcohol in drivers who were involved in
a trafﬁc accident (fatal or otherwise) found that alcohol is more prevalent than any
other psychoactive substance, but drugs are also frequently found, and in a higher
number of samples than in the general driving population. Of the drugs analysed,
cannabis is the most prevalent after alcohol, though when samples were analysed
for the presence of benzodiazepines, they were sometimes even more prevalent than
cannabis. Statistically, increased accident risks and/or risks of being responsible for
an accident were found for cannabis, benzodiazepines, amphetamines, heroin and
cocaine, and many of these risks increase when the drug is combined with another
psychoactive substance, such as alcohol.
The results of both epidemiological and experimental studies should be combined to
obtain a good estimate of the impact of certain drugs on driving performance and
accident risk. To obtain more compatible methodologies, in 2006–07 a committee
of international experts, including representatives from the EMCDDA and NIDA,
drafted guidelines for future research into drugs and driving. These have been
taken on board by the DRUID project, a large-scale EU funded project that will
conduct reference studies of the impact on ﬁtness to drive for alcohol, illicit drugs
and medicines, but also analyse the prevalence of alcohol and other psychoactive
substances in drivers involved in accidents and in the general driving population,
and calculate analytical and risk thresholds for several illicit drugs and medicines in
several European countries. DRUID will be completed in 2010.
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Chapter 1: Methodological issues
in determining the relationship between
drug consumption, impaired driving
and traffic accidents
In order to study driving under the inﬂuence of drugs (DUID), several methods are
used. These can largely be divided into two groups, namely experimental and
epidemiological studies. The methodology used in the various types of experimental
and epidemiological studies, possible problems associated with these different
methodologies and recent proposals will be described in this chapter.
Experimental studies
In experimental studies, the drug is administered in different doses to volunteers and
the effects on performance are measured and compared to placebo or a positive
control (for example, alcohol). The performance of the volunteers can be evaluated
using tests that assess various psychomotor and cognitive functions, tests in a driving
simulator, or ‘real’ driving tests.
While experimental studies can provide invaluable information, the reader should be
aware of their limitations:
Often the drug doses administered have a lower potency than those used in•
the street. For example, performance studies for cannabis traditionally used
low-potency cannabis with a maximum 4% Δ9-tetrahydrocannabinol (THC).
Ramaekers et al. (2006a) showed that high-potency cannabis (13% THC)
diminishes additional cognitive functions and has a more pronounced effect on
performance, compared to results from previous studies that used low-potency
cannabis. The concentration of THC in cannabis can be higher than 20 or
30 years ago because of new cultivation techniques (EMCDDA, 2004). This
underlines the importance of using realistic doses to estimate the effects of drugs
in real life.
The route of administration can inﬂuence the results. For example, Higgins et al.•
(1990) found that intranasally administered cocaine improved performance on
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(4) Dextroamphetamine is the d form of amphetamine (the new terminology refers
to the S form). http://www.emcdda.europa.eu/publications/drug-proﬁles/heroin
the digit symbol substitution test (DSST), while Rush et al. (1999) found no such
effects with orally administered cocaine.
Results are dependent on the delay between drug consumption and performance•
of the task. Dextroamphetamine (4) administered 3–4 hours before a movement
estimation task has no effect on performance of the task (Silber et al., 2006), while
MDMA administered 4–5 hours before the task impairs this function (Lamers et
al., 2003). Other possible causes of discrepancies in results in these studies could
include differences in drug type, dose and task.
Results of experimental studies assessing acute effects of drugs in recreational•
drug users may be inﬂuenced by the subjects’ drug use history. For example,
Rush et al. (1999) found no effect of oral cocaine on performance on the DSST,
while two previous studies found an improvement. The subjects in both previous
studies reported substantially less cocaine use than the subjects used by Rush et
al. (1999), and the authors suggested that perhaps their subjects were tolerant to
the performance-improving effects of cocaine.
The sensitivity of experimental studies to detect drug effects on performance may•
be reduced by inter-individual differences in a between-subject paradigm. This
can be countered by using a within-subject design, comparing each subject’s
postdrug performance to their pretest baseline performance (Swerdlow et al.,
2003). Mattay et al. (2000) showed that in normal subjects, the behavioural and
neurophysiological effects of dextroamphetamine are not homogeneous because
of genetic variation and differences in baseline cognitive capacity.
Experimental studies can only identify potential risks. The risk demonstrated in•
the experiment may not necessarily occur in real road trafﬁc. The risk seen in a
study might be qualitatively so small that it does not result in a crash, or it might
be so severe that the subjects feel so impaired that they do not drive (Berghaus et
al., 2007).
Some limitations are inherent to a speciﬁc type of experimental study:•
performance tests, driving simulator tests and ‘real’ driving tests. These are
described below.
F
o
r
m
a
t
:
(
1
4
8
.
0
0
x
2
1
0
.
0
0
m
m
)
;
D
a
t
e
:
1
2
0
2
,
2
0
0
8
0
7
:
5
3
:
2
9
;
O
u
t
p
u
t
P
r
o
f
i
l
e
:
S
P
O
T
I
S
O
C
o
a
t
e
d
v
2
(
E
C
I
)
;
I
n
k
S
a
v
e
2
8
0
Drug use, impaired driving and trafﬁc accidents
16
The advantage of experimental research is that it offers the chance to work on far
more differentiated questions and less frequently occurring risk factors compared to
epidemiological research. Another advantage is that experiments, with an adequate
design, can result in an interpretation by a single cause, which is not the case for
epidemiological research (Berghaus et al., 2007).
Performance tests
Subjects’ performance may be evaluated with tests performed in a laboratory
setting. These laboratory tests are intended to measure speciﬁc skills and abilities
that are involved in driving. Several publications have reviewed the available tests
(Baselt, 2001; Ferrara et al., 1994; Irving and Jones, 1992). The tests that are most
often used can be divided into ﬁve major groups: cognitive, psychomotor, impulsivity,
physiological and subjective evaluations.
Cognitive tests
Cognition is the conscious process of knowing or being aware of thoughts or
perceptions, including understanding and reasoning. Cognitive tests can assess a
variety of cognitive functions:
Attention: these tests can be subdivided into simple and divided attention•
tasks. In a simple attention task, the subject is asked to monitor one process
and to respond appropriately to speciﬁc stimuli. In a divided attention task, the
subject is asked to monitor two or more simultaneous processes and to respond
appropriately to speciﬁc stimuli.
Auditory, time and visual perception: these tests assess perception ability. An•
example of an auditory test is the auditory discrimination test: a series of pairs of
auditory tones is presented to the subject, who must indicate whether the second
tone is higher or lower than the ﬁrst. Time perception can be estimated by asking
the volunteers to estimate the duration of a certain time interval. An example of
a visual test is the assessment of visual acuity: the subject is shown a series of test
patterns of increasing complexity or decreasing size and is asked to identify or
discriminate between the patterns while distance, lighting conditions or degree of
contrast may be varied.
Information processing: these tests assess the ability of the volunteers to solve•
problems or to make decisions.
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Logical reasoning: a series of simple sentences, such as ‘Birds grow on trees’, is•
presented and the subject must indicate whether each statement is true or false.
Memory: subjects’ memory functioning (long- or short-term), such as delayed•
recall, episodic memory or working memory, is assessed.
Vigilance: this task generally uses an electronic device that presents a visual•
stimulus, moving in a rather monotonous pattern on a screen. The subject must
observe and report deviations in this pattern over a prolonged period of time
without feedback from the apparatus. An auditory pattern of signals may be
used instead of a visual stimulus.
Cognitive tests speciﬁcally used in assessing the effects of a psychoactive substance
on the ability to drive include:
Benton visual retention test (BVRT): this assesses visual perception, visual memory•
and visual constructive abilities.
Critical ﬂicker fusion (CFF): the subject is asked to view one or more lights•
on a computer screen or electronic apparatus and to indicate whether the
light appears to be ﬂickering or is continuous. The rate of ﬂicker is constantly
increased or decreased, and the frequency of the subject’s discriminative
threshold is recorded.
Digit symbol substitution test (DSST): the subject is shown a code sheet containing•
a series of numbers assigned to a series of symbols. Afterwards, the subject is
shown the symbols in random order and is asked to assign the corresponding
number. During repetitions of the task, the pattern of the digit-symbol pairings is
usually scrambled.
Hopkins verbal learning test: the subject repeats as many words as he or she•
can recall from a list of words that was read by the instructor. Afterwards, the
instructor reads another list of words and the subject has to respond with ‘yes’ if
the word was on the ﬁrst list and ‘no’ if it was not.
Learning memory task (LMT): a list of 21 simple, concrete and familiar words•
must be learned in four attempts. The words are presented on a computer screen
in lower-case letters at a rate of one word every 500 milliseconds, without any
gaps between stimuli. The words are presented in a different order at each
attempt. At the end of each presentation, the subject makes an immediate free
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recall. The subject is asked for a delayed free recall of the words for 1.5 minutes,
about 1 hour after learning.
Letter cancellation test: the subject is given a page ﬁlled with random letters•
and is asked to strike through one or more speciﬁc target letters whenever they
appear (Figure 1).
Mini-mental state examination (MMSE): this is a tool for measuring global cognitive•
function. It is an 11-question measure that tests orientation, registration, attention,
calculation, recall and language. The maximum score is 30. A score of 23 or
lower is indicative of cognitive impairment. The MMSE takes only 5–10 minutes to
administer and is therefore practical to use repeatedly and routinely.
Paced auditory serial addition task (PASAT): this measures working memory.•
It requires addition of simple digits presented verbally in a series with a
successively higher pace of presentation. The task reﬂects the capacity for
divided attention, is a measure of information processing speed and appears to
be sensitive to minor attention deﬁcits.
Rapid visual information processing task (RVIPT): this is a test of sustained•
attention, during which single digits are presented in quick succession
Figure 1: Four examples of a letter cancellation task.
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(100 or 200 digits/per minute) on a computer screen, and target sequences of
numbers must be detected with the press of a button.
Repeated acquisition task: the subject is given the opportunity in a series of•
trials to learn the appropriate responses to a collection of images. Folllowing
a speciﬁc interval, the subject is then tested on ability to recall the previously
acquired responses.
Sternberg test: this test explores short-term memory and working memory.•
A series of 2–6 numbers is presented to the subject, followed immediately by a
target number. The subject indicates as rapidly as possible whether the target
number was part of the list to be memorised.
Stroop word/colour test: the subject is asked to depress one of four keys•
labelled with a different colour in response to a stimulus. The stimulus is the
name of one of the four colours or of a non-represented colour or does not
represent a colour at all.
Time wall test: during this test of time estimation, subjects observe a brick•
descending from the top of the computer screen at a constant rate towards a target
at the bottom of the screen. The target disappears behind a brick wall about two-
thirds of the way down the screen. The subject responds by pressing a designated
key at the exact time that he or she estimates the object contacts the target.
Tower of London task: this measures planning function. The subject is asked to•
preplan mentally a sequence of moves to match a start set of discs to a goal, and
then to execute the moves one by one (Figure 2).
Wechsler adult intelligence scale (WAIS): this is a comprehensive test of cognitive•
ability for adults — a general test of intelligence. It is made up of 14 subtests,
comprising verbal (seven subtests: information, comprehension, arithmetic,
similarities, vocabulary, digit span, letter-number senquencing) and performance
scales (seven subtests: picture completion, digit symbol-coding, block design,
matrix reasoning, picture arrangement, symbol search, object assembly).
Wisconsin card sorting test (WCST): this measures abstract conceptual skills,•
cognitive ﬂexibility and ability to test hypotheses, and utilises error feedback. The
subject sorts 128 cards that depict coloured numbered shapes into four categories
using accuracy feedback given after each trial. The criterion for correct
categorisation changes whenever 10 consecutive cards are sorted correctly.
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Psychomotor tests
Psychomotor tests assess movements that are generated by certain stimuli of the brain.
Body sway: measurements of body movement of the subject with or without eyes•
closed are usually taken in both the lateral and sagittal directions over a speciﬁed
period of time using some type of metering device, such as an electronic platform.
Motor coordination: the ﬁnger tapping test (FTT) assesses motor speed and•
motor control. Other tests assess the motor response of volunteers to a certain
visual or auditory stimulus:
The circular lights task (CLT) typically employs an electronic device with◊
a series of 10–20 lights arranged in a circular pattern. As each light is
illuminated in random order, the subject must trigger a switch corresponding
to that light.
The grooved pegboard test is a manual dexterity test consisting of holes with◊
randomly positioned slots. Pegs with a key along one side must be rotated
to match the hole before they can be inserted.
During the trail making test (TMT), the subject is shown a page containing◊
jumbled numbers or numbers and letters, and is asked to connect the
Figure 2: A Tower of London test.
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numbers in numerical sequence or the letters in alphabetical sequence.
Accuracy and time to complete the task are assessed.
During the simplest form of a tracking task, the subject is asked to control◊
the position of a light bar on a screen using a hand-operated device. More
sophisticated versions involve variable speed control of the visual stimulus
and/or a computerised representation of a vehicle moving along a road. For
example, during the critical tracking test (CTT), the subject is asked to control
the position of a light bar on a display screen using a steering wheel or
joystick. The instability of the bar gradually increases until the subject reaches
a threshold of ability to control its position. In the compensatory tracking test,
subjects are also required to track a moving arrow on a visual display unit
screen, but in addition a peripheral awareness task is included in which the
subject responds to a stimulus presented in the periphery of vision
while simultaneously attending to the tracking test.
Reaction time: Several tests exist to measure psychomotor speed:•
The simple reaction time (SRT) is the interval elapsing between the mental◊
receiving of a sensory impression (visual, auditory or somatosensory) and the
execution of a movement in response to that impression.
In a choice reaction time (CRT) task, a series of stimuli, which may be◊
auditory and/or visual, is presented to the subject using an electronic
apparatus or a computer screen. The subject is instructed to respond
appropriately and rapidly through hand or foot movements to pre-selected
signals. The test may include disturbance signals to distract the subject, and it
may involve two or more simultaneous tasks. The subject is graded on speed
and accuracy. Three components of reaction time are measured: the motor
reaction time (MRT) between the start and response buttons, the total reaction
time (TRT) from stimulus onset to completion of response, and the processing
or recognition reaction time (RRT), obtained by subtracting MRT from TRT.
A go/no go task can be used to assess reaction time instead of impulsivity◊
(see below).
The serial reaction time task produces sequence learning through repetition◊
of uncued and unannounced serially ordered stimuli. Learning is assessed
by observing a deterioration in task performance when a random sequence
replaces a regularly repeating sequence.
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Impulsivity tests
Some performance tasks are behavioural measures of impulsivity:
In a go/no go task or a stop signal task, the subject is asked to respond to•
one particular event (e.g. a red colour or a horn sound) but ignore other events
(e.g. a blue colour or a rooster sound).
The Iowa gambling task measures decision-making and risk sensitivity as deﬁned•
by the inability to anticipate and reﬂect on the consequences of decision-making.
The subject sees four decks of cards on a computer screen labelled A, B, C and
D. The gains and losses for each card selection are set so that in each block
of 10 cards from deck A or B over the course of the trials, there is a total gain
of USD 1000, interspersed with unpredictable losses totalling USD 1250. For
decks C and D, the gains and losses for each card selection are set so that in
each block of 10 cards, there is a total gain of USD 500, interrupted by losses
totalling USD 250. Thus decks A and B are ‘disadvantageous’ in the long term
while decks C and D are ‘advantageous’. One dependent measure is collected
from this task: net score (total number of cards picked from C and D minus total
number of cards picked from A and B).
Physiological measurements
The parameters that can be assessed include eye movements, pupillary
response (miosis, mydriasis), pulse, blood pressure and tunnel vision.
Electroencephalography (EEG) can also be used. The Maddox wing device is
sometimes used to measure the balance of the extraocular muscles; it quantiﬁes
exophoria as an indicator of extraocular muscle relaxation and esophoria as an
indicator of extraocular muscle tension.
Subjective evaluations
In some experimental studies the subjects report their own observations on visual
analogue scales. These scales measure a characteristic or attitude that is believed
to range across a continuum of values. Visual analogue scales can be indicative
of both pleasant (e.g. drug liking, increased calmness) and unpleasant (e.g. ‘feel
bad’, ‘nauseous’, sedation, pain) effects of a drug. The line analogue rating scale
(LARS) consists of 10 cm line analogue scales on which the subjects indicate their
present feeling (concerning sedation) relative to a mid-point that represents their
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normal state of mind before treatment was started (Figure 3). Another example is the
Stanford sleepiness scale, a 7-level measurement in which subjects select a speciﬁc
statement best describing their state of sleepiness.
There are limitations inherent to studies that use performance tests. First, these
tests only measure a part of the performance needed to complete a task, and do
not cover driving ability as a whole. Second, the selection of speciﬁc tests can
inﬂuence the results of the study. For example, when the effect of the combination
of cannabis and alcohol is studied, sometimes an additive or even synergistic
effect is found, while other studies ﬁnd the opposite. Liguori et al. (2002) found no
signiﬁcant additive effects of alcohol and cannabis on brake latency. According
to the authors, this might have been because of the use of reaction time as the
key dependent variable, as several other studies found additive or multiplicative
cannabis and alcohol effects on other aspects of performance, such as visual
search and road tracking (Lamers and Ramaekers, 2001; Sexton et al., 2002).
Ramaekers et al. (2006a) found that THC use did not affect performance on the
Iowa gambling task; however, the sensitivity of this task to acute drug effects
may be low as the task was never speciﬁcally designed for this purpose.
Driving simulator and ‘real’ driving tests
Driving performance can be evaluated with tests in a driving simulator or ‘real’ driving
tests. In a driving simulator, subjects perform a computer simulation of a driving task.
Hoffman and Buld (2006) described and evaluated the design of a driving simulator.
The main advantages of driving simulation are that driving tasks can be standardised
and data can be gained safely. However, because a real environment can never be
fully replicated in a simulator, subjects must compensate for the incomplete driving
environment, delays and distortions in the graphics, and for having to act in two
different worlds. Since this often cannot be achieved immediately, subjects need a dry
run to learn how the simulator works. A major problem during dry runs is so-called
Figure 3: A visual analogue scale for the subjective feeling of ‘high’.
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‘simulator sickness’: nausea that can be mild to severe and last a few minutes to
several hours, possibly resulting in inadequate driving behaviour, whether consciously
or not. As a consequence, both the internal and the external validity are limited
and the acceptance of the method itself is likely to decrease. Experience shows that
repeated exposure to the simulator situation usually reduces physical discomfort;
however, empirical studies are very rare. Equally detailed information concerning
dry runs is not consistently given in studies using driving simulation, and if so, the dry
runs may vary in length from ﬁve minutes to several hours. Commonly used guidelines
do not exist. Hoffmann and Buld (2006) assessed the effectiveness of a training
programme, consisting of a familiarisation phase followed by special exercises
(braking, accelerating, steering, driving on a motorway, turning at intersections and
a ﬁnal driving test), in reducing drop-out rate. They found that without the simulator
training programme, the drop-out rate due to nausea was quite high, whereas no
subject who received training dropped out. The authors concluded that extensive
training is necessary to be able to drive satisfactorily in a simulator. Several situations
can be simulated, including (Sexton et al., 2002):
Pulling-out events: these are situations where a car pulls out in front of the•
driver’s car. The driver takes avoiding action that can be detected and a reaction
time is estimated.
Braking events: these events are controlled in a similar way to pulling-out events,•
except that the trigger vehicle brakes at a certain distance from the driver’s car.
The test that best assesses the effects of using a psychoactive substance on driving
performance is a ‘real’ driving test. The test can be performed in the presence or
absence of normal trafﬁc, but one disadvantage is the necessity of taking trafﬁc safety
into consideration. A ‘real’ driving test can be more sensitive than laboratory tests
in assessing impairment of driving ability. For example, Veldhuijzen et al. (2006b)
evaluated the effect of chronic nonmalignant pain on driving performance. An on-the-
road driving test showed signiﬁcant differences in driving performance between drivers
with chronic pain and drivers with no chronic pain, whereas laboratory tests did not.
The outcome measures used to assess performance during a driving simulation
test or a ‘real’ driving test include (de Waard et al., 2000; Ramaekers et al., 2004;
Sexton et al., 2000; Veldhuijzen et al., 2006b):
Standard deviation of the lateral position (SDLP): this parameter measures the•
extent to which the car ‘weaves’ within a trafﬁc lane. It is reasonable to assume
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that SDLP represents overall highway driving ability since it encompasses several
levels of information processing which are combined in an integrated driving
model. For example, basic vehicle control, such as road tracking, is required,
involving automatic or effortless performance. Further, negotiation of common
driving situations, such as curves, intersections and gap acceptance, requires
controlled processing and thus more effort. Also, subjects are required to
determine motivational aspects (i.e., to specify the risk they are willing to take)
and risk evaluation. Since SDLP increments ultimately result in lane crossing into
the adjacent trafﬁc lane, it can be regarded as an index of driving safety. Sexton
et al. (2000) showed that SDLP in the road-tracking test was the most sensitive
measure for revealing THC’s adverse effects on driving ability.
Standard deviation of speed.•
Mean speed.•
Mean lateral position.•
Car following: in a ‘real’ driving test, the subject may be asked to follow a car•
driven by the investigator.
Brake reaction time (BRT).•
Gap acceptance: this parameter measures if judgement is impaired.•
Accident involvement.•
Epidemiological studies
Epidemiological studies on drugs and driving examine the prevalence of drug use in
various driving populations. Some studies investigate the prevalence of drug use in
the general driving population, while others focus on certain subpopulations, such as
persons admitted to a hospital emergency department. By comparing the prevalence of
a certain drug in the general driving population to the prevalence in persons admitted
to an emergency department, an estimation can be made of the risk of being injured
by a trafﬁc accident while under the inﬂuence of a certain drug: these ﬁgures indicate
whether a person under the inﬂuence of the drug has a higher risk than a sober person
of being injured in a trafﬁc accident. Responsibility studies calculate the risk of being
responsible for a trafﬁc accident while driving under the inﬂuence of a drug.
The prevalence of drugs in various populations can be assessed by analysing
biological samples of the involved subjects, or by conducting surveys or
pharmacoepidemiological studies.
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Epidemiological research is, however, limited because there may be risk factors
associated with drug use that do not emerge from the study ﬁndings. This may
be because the appropriate study design (e.g. a long-term study or a multicentre
study) is difﬁcult to put into place from a methodological point of view (because
of a change in screening methods, lack of homogeneity of data, etc.). Another
disadvantage of epidemiological research is that it is not able to distinguish between
a ‘real’ risk factor and other factors that may be highly correlated with the risk
factor (Berghaus et al., 2007).
Epidemiological studies are also difﬁcult to compare with each other because of
several kinds of differences among them, such as the following:
The sample populations are different. They can differ in several•
sociodemographic factors, such as age, gender, etc. One study reporting results
of drivers who were killed in trafﬁc accidents in France only included drivers
under the age of 30 years, and found a much higher proportion of cannabis-
positive samples than other similar studies (Mura et al., 2006).
The time at which the studies are performed can differ. Not only can the year•
differ in which samples are collected, but so can the day of the week. Studies
conducted on weekend nights ﬁnd higher percentages of drug-positive drivers
than studies conducted over the whole week (Mathijssen, 1999).
Biological samples are analysed for different types of psychoactive substances.•
For example, for benzodiazepines, opiates and amphetamines, prevalence results
can depend upon the number and types of substances that are searched for in
the samples. In Norway, a study assessing benzodiazepines in drivers suspected
of DUID reported only the percentage of samples that were positive for diazepam
and ﬂunitrazepam, while in a study in Switzerland, the samples were analysed
for diazepam, desmethyldiazepam, midazolam, oxazepam and lorazepam
(Augsburger et al., 2005; Christophersen, 2000). For cannabis detection, some
studies only test for the presence of THC, while others test for the THC metabolites
THC-COOH (11-nor-Δ9-THC-9-carboxylic acid) or 11-OH-THC (11-hydroxy-Δ9-THC) or
for several metabolites. As the detection time of these metabolites differs, the choice
of the substances tested for can inﬂuence the results of the study (Verstraete, 2004).
Different types of biological samples are used, with varying detection•
times. The use of urine samples can pose some problems. As the metabolites
of cannabis can be detected in urine for a relatively long period following
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consumption, their presence in urine does not necessarily mean that the subject
was under the inﬂuence of the drug at the time of sampling; this can lead to
different results than when blood or saliva are sampled (Verstraete, 2004).
Different analytical techniques are used to analyse the samples, with different•
limits of detection and quantiﬁcation.
Different cut-off levels are used. For alcohol detection, for example, the cut-•
off level used to deﬁne a positive sample can range from 0.1‰ (Logan and
Schwilke, 2004; Logan, 2005; Plaut and Staub, 2000) to 0.8‰ (Assum et al.,
2005; Brault et al., 2004; del Rio et al., 2002; Longo et al., 2000a).
All of these factors can inﬂuence the outcomes of epidemiological studies, making
it nearly impossible to compare results. Thus, there is a need for methodological
guidelines (see section below on recent proposal pertaining to research).
In what follows, the methodology and limitations of the various types of
epidemiological studies are described, as are recent proposals regarding research
and methodological guidelines.
Roadside surveys
Roadside surveys investigate the prevalence of psychoactive substances in the
general driving population. Drivers are randomly stopped and tested for the
presence of alcohol, drugs and/or certain medicines in their body.
The results of these studies become more representative for the general driving
population as the number of included drivers increases. Some studies try to make
the results more representative by weighting them according to trafﬁc ﬂow (Assum et
al., 2005). The study design can greatly inﬂuence the results. In addition, roadside
surveys are expensive to conduct, as a large number of drivers need to be screened.
Moreover, this type of epidemiological study cannot be conducted in every country
as there may be legal obstacles to screening drivers without suspicion. A 2003
study found that random roadside testing was allowed in nine countries in Europe:
Belgium; Denmark; Finland; Germany; Italy; Luxembourg; Norway; Portugal and
Spain. In the Netherlands, roadside surveys may only be used for scientiﬁc research,
and in ﬁve other countries, some suspicion is needed: Ireland; France; Austria;
Sweden and the United Kingdom (EMCDDA, 2003) (5).
(5) http://www.emcdda.europa.eu/publications/topic-overviews/driving
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Subsets of drivers
Epidemiological studies may also look at only a subset of drivers, rather than the
general driving population:
Injured drivers: biological samples are collected from drivers admitted to hospital•
over a given period of time, and analysed in order to assess the involvement
of drugs, medicines and/or alcohol in accidents. These studies should take
into consideration the possibility that certain medications may have been
administered in hospital or at the crash site before the samples were taken.
Drivers killed in accidents: for these epidemiological studies, the involvement of•
drugs, medicines and/or alcohol in fatal accidents is assessed using samples
from drivers who were killed in a trafﬁc accident. Here too, there is a necessity to
distinguish whether positive test results for medicines were because of initial use
by the driver or a result of therapeutic administration during emergency care or
reanimation efforts.
Drivers involved in a trafﬁc accident: samples are collected from all drivers who•
were involved in a trafﬁc accident. In some studies, only fatal accidents
are included.
Drivers suspected of DUID: the methodology of these studies can vary in several•
ways, as the testing procedure varies by country. For example, in some countries
a ﬁeld sobriety test is used, while in others it is not. This ﬁeld sobriety test can
consist of different tests, and various on-site drug screening tests can be used.
Drivers suspected of driving under the inﬂuence of alcohol: in these ‘re-analysis’•
studies, samples that were initially collected for alcohol detection are later tested
for the presence of drugs, medicines and alcohol.
A possible difﬁculty of studies that try to assess the prevalence of psychoactive
substances in drivers who were injured or killed by a trafﬁc accident is the necessity
of distinguishing whether positive test results for medicines were from pre-injury use,
or therapeutically administered after admission.
Surveys
Surveys about driving under the inﬂuence of drugs, medicines and/or alcohol are
conducted over the telephone or in face-to-face interviews. Examples of questions
asked are: ‘Have you ever driven a vehicle under the inﬂuence of alcohol or drugs?’,
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‘Have you ever driven a vehicle shortly after the use of alcohol or drugs?’, ‘Have you
ever been involved in an accident while under the inﬂuence of alcohol or drugs?’,
etc. Some surveys include the general driving population, while others focus on a
subpopulation such as young drivers or drug users. Information gathered in surveys
should, however, be interpreted in light of several limitations. Subjects may, for
example, be unwilling to divulge certain information, misunderstand the questions or
forget events (McGwin et al., 2000).
Accident risk
The accident risk associated with the use of drugs, medicines and/or alcohol can be
assessed by comparing their prevalence in the general driving population (controls)
to the prevalence in drivers who were injured, killed or involved in a trafﬁc
accident (cases).
The accident risk can be expressed in various ways, such as an odds ratio (OR) or
relative risk (RR). OR and RR are calculated as follows, assuming that the data are
available as in Table 1:
Mostly, data for the control group (b+d) are collected using roadside surveys.
Some studies use a different methodology, using, for example, samples from drivers
who were hospitalised for reasons other than a trafﬁc accident as control samples
(Mura et al., 2003). Other studies may use questionnaire survey results rather than
biological sample analysis to calculate accident risks (Asbridge et al., 2005; Blows
et al., 2005; Fergusson and Horwood, 2001; Gerberich et al., 2003; Jones et al.,
2005; Wadsworth et al., 2006).
Table 1: Symbolic presentation of the data used to calculate accident risks
Drugs Accident
Yes No Total
Yes a b a+b
No c d c+d
Total a+c b+d n
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One limitation of using questionnaire data to calculate accident risk is a possible
underestimation of the prevalence, while with biological sample collection, there may
be a high percentage of dropouts. As most of the substances under investigation are
illicit, it is probable that potential controls who are users would be more likely than non-
users to refuse to supply a sample. This would result in bias of the results by showing
a stronger positive association between the drug and crash risk than is really the case.
Since generally, the proportion of non-crash drivers who test positive for drugs is likely
to be small, even a relatively small proportion of potential controls who do not supply a
sample would throw study results into serious doubt (Bates and Blakely, 1999).
Ramaekers (2003b) discusses two possible pitfalls in estimating drug-related crash
risk. First, a case-control analysis does not necessarily take into account the effects
of dose or treatment duration when estimating the crash risk following medicine use.
The possibility therefore exists that the failure to ﬁnd a positive association between,
for example, use of tricyclic antidepressants (TCA) and accidents may merely reﬂect
the occurrence of tolerance in drivers after prolonged treatment, while a positive
association might have been found in drivers who were just starting antidepressant
treatment. Second, the study’s statistical power may be insufﬁcient to detect
signiﬁcant proportional differences, as the prevalence rates of drugs in the samples
under study are mostly low, and sample sizes limited.
Responsibility analysis
Responsibility analyses investigate whether there is an association between driving
under the inﬂuence of drugs, medicines and/or alcohol and responsibility for a
trafﬁc accident. The prevalence of these substances in drivers who were responsible
for a trafﬁc accident (cases) is compared to the prevalence in drivers who were
involved in, but not responsible for a trafﬁc accident (controls).
There are a number of limitations to responsibility analyses:
Some cases can be misjudged on the real responsibility, and this might cause a•
misclassiﬁcation bias, which may lead to an underestimation of the real relative
risk (Dussault et al., 2002).
The control group consists mostly of crash-involved, but ‘not responsible’•
drivers. Some of the drivers that were judged ‘not responsible’ may, in fact,
have borne some responsibility, since they failed to avoid the crash. The
ideal control group would consist of drivers who were not involved in crashes
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but who were on the road under similar circumstances of time and place
(Lowenstein and Koziol-McLain, 2001).
A major limitation when fatally injured drivers are included is the high percentage•
of responsible drivers among the drug-free group. This high baseline ﬁgure means
that it is difﬁcult to ﬁnd statistically signiﬁcant differences between drug-free and
drug-positive drivers with respect to their level of responsibility. One of the beneﬁts
of using non-fatally injured drivers is that the percentage of drug-free drivers
judged responsible for the crash is generally much lower (Longo et al., 2000b).
For example, in two studies of non-fatally injured drivers, the percentage of drug-
free drivers judged responsible for the crash was 53% (Longo et al., 2000b) and
48% (Lowenstein and Koziol-McLain, 2001), while it was 71% in a study of fatally
injured drivers (Drummer et al., 2004).
Pharmacoepidemiological studies
Pharmacoepidemiological studies compare the involvement in trafﬁc accidents of
drivers using a certain medication to that of a control group not using the medication,
in order to assess the driving risks associated with medication use. Most of these
types of studies gather information through databases, such as prescription records,
police reports, health insurance records and databases from hospitals, but some
studies gather information in another way, by interviewing people, for example.
McGwin et al. (2000) used the following methodology to evaluate the association
between elderly drivers’ medication use and their risk of being responsible for an
accident. A total of 901 drivers aged 65 years and older were selected from the
Alabama Department of Public Safety driving records, including 244 at-fault drivers
involved in crashes, 182 not-at-fault drivers involved in crashes and 475 drivers not
involved in crashes. Information on demographic factors, chronic medical conditions,
medications used, driving habits, visual function and cognitive status was collected
by telephone interview. Frequency distributions were calculated for subjects involved
in and those not involved in crashes, and crude odds ratios and 95% conﬁdence
intervals were computed for the use of different types of medicines. The results
showed the various accident risks associated with the use of different medications.
Several possible limitations are inherent to pharmacoepidemiological studies:
The use of databases as a source of information can be a limitation. For•
example, not all trafﬁc accidents are reported to the police, which can lead to
an underestimation of accident rates in the studied population when using police
F
o
r
m
a
t
:
(
1
4
8
.
0
0
x
2
1
0
.
0
0
m
m
)
;
D
a
t
e
:
1
2
0
2
,
2
0
0
8
0
7
:
5
3
:
3
2
;
O
u
t
p
u
t
P
r
o
f
i
l
e
:
S
P
O
T
I
S
O
C
o
a
t
e
d
v
2
(
E
C
I
)
;
I
n
k
S
a
v
e
2
8
0
Drug use, impaired driving and trafﬁc accidents
32
reports (Barbone et al., 1998). In addition, databases do not contain all possible
information on other risk factors, such as alcohol use (Neutel, 1998).
Bias might result from the subjects’ patterns of medication use, such as non-•
compliance, or irregular as opposed to continuous use (Hemmelgarn et al., 1997).
Some studies do not control for unmeasured variation within an individual and thus•
cannot differentiate between the risks associated with use of the medication or with
the underlying disorder being treated by the medication (Barbone et al., 1998).
Driving patterns might differ between periods of use and non-use of a•
medication, such as choosing not to drive while using the medication.This could
lead to an underestimation of the risks of driving associated with the use of the
medicine (Barbone et al., 1998; Hemmelgarn et al., 1997).
Gathering information by interview or questionnaire is limited by the restrictions•
that are inherent to such surveys (see previous subsection on surveys).
Recent proposals pertaining to research
Because of the many limitations that are inherent to epidemiological and experimental
studies, it is difﬁcult to compare or combine the results of the different studies. Recent
proposals to improve research are described below.
Driving skills in opioid-dependent patients
In their review of studies of impaired driving skills in opioid-dependent/tolerant
patients, Fishbain et al. (2003) listed many confounders that might have inﬂuenced
the results. They also made several recommendations for future research to address
these confounders:
Future psychomotor and cognitive studies should control for pain levels,•
educational status and history of drug/alcohol abuse/dependence, in addition to
sex and age.
The types of control groups used can be improved upon. When a treatment group•
of patients taking opioids is compared to a control group of patients not on opioids,
the effects of a patient’s disease state, e.g. cancer (fatigue, etc.), pain, etc., are not
controlled for. A better control group might use patients as their own controls. As
such, psychomotor and cognitive studies should be conducted both before and
after opioid use. Another possible improvement to this type of research would be
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to include a patient control group. For example, when comparing cancer patients
using opioids to non-patient opioid-free controls, a control group of opioid-free
cancer patients might be added to control for the patients’ disease state. A third
improvement would be the use of positive controls as a benchmark. Patients in the
positive control group would be given drugs such as diazepam that are known to
affect cognitive and psychomotor performance. Opioid effects then would not only
be compared to opioid-free controls, but also to this positive control group.
Research into drugs and driving
Berghaus et al. (2007) describe the principal methodological approaches of
epidemiological research and the optimal design of an experimental study. Optimal
methods for the collection of the data, analysis of results, ethical issues and quality
control of different kinds of epidemiological research, namely roadside surveys,
case-control studies, responsibility analysis and pharmacoepidemiological studies,
and of experimental studies are described.
In the United States, Lacey et al. (2007) developed and tested procedures to
enhance roadside surveys to include collecting oral ﬂuid and blood samples from the
night-time weekend driving population and testing them for drugs as well as alcohol.
In the past, roadside surveys have been used to measure the extent of alcohol use
in the night-time driving population in order to establish regular measures of that
activity, which is a measure of progress in reducing impaired driving. The ﬁndings
indicated that this form of expanded roadside survey is practicable in the United
States and may be used in the next full-scale national roadside survey.
In June 2005, the International Council on Alcohol, Drugs, and Trafﬁc Safety’s
(ICADTS) Working Group on Illegal Drugs and Driving recognised a critical need for
standards or guidelines for research into drugs and driving and recommended that
international researchers meet to develop them. The meeting, held in September 2006,
resulted in a set of standards for future research into drugs and driving (6) that
should improve the comparability of data globally. The standards consist of
recommendations on three different topics: behaviour (around 30 recommendations),
epidemiology (40 recommendations) and toxicology (more than 60 recommendations)
(NIDA, 2007). The experts in attendance represented nine countries on three
continents, and the meeting was co-sponsored by the National Institute on Drug
(6) A modiﬁed Delphi method was used to develop an initial set of draft standards.
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Abuse (NIDA), the European Commission, EMCDDA, ICADTS, the International
Association of Forensic Toxicologists (TIAFT) and the French Society of Analytical
Toxicology (SFTA).
Conclusion
There are broadly two different methods to study driving under the inﬂuence of
drugs, namely experimental and epidemiological studies.
In experimental studies, subjects’ performance is evaluated by performance tests,
tests in a driving simulator or ‘real’ driving tests. While these studies allow the
assessment of the effects of a drug on differentiated functions, they can only identify
potential risks, but with an adequate design, they can result in an interpretation by
single cause. The results of these studies may be limited by the use of non-realistic
drug doses or by inter-individual differences.
Performance tests are conducted in a laboratory setting and are intended to
measure speciﬁc skills and abilities that are involved in driving, such as attention,
vigilance, auditory and visual skills, reaction time, cognitive tests, visual-motor
coordination skills, etc. They measure a part of the performance needed to complete
a task, but do not cover driving ability as a whole. In addition, the selection of the
test(s) to be performed can inﬂuence the results of the study, because the measure of
the acute drug effect is related to the sensitivity of the test chosen.
In a driving simulator, subjects perform a computer simulation of a driving task. The
main advantages of this type of study are that driving tasks can be standardised and
data can be gained safely. However, because a ‘real’ environment can never be fully
replicated, subjects must deal with certain difﬁculties in the driving simulation.
‘Real’ driving tests are able to most realistically show the effects of psychoactive
drugs on driving performance. They can be conducted in the presence or absence
of normal trafﬁc. One main disadvantage of this kind of experimental study is the
necessity of taking trafﬁc safety into consideration.
Because of small sample sizes and a multitude of variable factors in experimental
studies, it is difﬁcult to compare or combine results of different studies.
Epidemiological studies on drugs and driving examine the prevalence of drugs in
various driving populations. These studies include roadside surveys, prevalence
studies in subsets of drivers, accident risk studies, responsibility analyses, surveys by
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interview and pharmacoepidemiological studies. Legislation, data protection, data
availability and funding may affect the choice of type of survey. A roadside survey
offers the closest representation of the general driving population.
In epidemiological research, the appropriate study design may be difﬁcult to put
into place because of limitations to the methodology, and there may be risk factors
associated with drug use that do not emerge from the study ﬁndings. Moreover,
epidemiological studies are not always easy to compare, if, for example, the data
are from different populations, investigators use different types of samples or
detection techniques, samples are tested for different psychoactive substances.
Guidelines have recently been developed for future research into drugs and driving
that aim to improve the comparability of studies.
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Chapter 2: Prevalence of drugs in drivers
In order to estimate the size of the danger that driving under the inﬂuence of drugs
poses for trafﬁc safety, it is necessary to assess the prevalence of driving under
the inﬂuence of drugs. The epidemiological studies on drugs and driving published
since 1999 are discussed in this chapter. A more detailed description of the types,
methodology and limitations of these types of studies is given in Chapter 1.
Roadside surveys
Roadside surveys investigate the prevalence of psychoactive substances in the
general driving population. Drivers are randomly stopped and tested for the
presence of alcohol, drugs and/or medicines in their body.
The results of recent roadside surveys are given in Table A1 (Appendix). Eight
studies were found that were published since 1999. One study was conducted in
Australia (P. Swann, personal communication), one in Canada (Dussault et al.,
2002), one in Denmark (Behrensdorff and Steentoft, 2003), two in the Netherlands
(Assum et al., 2005; Mathijssen, 1999), one in Norway (Assum et al., 2005), one
in the United Kingdom (Glasgow) (Assum et al., 2005) and one in the United States
(Lacey et al., 2007).
It is difﬁcult to compare the results of the different studies, because of the many
differences in methodology (see Chapter 1). There are, however, some similarities.
In most of these studies, the drug that is most frequently detected in the general
driving population is cannabis. However, in Australia, methamphetamine was more
prevalent, and in the United Kingdom, 3,4-methylenedioxyamphetamine (MDA),
3,4-methylenedioxyethylamphetamine (MDEA) and MDMA were more prevalent
than cannabis. The study in Australia only tested for the presence of cannabis and
methamphetamine. Moreover, oral ﬂuid was tested using oral ﬂuid screening devices,
and only positive samples were sent to the laboratory for conﬁrmation. The lower
prevalence of cannabis than of methamphetamine in the Australian study could
be due to the low sensitivity of the oral ﬂuid screening devices for cannabis. In the
United Kingdom study, no explanation was found for the higher prevalence
of amphetamines compared to cannabis.
Benzodiazepines are the second most prevalent drug/medicine found in drivers in
Canada, Denmark, the Netherlands (2000–04) (Assum et al., 2005) and Norway.
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However, in Norway, opiates were as prevalent as benzodiazepines. In the
1997–98 study in the Netherlands (Mathijssen, 1999), cocaine was the second most
prevalent drug after cannabis. However, the difference between the percentage
of cocaine-positive and benzodiazepine-positive urine samples was small, as
there were six urine samples positive for cocaine and ﬁve for benzodiazepines. In
the study conducted in the United States, cannabis was the most prevalent drug,
followed by cocaine and amphetamines, both present in the same number of
samples. But given that it was a pilot study, the results should be interpreted with
caution. In addition, the aim was to develop and test procedures that would be used
in the next full-scale national roadside survey; the results are thus not representative
of the American driving population as a whole.
The data in Table A1 (Appendix) also show that the combination of alcohol and
drugs is prevalent in about 0.3% to 1.3% of the general driving population. The
percentage of drug-positive drivers ranged from about 1% to 15%. About 1% to
2% of drivers stopped during roadside surveys tested positive for drugs in saliva.
In Canada, the Netherlands and the United States, the percentages were relatively
high, possibly because of these methodological reasons:
the 1997–98 study in the Netherlands (Mathijssen, 1999) and the study in the•
United States were conducted on weekend nights;
the study in Canada and both studies in the Netherlands used urine as the•
biological sample, which has a longer detection time.
Subsets of drivers
Drivers injured in trafﬁc accidents
Table A2 (Appendix) shows nine studies on drug prevalence in injured drivers
published since 1999: one in Australia (Longo et al., 2000a); one in Denmark
(Bernhoft et al., 2005); two in France (Kintz et al., 2000; Mura et al., 2003); one in
the Netherlands (Assum et al., 2005); one in South Africa (Sukhai, 2004) and three
in the United States (Lowenstein and Koziol-McLain, 2001; Soderstrom et al., 2001;
Walsh et al., 2005).
Drugs and/or alcohol were frequently detected in injured drivers, more frequently
than in the general driving population. This is particularly shown by the results of the
study conducted in 2003 in the United States by Walsh et al. (2005). About half of
the injured drivers in this study tested positive for drugs, higher than the percentage
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of alcohol-positive drivers (30.6%). Cannabis was the most frequently detected
drug in most of the studies, with a maximal prevalence of 26.9% in the 2003
study in the United States (Walsh et al., 2005). In the 1994–96 study in the United
States (Soderstrom et al., 2001), however, opiates were detected in 23.7% of blood
samples, cocaine in 18.7% and cannabis in only 9.6%. However, in this latter study,
only 58% of eligible, injured patients were approached and screened for drugs,
raising questions about selection bias.
Benzodiazepines were the most frequently detected drug in the 2000–01 study in
France (Mura et al., 2003) and in the Dutch study.
In all studies that tested for alcohol as well as drugs, alcohol was found in a
higher percentage of samples than any other drug, except in one American study
(Lowenstein and Koziol-McLain, 2001) in which cannabis was more prevalent than
alcohol. The combination of alcohol and drugs was also frequently encountered,
with prevalence ranging from 1.4% to almost 20%. There is large variation in the
percentages of drug-positive samples in the different studies, but this is probably
due to the differences in methodology and study location (see Chapter 1).
Drivers killed in trafﬁc accidents
The results of recent epidemiological studies that investigated the presence of
alcohol, drugs and/or medicines in drivers that were killed in trafﬁc accidents are
given in Table A3 (Appendix). Eleven studies have been published since 1999:
one in Australia (Drummer et al., 2003); one in Canada (Brault et al., 2004); one
in France (Mura et al., 2006); one in Hong Kong (Cheng et al., 2005); two in Italy
(Sironi et al., 1999; Vignali et al., 2001); two in Spain (del Rio et al., 2002;
Lopez-Rivadulla and Cruz, 2000); one in Sweden (Holmgren et al., 2005);
one in the United Kingdom (Assum et al., 2005) and one in the United States
(Logan and Schwilke, 2004; Logan, 2005).
Alcohol was the most frequently detected psychoactive substance in drivers killed
in accidents. However, drugs were also frequently detected, and just as in injured
drivers, at a higher prevalence rate than in the general driving population. The
combination of alcohol and drugs was also prevalent in a substantial number of
samples, ranging from 2.5% to 17%. In ﬁve studies, cannabis was the most prevalent
drug, with a maximal value of about 29% in the study in France. In this study,
however, only drivers younger than 30 years were included, which may partially
explain the high number of cannabis-positive samples.
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Drivers involved in trafﬁc accidents
Table A4 (Appendix) shows the results from four studies of drivers involved in trafﬁc
accidents published since 1999: three in France (Laumon et al., 2005; Pépin et al.,
1999, 2003) and one in Greece (Maravelias, 2003).
The data from these studies are in agreement with the ﬁndings from the studies
of drivers injured or killed in trafﬁc accidents. Alcohol is more prevalent than any
other psychoactive substance, cannabis is the most prevalent after alcohol (however,
the studies in France did not test for benzodiazepines, and benzodiazepines were
as prevalent as cannabis in Greece) and the combination of alcohol and drugs is
detected in a substantial number of samples.
Drivers suspected of driving under the inﬂuence of drugs
Table A5 (Appendix) shows 15 studies published since 1999 of drivers stopped on
suspicion of drug use: one in Australia (Kotsos et al., 2003); two in Belgium (Maes et
al., 2003; Raes and Verstraete, 2005); one each in Finland (Lillsunde, 2000); France
(Pépin et al., 1999); Germany (Toennes et al., 2005); Iceland (Thorsdottir et al.,
2004); Luxembourg (Wennig, 2005); the Netherlands (Smink et al., 2001); Norway
(Christophersen, 2000); and Slovenia (Zorec-Karlovsek et al., 2003), and two studies in
both Sweden (Ceder, 2000; Jones, 2005) and Switzerland (Augsburger et al., 2005;
Plaut and Staub, 2000).
The studies show a large variation in the number of drug-positive samples found on
suspicion (55% to 99%). This reﬂects differences in methodology, but also differences
in procedures used to detect drivers who may be under the inﬂuence
of drugs (see Chapter 1).
In all the studies where samples were tested for alcohol and drugs, a psychoactive
substance other than alcohol was most frequently detected, except in one study in
Switzerland (Plaut and Staub, 2000) in which alcohol was most prevalent. In this
study, this was probably due to the very low cut-off level used to detect alcohol
(BAC > 0.1‰).
Cannabis is the most frequently detected psychoactive substance in eight studies. In
both studies in Sweden, amphetamines were the most frequently encountered drug;
Jones (2005) remarks that this has been so for several decades. In the Netherlands,
cocaine was the most prevalent drug, but benzodiazepines were almost as prevalent.
Smink et al. (2001) remark that the situation in the Netherlands is different from that
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in neighbouring countries, where cannabis is most frequently encountered. In France
and Germany, cannabis was most frequently encountered, but samples were not
tested for the presence of benzodiazepines. Cannabis was also the most prevalent
drug in Norway, but samples were not tested for cocaine.
In the study in Australia, blood samples were only collected from drivers who had
failed the ﬁeld sobriety test. As drugs were found in 99% of the blood samples,
Kotsos et al. (2003) concluded that the ﬁeld sobriety test used in the study is an
effective initial method for detecting drug use.
In Sweden, an increase in the prevalence of amphetamines and cannabis was
detected after the implementation of new zero tolerance legislation for narcotic
drugs, while there was no change in the prevalence of therapeutic drugs. According
to Ceder (2000), this may be because police in Sweden were allowed to carry out
eye examinations on drivers following the change in legislation, as amphetamines
and cannabis have a pronounced effect on pupil size and reaction to light.
Drivers suspected of driving under the inﬂuence of alcohol
Three epidemiological studies have been published since 1999 investigating the
presence of drugs in biological samples of drivers suspected of driving under
the inﬂuence of alcohol in Table A6 (Appendix). Two studies were conducted
in Germany (Rentsch et al., 2002; Römhild et al., 2005) and one in the United
Kingdom (Scotland) (Ofﬁcer, 2003). The data show that drivers stopped on suspicion
of alcohol use are frequently under the inﬂuence of drugs. Cannabis is the most
frequently detected drug in these samples.
In Ireland, Fitzpatrick et al. (2006) analysed samples from drivers suspected of
driving under the inﬂuence of an intoxicant. Of these, 1 000 drivers were below
the legal limit for alcohol and 1000 were over the limit. The samples were
tested for the presence of amphetamines, methamphetamines, benzodiazepines,
cannabinoids, cocaine, opiates and methadone. The results showed that the
prevalence of drugs decreased steadily as alcohol concentrations increased. Of the
drivers under the legal limit for alcohol, 33% tested positive for drugs; this ﬁgure
was 14% among drivers over the limit. Being under the legal limit for alcohol,
stopped in a city area, stopped between 6.00 a.m. and 4.00 p.m., stopped
between 4.00 p.m. and 9.00 p.m., and younger age was each independently
associated with a positive drug test.
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Surveys on driving under the inﬂuence of drugs
In this type of epidemiological study, a study population is surveyed using interviews
or questionnaires about whether they have driven while under the inﬂuence of drugs
or after the use of drugs. The results of nine surveys of the general population and
the general driving population that have been published since 1999 are described
in Table A7 (Appendix): two are from Australia (Australian Institute of Health
and Welfare, 2001, 2004); three from Canada (Adlaf et al., 2003b; Beirness et
al., 2003; Walsh and Mann, 1999); and one each from Denmark (Behrensdorff and
Steentoft, 2003); Spain (del Rio and Alvarez, 2001); the United Kingdom (Neale et al.,
2000) and the United States (SAMHSA, 2006). Table A8 (Appendix) lists the results of
eight surveys from 1999 or later of young drivers: three studies from Australia (Davey
et al., 2005; Lenné et al., 2004; Lenton et al., 1999); two from Canada (Adlaf et
al., 2003a; Asbridge et al., 2005); two from the United Kingdom (Neale et al., 2000;
Terry and Wright, 2005) and one from the United States (SAMHSA, 2006).
The results of 10 surveys among drug users are described in Table A9 (Appendix).
Published in 1999 or later, these include four studies from Australia (Aitken et
al., 2000; Darke et al., 2004; Jones et al., 2005; Lenné et al., 2001), one from
Canada (Walsh and Mann, 1999), one from Germany (Kubitzki, 2001), three from
the United Kingdom (Albery et al., 2000; Neale et al., 2000; Terry and Wright,
2005) and one from the United States (Buchan et al., 2000).
From the survey data described in Tables A7–A9 in the Appendix, medians were
calculated of the proportions of the various populations surveyed that report ever
having driven under the inﬂuence of drugs, alcohol or cannabis (Figure 4).
About a quarter of the general driving population reports ever having driven under
the inﬂuence of alcohol (25%, min.: 13%, max.: 64%). Driving under the inﬂuence
of drugs is reported by about 3.4% (min.: 2.8%, max.: 4.3%) of the general driving
population, and cannabis is the most frequently consumed drug (2.4%, min.: 1.5 %,
max.: 3%). Among young drivers, 14.6% (min.: 7.5%, max.: 69%) report ever having
driven under the inﬂuence of alcohol and 15% (min.: 13.4%, max.: 25 %) under the
inﬂuence of drugs. Driving under the inﬂuence of cannabis is most frequently reported
(30%, min.: 15.1%, max.: 59%) (7). The data from the surveys of drug users indicate
that 83.5% (min.: 67.1%, max.: 94%) have ever driven a vehicle shortly after having
(7) The percentage of young drivers that reports driving under the inﬂuence of cannabis is
higher than the percentage that reports driving under the inﬂuence of drugs. This is because
the data that were used to calculate these percentages were not all from the same studies.
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used drugs. About half of drug users have driven under the inﬂuence of alcohol
(51%, min.: 23%, max.: 92%). In a study in Germany, 92% of young drug users
said that they had driven under the inﬂuence of a combination of alcohol and drugs
(Kubitzki, 2001). In a survey in Scotland of visitors to discos and nightclubs (Neale et
al., 2000), the patterns of the respondents’ answers seem to be more in agreement
with surveys of drug users than with surveys of young drivers.
Conclusion
In Europe, the United States, Australia and Canada, about 1% to 2% of drivers
stopped during roadside surveys, tested positive for drugs in saliva. One outlier was
identiﬁed, namely a roadside survey in Scotland which found that about 11% of
the drivers tested positive for drugs in their saliva. Driving under the inﬂuence of
a combination of alcohol and drugs is not uncommon. Not unexpectedly, higher
prevalence rates were found in studies using urine samples (6.4–12%) and in studies
where samples were only collected on weekend nights (15%). Studies conducted
among drivers stopped on suspicion of alcohol or drug use or other subsets of drivers
Figure 4: Median of the percentages of the general driving population, young drivers and
drug users that report ever having driven under the inﬂuence of drugs, alcohol or
cannabis (see Tables A7–A9 in the Appendix for survey details).
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usually ﬁnd a higher prevalence rate of drugs than roadside surveys of general driving
populations. The reason is the selection of drivers inherent to such subset surveys.
In drivers who were injured, killed or involved in a trafﬁc accident, alcohol is more
prevalent than any other psychoactive substance; illicit and medicinal drugs are
also frequently detected, more often than in the general driving population (studies
in Europe, the United States, South Africa, Canada and Hong Kong). Not all of the
most common drug types are tested for. After alcohol, cannabis is the drug most
commonly tested for, and the combination of alcohol and drugs is detected in a
substantial number of samples. When samples were analysed for the presence of
benzodiazepines, these substances were found in a substantial number of cases, and
were sometimes even more prevalent than cannabis.
Among drivers stopped on suspicion of driving under the inﬂuence of drugs, a
psychoactive substance other than alcohol is most frequently detected and, in most
studies, it is cannabis. Drivers suspected of driving under the inﬂuence of alcohol are
frequently also under the inﬂuence of drugs.
In surveys conducted by interview or questionnaire, driving under the inﬂuence of
drugs is less frequently reported (about 3.4%) by the general driving population
in seven countries than driving under the inﬂuence of alcohol (25%). In young
drivers, on the other hand, the ﬁgures are similar for alcohol (14.6%) and drugs
(15%). Cannabis is the drug most frequently reported by both the general driving
population and young drivers. Among drug users, about 83% have ever driven a
vehicle shortly after having used drugs. It is also worth noting that drug users often
drive under the inﬂuence of alcohol.
The comparability of these prevalence studies is low. For future research,
comparability may be improved if certain minimum common standards are adopted.
Nevertheless, from the studies that have been published since 1999, it can be
concluded that driving under the inﬂuence of drugs is not uncommon and that it can
cause a substantial risk to trafﬁc safety.
A promising large-scale epidemiological study called DRUID (Driving under the
inﬂuence of drugs, alcohol and medicines) was started in October 2006 and is
expected to be completed in 2010 (8). One of its aims is to analyse the prevalence
of alcohol and other psychoactive substances in accidents and in the general driving
population in 19 different European countries.
(8) www.druid-project.eu/cln_007/nn_107534/Druid/EN/home/
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Chapter 3: Effects and risks associated with drugs
For each type of drug considered, the effects on performance that have been
assessed by experimental studies will be described. These effects are mostly divided
into acute and chronic effects. Acute effects are the effects associated with the use of
a single dose of a drug. Chronic effects are the effects of using a speciﬁc drug over
a long period of time. Where possible, epidemiological data on the risks associated
with these drugs in trafﬁc will also be described.
Cannabis
Acute effects
The effects of cannabis vary with dose, route of administration, experience of the
user, vulnerability to psychoactive effects and setting of use. In small doses, cannabis
Pharmacology of cannabis
Cannabis is a natural product, the main psychoactive constituent of which is
tetrahydrocannabinol (THC). The cannabis plant (Cannabis sativa L.) is broadly
distributed and grows in temperate and tropical areas. Cannabis resin is a compressed
solid made from the resinous parts of the plant, and cannabis (hash) oil is a solvent
extract of cannabis.
The pharmacology of cannabis is complicated by the presence of a wide range of
cannabinoids. Anandamide has been identiﬁed as the endogenous ligand for the
cannabinoid receptor and has pharmacological properties similar to those of THC.
When cannabis is smoked, THC can be detected in plasma within seconds of inhalation;
it has a half-life of 2 hours. Following smoking of the equivalent of 10–15 mg over a
period of 5–7 minutes, peak plasma levels of THC are around 100 μg/l. It is highly
lipophilic and widely distributed in the body. Two active metabolites are formed:
11-hydroxy-Δ9-THC and 8β -hydroxy-Δ9-THC. The ﬁrst is further metabolised to
Δ9-THC-11-oic acid. Two inactive substances are also formed (8α-hydroxy-Δ9-THC and
8α,11-dihydroxy-Δ9-THC) as are many other minor metabolites, most of which appear in
the urine and faeces as glucuronide conjugates. Some metabolites can be detected in the
urine for up to 2 weeks following smoking or ingestion.
Source: EMCDDA drug proﬁles (http://www.emcdda.europa.eu/publications/drug-proﬁles).
F
o
r
m
a
t
:
(
1
4
8
.
0
0
x
2
1
0
.
0
0
m
m
)
;
D
a
t
e
:
1
2
0
2
,
2
0
0
8
0
7
:
5
3
:
3
6
;
O
u
t
p
u
t
P
r
o
f
i
l
e
:
S
P
O
T
I
S
O
C
o
a
t
e
d
v
2
(
E
C
I
)
;
I
n
k
S
a
v
e
2
8
0
Drug use, impaired driving and trafﬁc accidents
50
produces euphoria, relief of anxiety, sedation and drowsiness. In some respects, the
effects are similar to those caused by alcohol (9). Occasionally, the use of cannabis can
cause anxiety that may escalate to panic attacks and paranoia. A sense of enhanced
well-being may alternate with a depressive phase (Huestis, 2002). The users are aware
of the effects of the drug, and this awareness increases with higher doses (Lane et al.,
2005; Liguori et al., 2002; Menetrey et al., 2005; Sexton et al., 2000). Cannabis can
also cause some physiological effects such as mydriasis (Sexton et al., 2000).
Cannabis acutely reduces some cognitive and psychomotor skills that are
necessary to drive such as motor control, psychomotor speed, executive function,
motor impulsivity, visual processing, short-term memory, working memory (reaction
time and accuracy), perception and balance, and these effects are mostly dose-
dependent (Hart et al., 2001; Ilan et al., 2004; Kurzthaler et al., 1999; Liguori et
al., 2002; Menetrey et al., 2005; Nicholson et al., 2004; Ramaekers et al., 2006a;
Sexton et al., 2000). Using driving simulator tests, Menetrey et al. (2005) found
that keeping a vehicle on a track is the most difﬁcult task for participants under the
inﬂuence of cannabis. Liguori et al. (2002) found a signiﬁcant effect of cannabis on
body sway, but no effect on brake latency. In agreement with these results, Sexton
et al. (2000) showed that the SDLP in the road-tracking test was the most sensitive
measure for revealing THC’s adverse effects.
A study by Ramaekers et al. (2006b) deﬁned performance impairment (in terms
of motor control, motor impulsivity and executive function) as a function of THC
concentration in serum and oral ﬂuid. The authors concluded that 2 and 5 ng/ml
are the lower and upper ranges of a serum THC limit for impairment. Binomial tests
showed an initial and signiﬁcant shift toward impairment in the critical tracking task
for serum THC concentrations between 2 and 5 ng/ml. At concentrations between
5 and 10 ng/ml, approximately 75–90% of the observations were indicative of
signiﬁcant impairment in every performance test. At THC concentrations above
30 ng/ml, 100% of observations in every performance test were indicative of
signiﬁcant impairment. According to Mura et al. (2005), cannabis can be detected
in those regions of the brain on which it has an inﬂuence even after it is no longer
detectable in blood.
Cannabis can also have an effect on behaviour. The effects of cannabis on risk-
taking is, however, unclear. Laboratory experiments revealed an increased
(9) See EMCDDA Drug proﬁle, Cannabis
(http://www.emcdda.europa.eu/publications/drug-proﬁles/cannabis).
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impulsive response in the stop signal task, indicating that the subjects were unable
to inhibit a response in a rapid response model while under the inﬂuence of
cannabis (McDonald et al., 2003; Ramaekers et al., 2006a). Lane et al. (2005)
found that when subjects are presented with a choice between two response options
operationally deﬁned as risky and non-risky, cannabis increased selection of the
risky option. However, performance on other behavioural measures of impulsivity
(go/no go, Iowa gambling task) were not affected (McDonald et al., 2003;
Ramaekers et al., 2006a). In some driving studies that used low doses of cannabis,
it was observed that the subjects are aware of the impairment and compensate their
driving style by driving more slowly, overtaking less or keeping longer distances.
However, they are still unable to compensate for the loss of capability in some
psychomotor skills (Sexton et al., 2000, 2002). The experimental studies on cannabis
traditionally used low-potency cannabis (maximum 4% THC). Other studies that have
used high-potency cannabis (13% THC) show that impairment is more pronounced
compared to the low-potency studies (see Chapter 1).
Duration of effects
The desired effect of cannabis, the ‘high’, lasts for up to 2 hours (Couper and Logan,
2004b). However, most studies found signiﬁcant negative effects of cannabis on
performance up to 10 hours after use (Hart et al., 2001; Kurzthaler et al., 1999;
Lane et al., 2005; McDonald et al., 2003; Menetrey et al., 2005; Ramaekers et al.,
2006a). Nicholson et al. (2004), for example, found that memory was impaired in
healthy volunteers 10 hours after administration of 15 mg of THC.
Combination with other psychoactive substances
Some deleterious effects of cannabis appear to be additive or even synergistic with
those of alcohol; the combination of both substances results in a prolongation as
well as enhancement of their effects (Baselt, 2001). For example, stronger subjective
effects are generated after the use of a combination of alcohol and cannabis than
after the use of either substance alone (Sexton et al., 2002). Driving studies show
that drivers under the inﬂuence of both alcohol and cannabis are less attentive to trafﬁc
approaching from side streets, while the use of either cannabis or alcohol had no effect
(Lamers and Ramaekers, 2001), and that the combination of cannabis and alcohol
generates an additional decrement in lateral control on top of the decrement caused by
either cannabis or alcohol (Sexton et al., 2002). Liguori et al. (2002), however, found
no additive effects of alcohol and cannabis on brake latency or body sway.
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Chronic effects
Chronic use of cannabis can lead to deﬁciencies in skills concerning memory,
attention, manual dexterity, executive functioning and psychomotor speed
(Bolla et al., 2002; Ehrenreich et al., 1999; Pope et al., 2001; Solowij et al., 2002).
These effects can last longer than the period of intoxication and worsen with either
increasing number of years or frequency of cannabis use. The defects are partially
reversible with prolonged abstinence, but some impairment may be permanent.
Risks
When studying the risks associated with cannabis use, the results can be misleading
if samples are analysed for THC-COOH, as this is an inactive metabolite of cannabis
that can be present in blood or urine even though the subject is no longer impaired.
Better correlation with impairment can be achieved by testing for THC, the primary
active ingredient of cannabis (Verstraete, 2004).
Accident risk
Four epidemiological studies investigated the risk of being involved in a trafﬁc
accident while driving under the inﬂuence of cannabis. A case-control study in
Canada (Québec) showed that driving under the inﬂuence of cannabis alone was
associated with an OR of 2.2 (95% CI: 1.5–3.4), while when all cannabis cases
were taken into account, an OR of 4.6 (95% CI: 3.4–6.2) was found (Dussault et
al., 2002). Driving under the inﬂuence of a combination of alcohol (BAC > 0.08%)
and cannabis was associated with an increased accident risk of 80.5 (OR, 95% CI:
28.2–230.2). In France, the prevalence of alcohol, cannabis and other drugs was
compared between 900 injured drivers and 900 control subjects (Mura et al., 2003).
Among drivers below the age of 27 years, driving under the inﬂuence of cannabis
alone was associated with an increased accident risk of 2.5 (OR, 95% CI: 1.5–4.2),
and with alcohol (BAC > 0.05%) plus cannabis, the increased risk was
4.6 (OR, 95% CI: 2.0–10.7). The Immortal study in the Netherlands and Norway
showed an increased accident risk (albeit not statistically signiﬁcant) for driving
under the inﬂuence of cannabis alone (Assum et al., 2005).
The accident risk associated with driving under the inﬂuence of cannabis has also
been studied based on the results of surveys instead of detection procedures.
Fergusson and Horwood (2001) examined associations between cannabis use and
trafﬁc accident risks in a birth cohort of 907 New Zealanders aged 18 to 21 years.
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They found statistically signiﬁcant relationships between reported annual cannabis
use and annual accident rates, but only for ‘active’ accidents in which the driver’s
behaviour contributed to the accident. Those using cannabis more than 50 times per
year had estimated rates of active accidents that were 1.6 (95% CI: 1.2–2.0) times
higher than for non-users. However, when driver behaviours and characteristics
related to cannabis use were controlled for, no association between cannabis use
and accident risks was apparent. These data thus suggest that cannabis use is
associated with an increased risk of being responsible for an accident, but that this
increased risk appears to reﬂect the characteristics of the young people who used
cannabis rather than the effects of cannabis on driver performance.
Gerberich et al. (2003) conducted a retrospective study in northern California
among members of a large health insurance cohort who had completed baseline
questionnaires about health behaviours, including cannabis use, and health status
between 1979 and 1985. In addition, all subjects’ hospitalisations for injuries until
31 December 1991 were identiﬁed. Statistical analysis showed a higher incidence
of motor vehicle injuries in men who were current users of cannabis compared with
non-users. There were no differences for women or former users.
In a case-control study, Blows et al. (2005) recorded drivers’ self-reported cannabis
use in the three hours prior to the crash or survey and habitual cannabis use
in the previous 12 months. The cases were drivers involved in crashes and the
control group consisted of drivers in a random sample of cars. Acute cannabis
use was signiﬁcantly associated with car crash injury. However, after adjusting for
confounders (BAC, seatbelt use, speed and sleepiness score), this effect was no
longer signiﬁcant. There was a strong signiﬁcant association between habitual use
and car crash injury, even after adjustment for all the above confounders plus acute
use prior to driving (OR 9.5, 95% CI: 2.8–32.3).
Asbridge et al. (2005) questioned 6 087 senior students about driving under the
inﬂuence of cannabis and involvement in motor vehicle collisions. Students who
drove under the inﬂuence of cannabis in the past year were over four times as likely
as cannabis-free drivers to be involved in a motor vehicle collision, yet those who
used the drug but did not drive while under its inﬂuence did not have an elevated
accident risk.
A similar study was conducted among cannabis users in Australia (Jones et al.,
2005). The likelihood of having had an accident in the previous year was 7.4% for
those who had not driven within an hour of using a drug in the previous 12 months
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and 10.7% for those who reported driving after using cannabis only. The proportion
who had had an accident in the previous year was much higher among those
who reported driving after using cannabis with alcohol or other illicit drugs —
either simultaneously (24%) or on different occasions (23%) — than it was for
the other drivers.
In the United Kingdom, results from a postal questionnaire survey showed that
cannabis use was associated with an increased risk of road trafﬁc accidents
(OR 1.9, 95% CI: 1.0–3.5), and this risk increased with higher levels of other
associated risk factors (Wadsworth et al., 2006).
Responsibility analyses
A study conducted from 1990 to 1999 in 3 398 fatally injured drivers in Australia
found an OR of 2.7 (95% CI: 1.02–7.0) for being responsible for an accident while
driving under the inﬂuence of cannabis alone (Drummer et al., 2004). For drivers
with blood THC concentrations of 5 ng/ml or higher, the OR was greater and more
statistically signiﬁcant (OR 6.6, 95% CI: 1.5–28.0). A signiﬁcantly stronger positive
association with accident responsibility was seen in drivers positive for cannabis
and with a BAC of 0.05% or higher compared with a BAC of 0.05% or higher and
no cannabis use (OR 2.9, 95% CI: 1.1–7.7). In another study in Australia, conducted
in 1995–96 using blood samples from 2 500 injured drivers, no signiﬁcant increase
in responsibility (OR 0.8, 95% CI: 0.4–1.5) was found when cannabis was used
alone (Longo et al., 2000b). The combination of alcohol and cannabis produced a
signiﬁcant increase in responsibility (OR 5.4, 95% CI: 1.2–24.0), but this increase
was not signiﬁcantly greater than that produced by alcohol alone. A responsibility
analysis performed in Canada with 482 fatally injured drivers showed no statistically
signiﬁcant results for either cannabis alone (OR 1.2, 95% CI: 0.4–3.9) or for the
combination of alcohol (BAC > 0.08%) and cannabis (OR 2.5, 95% CI: 0.3–20.2)
(Dussault et al., 2002). In 10 748 drivers involved in fatal crashes in France from
October 2001 to September 2003, positive cannabis detection was associated
with increased risk of responsibility (OR 3.3, 95% CI: 2.6-4.2) (Laumon et al., 2005).
Moreover, a signiﬁcant dose effect was identiﬁed, with OR increasing from 1.6
(95% CI: 0.8–3.0) for THC concentrations in blood of 0–1 ng/ml to 2.1 (95% CI:
1.3–3.4) for THC concentrations above 5 ng/ml. The effects of cannabis were
adjusted for different co-factors, including BAC, age, vehicle type and time of crash.
For driving under the inﬂuence of a combination of alcohol and cannabis, an OR of
14 (95% CI: 8.0–24.7) was calculated, which is very close to the value obtained from
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the product of the adjusted individual effects of alcohol and cannabis. In the United
States, two responsibility analyses in injured drivers did not ﬁnd an association
between cannabis use and crash responsibility (Lowenstein and Koziol-McLain, 2001;
Soderstrom et al., 2005). This may be due to some methodological limitations, as
both studies used urine for the toxicological analysis. As cannabis metabolites can
be detected in urine for up to several days after chronic use, a sample being positive
for cannabis did not necessarily indicate recent use. Lowenstein and Koziol-McLain
(2001), however, performed secondary cannabis testing on the same urine samples
by using a liquid — liquid extraction procedure that tests for the parent drug (THC)
to differentiate between recent and non-recent use. Drivers were categorised as
follows: acute cannabis use (THC positive), recent cannabis use (11-OH-THC positive)
and remote cannabis use (THC-COOH).
The researchers found no association between crash responsibility and acute
cannabis use, nor between crash responsibility and recent cannabis use or remote
cannabis use. However, the samples were frozen for up to one year; the freezing
and thawing may have led to some degradation of the cannabis and possibly to an
underestimation of the prevalence of acute and recent cannabis use.
In the Netherlands, Smink et al. (2005) investigated the relationship between cannabis
use and the severity of a trafﬁc accident in drivers involved in crashes from October
1998 through September 1999. Blood samples were screened for the presence of
alcohol, illicit drugs and medicinal drugs. Logistic regression analysis showed no
association between the use of cannabis and the severity of a trafﬁc accident.
Meta-analysis
We performed a meta-analysis (10) on the risk data for driving under the inﬂuence
of cannabis alone. For the risk of being involved in a trafﬁc accident, the data were
based on the results from studies in France, the Netherlands and Norway (Assum et
al., 2005; Mura et al., 2003). For the risk of being responsible for an accident, the
data from four studies from Australia and the United States were used (Drummer et
al., 2004; Longo et al., 2000b; Lowenstein and Koziol-McLain, 2001; Soderstrom
et al., 2005). The results indicate a signiﬁcantly increased risk of being involved in
an accident (OR 3.0, 95% CI: 2.4–3.8; RR 2.2, 95% CI: 1.9–2.5), but no signiﬁcant
(10) A meta-analysis is a statistical analysis of a large collection of analysis results from
individual studies. The meta-analysis performed in this report was computed using the
statistical programme MedCalc.
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association between cannabis use and crash responsibility (OR 1.1, 95% CI: 0.8–1.6;
RR 1.0, 95% CI: 0.9–1.2). Future research should investigate whether this might be
due to the limitations inherent to responsibility analysis.
Conclusion
The results of experimental studies clearly indicate that cannabis use can have a
detrimental impact on driving ability, as it impairs some cognitive and psychomotor
skills that are necessary in driving. Most of these effects increase in a dose-dependent
way. A cannabis user is aware of the impairment, but can only partially compensate
for the decrements. The combined use with alcohol can cause additional impairment.
Chronic use of cannabis can lead to deﬁciencies in performance that last longer
than the period of intoxication and worsen with either increasing number of years or
frequency of cannabis use.
A meta-analysis of the data from epidemiological studies has shown that cannabis
use is associated with an increased risk of being involved in an accident, but
not an increased risk of being responsible for an accident. One responsibility
analysis, however, found an increased responsibility risk with increased cannabis
concentration, indicating a possible causal relationship. Several studies found that
the risk of being involved in or responsible for a trafﬁc accident is higher for the
combination of alcohol and cannabis than for cannabis or alcohol use alone.
Opiates
Opiates can be divided into three groups, namely the opiates with morphine-like
activity (for example, morphine, heroin, fentanyl and methadone), the opiates
that block the activity of morphine and the opiates that exhibit mixed activity
(for example, codeine, buprenorphine and pentazocine) (Drummer, 2001). In this
report, the acute and chronic effects and risks associated with the following opiates
will be discussed: morphine, heroin, methadone, buprenorphine and fentanyl.
Fishbain et al. (2003) conducted a structured, evidence-based review of whether
the driving-related skills of opioid-dependent/tolerant patients are impaired. They
found moderate, generally consistent evidence of no impairment of psychomotor
abilities and inconclusive evidence of no impairment of cognitive function. In
addition, the evidence that there is no impairment of psychomotor abilities
immediately after being given doses of opioids was strong and consistent. The
evidence was also strong and consistent that the incidence of motor vehicle violation
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or motor vehicle accidents is not higher versus comparable controls. The analysis
also revealed consistent evidence of no impairment in driving simulators and
off- or on-road studies. The authors also discuss possible causes for the inconsistent
evidence in the cognitive impairment studies. One is the issue of unrelieved pain,
as there is strong evidence that unrelieved pain may decrease psychomotor and
cognitive performance. Another confounder could be educational level, as this has
been shown to better correlate with measures of neuropsychological function than
current or past levels of opioid use. In the studies in cancer patients, disease state
could be a confounder, as recent evidence indicates that in cancer patients using
opioids, the disease itself has the greatest impact on alertness. Another potential
confounder in the studies in drug addicts is associated non-opioid
drug abuse history; drug users with a history of alcohol dependence/abuse and/or
polysubstance dependence/abuse have greater neuropsychological impairment
than cocaine dependence/abuse addicts, who in turn will have greater impairment
than controls.
Acute effects
Morphine
Experimental studies have investigated the effects of single or repeated doses
of morphine on healthy subjects in a laboratory setting. The results indicate that
morphine can increase visual analogue scale ratings indicative of both pleasant
(e.g. drug liking, increased calmness) and unpleasant (e.g. ‘feel bad’, ‘nauseous’)
effects (Hill and Zacny, 2000; O’Neill et al., 2000; Walker et al., 2001). Hill and
Zacny (2000) found that psychomotor impairment was absent after a single morphine
dose of 5 or 10 mg/70 kg. Walker et al. (2001) compared the effects of cumulative
morphine doses of 2.5, 7.5 and 17.5 mg/70 kg to the effects of mixed-action
opiates. They found that morphine decreased performance on the DSST test — in
which speed decreased while accuracy was not affected — in a dose-dependent
manner. Morphine also induced miosis and impaired eye-hand coordination in a
dose-dependent manner. The impairment caused by morphine was of less magnitude
than that caused by mixed-action opiates. Knaggs et al. (2004) also observed an
induction of miosis with morphine. Intravenous morphine (0.125 mg/kg) resulted in
a 26% decrease in pupil diameter in 10 healthy volunteers. O’Neill et al. (2000)
administered repeated doses of morphine to subjects, and found one major effect,
namely an increase in accuracy on the CRT task, but the speed of the response
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tended to be lower. Other effects were improvements in the accuracy of delayed
recall and a reduction in the frequency at which fusion was detected in the CFF task.
These effects lasted for up to 36 hours after repeated doses. The authors concluded
that the effects of morphine were not substantial compared with lorazepam (one of
the comparator drugs in the study).
Fentanyl
Schneider et al. (1999) found that fentanyl in concentrations commonly used in
outpatient surgical procedures (0.2 µg/kg) produces pronounced cognitive impairment
(auditory reaction time, signal detection, sustained attention, recognition) compared
with placebo. Lichtor et al. (2002) investigated the drug effects after ambulatory
anaesthesia of propofol (2.5 mg/kg), propofol (2.0 mg/kg) and fentanyl (2 µg/kg),
propofol (2.0 mg/kg) and midazolam (2 mg/70 kg) or midazolam (0.07 mg/kg) and
fentanyl (2 µg/kg). Psychomotor function was impaired up to 2 hours after injection
with each of the drug combinations. The multiple sleep latency test demonstrated
sleepiness up to 8 hours after an injection of midazolam and fentanyl. Driving
simulator tests, however, found no signiﬁcant impairment at 2, 3 or 4 hours after a
treatment with 2.5 mg/kg propofol and 1 µg/kg fentanyl (Sinclair et al., 2003).
Heroin
No experimental studies on the acute effects of heroin in humans have been
published since 1999. Therefore, a short overview will be given on the results
of studies that were published before 1999. Several studies conﬁrmed the acute
effects of heroin on subjective sedation and on miosis (Cone et al., 1993; Jasinski
and Preston, 1986; Jenkins et al., 1994; Martin and Fraser, 1961). One study found
a trend towards decreased performance on the CLT, which is an indicator of
psychomotor performance (Cone et al., 1993). In another study, the administration
of heroin impaired performance on a reaction time task (Jenkins et al., 1994).
However, the doses used in these studies ranged from 2 to 20 mg, while average
daily doses range from 300 to 500 mg in addicts (Couper and Logan, 2004b).
The effects of heroin on performance can last up to six hours (Cone et al., 1993;
Jasinski and Preston, 1986; Jenkins et al., 1994; Martin and Fraser, 1961). The
duration of the effects is dependent upon the dose and the route of administration.
For example, Jenkins et al. (1994) assessed subjective effects of sedation, miosis and
increased reaction time that lasted for two hours after smoking and four hours after
intravenous administration.
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Methadone
Several recent experimental studies have investigated the performance effects
with substances used for substitution treatment. In a study of the acute effects of
methadone in patients admitted to an opiate detoxiﬁcation programme, patients
were tested after three and ﬁve days of methadone treatment (Curran et al., 2001).
Performance on an episodic memory task was signiﬁcantly impaired following
the 100% daily dose of methadone. The effect could, however, be avoided by giving
methadone in divided doses. No effects were observed on DSST, FTT and digit
cancellation records.
Buprenorphine
As a partial opioid receptor agonist, buprenorphine has a ceiling effect on its
agonist activity, which greatly increases its safety proﬁle relative to full-agonist
Pharmacology of heroin
Heroin is a crude preparation of diamorphine. It is a semisynthetic product obtained
by acetylation of morphine, which occurs as a natural product in opium: the dried
latex of certain poppy species (e.g. Papaver somniferum L.).
Diamorphine, like morphine and many other opioids, produces analgesia. It behaves as
an agonist at a complex group of receptors (the μ, κ and δ subtypes) that are normally
acted upon by endogenous peptides known as endorphins. Apart from analgesia,
diamorphine produces drowsiness, euphoria and a sense of detachment. Negative
effects include respiratory depression, nausea and vomiting, decreased motility in the
gastrointestinal tract, suppression of the cough reﬂex and hypothermia. Tolerance and
physical dependence occur with repeated use. Cessation of use in tolerant subjects
leads to characteristic withdrawal symptoms. Subjective effects following injection
are known as ‘the rush’ and are associated with feelings of warmth and pleasure,
followed by a longer period of sedation. Diamorphine is 2–3 times more potent than
morphine. The estimated minimum lethal dose is 200 mg, but addicts may be able to
tolerate 10 times as much. Following injection, diamorphine crosses the blood–brain
barrier within 20 seconds, with almost 70% of the dose reaching the brain. It is
difﬁcult to detect in blood because of rapid hydrolysis to 6-monoacetylmorphine and
slower conversion to morphine, the main active metabolite. The plasma half-life of
diamorphine is about three minutes.
Source: EMCDDA drug proﬁles (http://www.emcdda.europa.eu/publications/drug-proﬁles).
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medications such as methadone. Strain et al. (2000) administered sublingual
buprenorphine (4, 8 or 16 mg) or a combination of sublingual buprenorphine
and naloxone to seven non-dependent opioid users, and investigated the effects
on psychomotor and cognitive performance. Results from the DSST showed no
signiﬁcant changes for any of the dose conditions tested, and no signiﬁcant
differences for the total number of sequence errors made on a TMT. However,
the highest buprenorphine/naloxone dose (16/4 mg) produced a signiﬁcantly
higher total line length for the trails. The CLT showed signiﬁcant decreases in
performance with 16 mg buprenorphine. The same researchers investigated the
effects of a combination of intramuscular and sublingual buprenorphine and
naloxone in opioid-dependent subjects, once given by intramuscular injection and
once given sublingual. There was no evidence that sublingual buprenorphine and
naloxone impair psychomotor performance. There were no signiﬁcant effects of
any test condition on the trails total length or total errors, or on the DSST’s number
attempted, number correct, or percent errors. CLT performance was decreased with
the highest intramuscular dose (16/4 mg). There was also a signiﬁcant increase
in the number of trails sequence errors for the two highest intramuscular doses
of buprenorphine/naloxone (Stoller et al., 2001). Comer et al. (2002) studied the
effects of intravenously administered buprenorphine (2 or 8 mg) or placebo on the
performance of detoxiﬁed heroin users on a DSST, a divided attention task, a rapid
information processing task and a repeated acquisition of response sequences task.
There were few effects of buprenorphine on performance, with the exception of
impairments in performance on the divided attention task. The latency to respond
to a brief target randomly appearing on the computer screen was greater, the
number of missed targets signiﬁcantly increased and of correctly identiﬁed targets
signiﬁcantly decreased.
Chronic effects
Opioid therapy
Larsen et al. (1999) compared attention and reaction time of patients on long-term
opioid therapy (patients with cancer pain or chronic non-malignant pain) with
patients receiving non-opioid analgesic therapy for chronic non-malignant pain
and a control group of patients without pain or analgesic therapy. No signiﬁcant
difference in attention/concentration could be demonstrated between the three
groups. However, in cancer patients, attention/concentration was more impaired
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than in non-cancer patients taking opioids. Auditory and optical reaction times
were signiﬁcantly slower in patients on opioids than in the non-opioid analgesic
group and highly signiﬁcantly slower than in the control group. Galski et al.
(2000) determined the effects of medically prescribed stable opioid use on the
driving abilities of patients with persistent, non-malignant pain, using a pre-driver
evaluation, a simulator evaluation and behavioural observation during simulator
performance. The control group consisted of cerebrally compromised patients
who had undergone the same evaluation. The opioid-treated patients generally
outperformed the control group. However, the opioid-treated patients had signiﬁcant
difﬁculty in following instructions and had more similar ratings to the subjects in
the control group who had failed rather than passed the evaluation. Sjogren et al.
(2000b) assessed neuropsychological performance in chronic non-malignant pain
patients receiving long-term oral opioid therapy and in a control group of healthy
volunteers. The neuropsychological tests consisted of continuous reaction time,
FTT and PASAT. The patients performed more poorly than the controls in all the tests,
with the differences being statistically signiﬁcant. Signiﬁcantly positive correlations
were found between the results on the PASAT and the pain visual analogue scales.
The authors concluded that pain itself seems to have an arousal effect on working
memory. The same research group evaluated the effects of oral opioids and pain
on performance of cancer patients on the same neuropsychological tests (Sjogren
et al., 2000a). The use of long-term oral opioid treatment per se did not affect
neuropsychological performance and, according to the authors, pain itself, more
than oral opioid treatment, worsens performance on PASAT. Strumpf et al. (2005)
studied the safety-relevant performance of patients taking chronic opioid therapy.
The patients’ results were worse on a concentration test and better on a coordination
test than the results of healthy controls. The patients did not perform worse than
healthy controls on tests of reaction time, vigilance and perception. Patients receiving
an antidepressant in addition to the opioid performed more poorly on the test for
concentration than patients not on antidepressants. Pain intensity did not inﬂuence
patients’ results; nor did opioid dose, state of mind or side-effects. Byas-Smith et al.
(2005) compared the psychomotor performance and driving ability of patients with
chronic pain managed with stable opioid doses with that of healthy controls. Patients
were evaluated for errors while driving their own car along a predetermined route in
the community, including variable residential and highway conditions, and for speed
and accuracy on repeated trials through a ﬁve-station obstacle course that evaluated
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forward and reverse driving, turning and parallel parking. No signiﬁcant differences
were observed between the group of patients and the control group.
Several experimental studies have investigated the effects of chronic use of speciﬁc
opioids. Raja et al. (2002) compared the cognitive and psychomotor effects of
morphine versus a TCA in patients with neuropathic pain syndrome. Each subject
received approximately eight weeks each of morphine, nortriptyline and placebo.
Patients who could not tolerate a drug were offered an alternative drug of the same
class within that period; for morphine, the alternative was methadone. Performance
was measured on the symbol substitution task from the WAIS (concentration and
psychomotor function), the Hopkins verbal learning test and the grooved pegboard
task (manual dexterity and psychomotor speed). Treatment with opioids did not
inﬂuence performance on any measure. Tassain et al. (2003) investigated the long-
term effects of oral sustained-release morphine on neuropsychological performance
in patients with chronic non-cancer pain. Evaluations were performed at baseline
in patients free from opioids and then after 3, 6 and 12 months. There was no
impairment of any neuropsychological variable over time in the morphine-treated
patients compared with the control group. Information processing speed was
improved at 6 and 12 months and there were signiﬁcant correlations with pain relief
and improvement of mood. Patients, however, often require more pain relief than
is afforded by sustained-release opioid drugs. Kamboj et al. (2005) examined the
effects of additional immediate-release doses of morphine on cognitive functioning
in patients receiving chronic opioid therapy in palliative care. The results suggested
that immediate-release morphine, when taken on top of a sustained-release opioid,
produces transient anterograde and retrograde memory impairments and a
decrement in two-target tracking.
In pre-marketing clinical trials of transdermal fentanyl, somnolence and confusion
each occurred in more than 10% of the 153 cancer patients, and tremor, abnormal
coordination, abnormal gait, amnesia and syncope each occurred in 1 to 2%
(Kornick et al., 2003). Sabatowski et al. (2003) compared the performance of
patients with continuous non-cancer pain, who had received stable doses of
transdermal fentanyl for at least two weeks, on a series of computerised tests to
measure attention, reaction, visual orientation, motor coordination and vigilance
to the performance of healthy controls. None of the performance measures was
signiﬁcantly inferior in the group of patients compared to the control group. In a
study of the psychomotor effects of long-term fentanyl use, patients with low back
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pain were administered two neuropsychological tests (DSST and TMT) before being
prescribed opioids for pain, and tests were re-administered at 90- and 180-day
intervals (Jamison et al., 2003). No impaired cognition or psychomotor function
was observed, and in fact, test scores were even signiﬁcantly improved while
subjects were taking opioids for pain. Menefee et al. (2004) compared the baseline
performance of patients taking oxycodone to their performance after being stabilised
for one month on transdermal fentanyl. The tests included driving performance
in a driving simulator as well as cognitive and balance tests. No differences were
found in driving simulation measures between the pre- and post-treatment periods.
No decrements in cognitive performance were found, nor were there differences in
balance or body sway. Improvements in visual motor tracking, visual memory and
attention were observed during treatment with transdermal fentanyl.
The fact that pain plays a role in the cognitive defects detected in pain patients was
conﬁrmed in a study by Veldhuijzen et al. (2006b), who determined the effects of
chronic non-malignant pain on actual highway driving performance during normal
trafﬁc. In addition, driving-related skills (tracking, divided attention and memory)
were examined in the laboratory. Subjective driving quality was rated on visual
analogue scales. The results showed that a subset of pain patients had SDLP values
that were higher than the matched healthy controls, which resulted in an overall
statistically signiﬁcant difference in SDLP between pain patients and healthy controls.
Further, chronic non-malignant pain patients rated their subjective driving quality to
be normal, although their ratings were signiﬁcantly lower than those of the healthy
controls. No signiﬁcant effects were found in the laboratory tests.
Heroin dependence
Chronic heroin use can have long-lasting effects on some cognitive and psychomotor
skills. Studies have found an impairment of the planning function (Bryun et al., 2001),
reaction time (Liu et al., 2006), time perception (Alexandrov, 2004), spatial working
memory (Ornstein et al., 2000), pattern recognition memory (Ornstein et al., 2000),
executive functioning (Lyvers and Yakimoff, 2003; Ornstein et al., 2000; Verdejo et
al., 2004) and right-left discrimination (Ning et al., 2005). Chronic heroin users also
tend to be reckless and ignore the rules and regulations of tasks (Pau et al., 2002).
For some tasks, there is a signiﬁcant relationship between the severity of heroin
dependence or duration of use and the impairment (Bryun et al., 2001; Lyvers and
Yakimoff, 2003; Verdejo et al., 2004). For example, male addicts with a duration
of use longer than 1.5 years perform worse on a Tower of London task than addicts
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with a shorter duration of use (Bryun et al., 2001). Some chronic effects can persist
for more than a year after the last use of the drug (Pau et al., 2002), whereas some
impairments last only a short period — for example, the effect on time perception
disappears after 15 days of abstinence (Alexandrov, 2004).
Substitution treatment (methadone and buprenorphine)
The effects of substitution treatment on performance has been studied in former
heroin addicts. Dittert et al. (1999) compared the performance of 28 patients taking
methadone on reaction, visual perception and concentration tests to that of a control
group matched for age, sex and education level. The methadone-treated patients
showed signiﬁcantly reduced performance, but six of them passed the tests to a
level corresponding to sufﬁcient driving skills. Darke et al. (2000) found that patients
receiving methadone maintenance treatment show cognitive deﬁcits compared to a
control group not using heroin. The patients’ performance was signiﬁcantly worse
than that of controls on all neuropsychological domains measured: information
processing, attention, short-term visual memory, delayed visual memory, short-term
verbal memory, long-term verbal memory and problem-solving. A history of alcohol
dependence and repeated exposure to overdose increased the likelihood of cognitive
impairment. The authors remarked that it was possible that other factors (which they
did not specify) that were not measured in the study may have contributed to the
cognitive impairment. In another study in methadone-maintained patients, higher
speed in decision-making and motor reaction, but more decision errors on a simple
CRT, were observed in patients than in healthy controls (Specka et al., 2000). The
patients also showed poorer performance on an attention task and a tachistoscopic
perception task. Performing a tracking test and a test concerning visual structuring,
patients showed a higher accuracy combined with more time needed. However, the
effects were moderate and in most cases, the observed variance could be better
explained by sociodemographic features than by treatment group. The authors
suggest the need to investigate whether impairments in one area of demand are not
compensated by, for example, reducing speed. Mintzer and Stitzer (2002) found
that patients on methadone maintenance treatment exhibit impairment relative to
healthy controls in psychomotor speed, working memory, decision-making and meta-
memory. The results also suggested possible impairment in inhibitory mechanisms.
There was no impairment observed in time estimation, conceptual ﬂexibility or
long-term memory. The control group used in these three studies (Darke et al., 2000;
Mintzer and Stitzer, 2002; Specka et al., 2000) consisted of subjects who were not
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addicted to heroin. The observed effects in the patients on methadone could thus
partially be caused by the heroin addiction instead of the methadone treatment.
Some experimental studies have tried to differentiate between impairment caused
by heroin addiction and impairment caused by methadone treatment. Davis et
al. (2002) compared neuropsychological performance in methadone-maintained
patients with that of drug-free ex-opiate users and of matched controls with no
history of drug abuse. Methadone-maintained patients performed more poorly on
a measure of verbal ﬂuency than the two control groups. The performance of the
drug-free ex-opiate users fell between that of the other two groups, without signiﬁcant
differences. Verdejo et al. (2005) also compared patients on methadone maintenance
treatment patients with abstinent heroin users in terms of neuropsychological
performance. A signiﬁcantly slower performance was seen in methadone patients
on processing speed, visuospatial attention and cognitive ﬂexibility tests, and less
accuracy was observed on working memory and analogical reasoning tests. Mintzer
et al. (2005) also observed that cognitive and psychomotor performance of patients
on methadone maintenance treatment was worse than that of abstinent former opioid
users, whose performance was in turn worse than that of healthy control subjects.
These data suggest that methadone maintenance may be associated with additional
impairment over and above that associated with long-term heroin abuse. Gruber et
al. (2006) compared cognitive function in 17 opiate-dependent subjects at baseline
and after two months of methadone treatment. Signiﬁcant improvements from
baseline were seen in measures of verbal learning and memory, visuospatial memory
and psychomotor speed. These improvements remained signiﬁcant after co-varying
for illicit drug use. The authors suggest that impairment caused by methadone
maintenance treatment may be reversible.
In a randomised controlled trial comparing the effects of a 28-day withdrawal
treatment with either buprenorphine or clonidine on DSST performance in
opioid-dependent adolescents, no evidence of psychomotor impairment was
observed (Marsch et al., 2005). Mintzer et al. (2004) evaluated the dose-effects
of buprenorphine/naloxone combination therapy in opioid-dependent volunteers
following a period of 7–10 days of administration, in a double-blind, within-
subject, crossover design. The tests included measures of psychomotor speed,
time perception, conceptual ﬂexibility, focused attention, working memory, long-
term/episodic memory and meta-memory. Results revealed little impairment in
performance as the dose was increased four-fold (from 8/2 mg to 32/8 mg).
F
o
r
m
a
t
:
(
1
4
8
.
0
0
x
2
1
0
.
0
0
m
m
)
;
D
a
t
e
:
1
2
0
2
,
2
0
0
8
0
7
:
5
3
:
3
9
;
O
u
t
p
u
t
P
r
o
f
i
l
e
:
S
P
O
T
I
S
O
C
o
a
t
e
d
v
2
(
E
C
I
)
;
I
n
k
S
a
v
e
2
8
0
Drug use, impaired driving and trafﬁc accidents
66
The only signiﬁcant effect of dose was impairment in episodic/long-term memory
performance at the highest dose, relative to the two lower doses.
Rogers et al. (1999) assessed decision-making in 13 opiate users, three of whom
were currently using heroin and 10 were receiving methadone. The opiate users were
found to deliberate signiﬁcantly longer before making their choices than healthy
volunteers. There was, however, no difference in the quality of decision-making
Comparison of chronic effects of the two main substitution treatments
Soyka et al. (2001) found an overall better psychomotor performance in patients
taking buprenorphine than in those taking methadone, especially in tests under stress
conditions and monotony. These ﬁndings were conﬁrmed by several other studies.
Schindler et al. (2004) found that opioid-dependent patients receiving maintenance
treatment with either methadone or buprenorphine performed worse than controls
on an attention test under monotonous circumstances and on decision and
reaction time while driving in a dynamic environment. However, when separated
into treatment groups, the mean decision and reaction times of buprenorphine-
maintained patients did not differ from controls, whereas patients on methadone
showed signiﬁcantly prolonged mean decision and reaction times. A controlled
clinical study also showed that buprenorphine produces partially less impairment
of cognitive functions on psychomotor testing than methadone (Soyka et al., 2005).
Pirastu et al. (2006) evaluated decision-making in individuals on maintenance
treatment with methadone or buprenorphine and in a control group of subjects who
were not drug-dependent. Subjects on buprenorphine performed better on the Iowa
gambling task than those taking methadone, and about the same as the control
group. The methadone group had more perseverative errors on the WCST compared
with the control group whereas the buprenorphine group had intermediate scores.
Scores on the WAIS-revised and the BVRT were similar for both opiate-dependent
groups whereas the drug-free control group had signiﬁcantly higher scores. The
effects of methadone and buprenorphine substitution treatment on performance in
a driving simulator were studied by Lenné et al. (2003). All participants attended
one session without alcohol and one session with alcohol (BAC of 0.05%). SDLP,
speed and steering wheel angle were used to measure simulated driving skills, and
reaction time to a subsidiary task was also assessed. While the combination with
alcohol impaired all measures of driving performance, there were no differences in
driving skills across the participant groups. Giacomuzzi et al. (2005b) compared the
driving capacity of drug-dependent patients using buprenorphine or slow-release
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oral morphine. The data indicated better psychomotor performance in patients
taking buprenorphine, especially on the Visual Pursuit Test. The same researchers
compared the driving capacity of patients treated with methadone or slow-release
oral morphine, and observed better psychomotor performance in patients taking
methadone (Giacomuzzi et al., 2005a).
McNamara (2002) studied cognitive function and well-being in patients switching
treatment from morphine to transdermal fentanyl. Cognitive function tests revealed a
signiﬁcant improvement in working (short-term) memory and speed of memory although
not in secondary (long-term) memory. The incidence of dizziness was signiﬁcantly
reduced, and sleepiness and drowsiness were signiﬁcantly less of a problem.
Risks
Accident risk
In a longitudinal study of 13 548 participants from a cohort study of workers in France
from 1989 to 2000, the risk of a serious accident was compared among participants
who did and did not report a speciﬁc health problem during the 12 months before the
accident (Lagarde et al., 2005). The results indicated that pain and treatment for pain
could increase the risk of a road trafﬁc accident.
Four epidemiological studies have investigated the risk of being involved in a trafﬁc
accident while driving under the inﬂuence of opiates. A case-control study in Canada
showed that driving under the inﬂuence of opiates is not associated with an increased
accident risk (RR 2.1, 95% CI: 0.8–5.3) (Dussault et al., 2002). In contrast, a case-
control study in France found that morphine use is associated with an increased
accident risk (OR 8.2, 95% CI: 2.5–27.3) (Laumon et al., 2005). In the Netherlands,
the Immortal study found that use of codeine alone is not associated with an increased
accident risk (RR 3.0, 95% CI: 0.7–14.2), while heroin and morphine alone are
associated with an increased accident risk of 32.4 (OR, 95% CI: 1.8–592.0) (Assum et
al., 2005). The results of the Immortal study in Norway also showed that driving under
the inﬂuence of opiates alone (morphine, heroin or codeine) is associated with an
increased accident risk of 13.8 (OR, 95% CI: 1.2–154.2) (Assum et al., 2005).
Responsibility analyses
Three epidemiological studies studied the risk of being responsible for a trafﬁc
accident while driving under the inﬂuence of opiates. Drummer et al. (2004) found
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that driving under the inﬂuence of opiates alone is not associated with an increased
risk of being responsible for an accident (OR 1.4, 95% CI: 0.7–2.9). According to
the authors, however, this does not mean that opiate use does not increase the risk
of a driver being responsible for a crash. Because 65% of the opiate-positive drivers
in the study who were also using other drugs (predominantly benzodiazepines and
cannabis) were excluded from the analysis, the statistical power of the analysis was
greatly reduced. Also, some drivers would have been tolerant to the effects of opiates
and effectively misclassiﬁed as opiate-intoxicated, further reducing the study’s ability
to detect a real association between opiates and accident responsibility. Dussault
et al. (2002) found that driving under the inﬂuence of opiates is associated with
an inﬁnite risk of being responsible for an accident. This is probably caused by the
fact that of the limited number of fatally injured drivers testing positive for opiates,
all drivers were judged responsible for the accident. In a study by Laumon et al.
(2005), a blood concentration of opiates above 20 ng/ml was not associated with
an increased risk of being responsible for a fatal accident (OR 0.9, 95% CI: 0.6–1.5);
however, the OR was not adjusted for confounding factors.
Meta-analysis
It was not possible to conduct a meta-analysis (11) on the data from the responsibility
analyses. It was possible to conduct a meta-analysis on the data from the Immortal
studies in Norway and the Netherlands that assessed the accident risk while driving
under the inﬂuence of opiates alone (Assum et al., 2005). The results indicate that
drivers under the inﬂuence of opiates alone are at increased risk of being involved
in an accident, as indicated by RR of 3.2 (95% CI: 1.4–6.9) and an OR of 3.7
(95% CI: 1.4–10.0).
Conclusion
Opiates acutely cause some cognitive and psychomotor impairment, but these are
highly dependent on the type of opiate and the dose administered. The effects are
mostly moderate. Morphine tends to slow users’ responses, though accuracy is not
diminished. Fentanyl produces cognitive impairment in doses common in out-patient
surgical procedures, but shows little impairment effect when used for longer-term
pain management. With use of heroin, severe impairment can be expected; however,
(11) A meta-analysis is a statistical analysis of a large collection of analysis results from
individual studies. The meta-analysis performed in this report was computed using the
statistical programme MedCalc.
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no recent experimental studies have been conducted using doses that approximate
realistic doses. Heroin users show clear impairment of psychomotor and cognitive
skills, some of which can last for more than a year after the last use of the drug.
Some of the impairments are related to the severity of dependence and the duration
of use. Acute effects of methadone can be avoided by dividing the daily dose.
Methadone maintenance treatment does cause impairment, including additional
impairment over and above that associated with heroin dependence, though this
latter can in some cases be better explained by other associated risk factors. The
results of one study suggest that impairment caused by methadone maintenance
treatment may be reversible. Buprenorphine users have not generally shown
impairment, except at high doses.
Patients on long-term opioid therapy exhibit some impairment of psychomotor and
cognitive performance. However, the effect of the opioid drug itself on impairment in
patients taking opioid maintenance therapy is unclear. Other factors, such as the disease
and pain, seem to be of greater importance than the effects of the opioids, per se.
The limited epidemiological studies demonstrate inconclusive evidence on the
accident risk associated with opiate use. Some studies found signiﬁcantly elevated
accident risks associated with driving under the inﬂuence of opiates. Two out of
three responsibility analyses found no increased risk of being responsible for an
accident while under the inﬂuence of opiates, whereas the third found that opiates
were associated with an inﬁnite risk of being responsible for a trafﬁc accident. Future
studies should investigate whether this could be because of the limitations inherent to
the responsibility analyses.
Amphetamines
On the illicit drug market, the main representatives of the amphetamines group
are amphetamine, methamphetamine and their salts. MDMA is also a derivative of
amphetamine and a member of the phenethylamine family (as are amphetamine
and methamphetamine).
It is important to mention that the doses of amphetamine and methamphetamine
administered in the following experimental studies were very low (10–30 mg) and
thus not representative of realistic situations (100–1000 mg/day) (Couper and
Logan, 2004b).
No recent experimental studies were found for the designer amphetamines MDA,
MDEA and N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB).
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Acute effects
Amphetamine
Laboratory studies investigating the effects of (dextro)amphetamine (12) on
performance on neurocognitive measures by non-fatigued healthy adults found
varying results. McKetin et al. (1999) found that 10 and 20 mg dextroamphetamine
produced a dose-response increase in hit-rate and a decrease in reaction time
without changing false alarm rate during a complex auditory selective attention
task. Asghar et al. (2003) also found that the use of dextroamphetamine (25 mg)
decreased reaction times. Dextroamphetamine (10 mg) enhances performance
Pharmacology of amphetamine
Amphetamine is a central nervous system stimulant that causes hypertension and
tachycardia with feelings of increased conﬁdence, sociability and energy. It
suppresses appetite and fatigue and leads to insomnia. Following oral use, the
effects usually start within 30 minutes and last for many hours. Later, users may
feel irritable, restless, anxious, depressed and lethargic. Amphetamine is less
potent than methamphetamine, but in uncontrolled situations the effects are almost
indistinguishable. It is rapidly absorbed after oral administration. After a single oral
dose of 10 mg, maximum plasma levels are around 0.02 mg/l. The plasma half-
life varies from 4 to 12 hours and is dependent on the urinary pH: alkaline urine
decreases the rate of elimination. Analysis of amphetamine in urine is confounded
because it is a metabolite of methamphetamine and certain medicinal products.
Acute intoxication causes serious cardiovascular disturbances as well as behavioural
problems that include agitation, confusion, paranoia, impulsivity and violence.
Chronic use of amphetamine causes neurochemical and neuroanatomical changes.
Dependence — as shown by increased tolerance — results in deﬁcits in memory
and in decision-making and verbal reasoning. Some of the symptoms resemble
those of paranoid schizophrenia. These effects may outlast drug use, although often
they resolve eventually. Fatalities directly attributed to amphetamine are rare. The
estimated minimum lethal dose in non-addicted adults is 200 mg.
Source: EMCDDA drug proﬁles (http://www.emcdda.europa.eu/publications/drug-proﬁles).
(12) Dextroamphetamine is the d form of amphetamine (which is more active than the l form).
For more details, the reader can refer to: http://www.emcdda.europa.eu/publications/
drug-proﬁles/amphetamine
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on single-target and divided-attention responses in different parts of the visual
ﬁeld (Mills et al., 2001). Another study found individual-speciﬁc effects of
dextroamphetamine (0.25 mg/kg) on working memory, with improved performance
in subjects who had relatively low working-memory capacity at baseline and
deteriorated performance in subjects with high working-memory capacity at
baseline (Mattay et al., 2000). Barch and Carter (2005) also observed that
dextroamphetamine (0.25 mg/kg) has positive effects on cognitive function, namely
improved reaction times on the spatial working memory and Stroop tasks, improved
working memory accuracy and improved language production. Silber et al. (2006)
found that dextroamphetamine (0.42 mg/kg) improves various aspects of attention
(reaction time during digit vigilance, DSST and movement estimation performance),
and some aspects of psychomotor functioning (tracking ability) and perceptual speed
(inspection time). Experimental studies on the effect of dextroamphetamine (10 and
20 mg) on impulsivity and decision-making showed a decrease in several forms of
impulsive behaviour, while alcohol (0.2, 0.4 and 0.8 g/l) showed the opposite effect
(de Wit et al., 2000, 2002). Some laboratory studies, however, report negative acute
effects of amphetamine on neurocognitive performance. Hutchison and Swift (1999)
found that 20 mg dextroamphetamine causes subtle but signiﬁcant negative effects
on prepulse inhibition of the startle reﬂex, reﬂecting deﬁcits in the ability to ﬁlter out
irrelevant or intrusive stimuli, which subsequently causes an overload of information.
This ﬁnding was conﬁrmed by Swerdlow et al. (2003).
Silber et al. (2005) found during tests in a driving simulator that the intake of
dextroamphetamine (0.42 mg/kg) causes a decrease in overall simulated driving
performance by inducing problems such as incorrect signalling, failing to stop at a
red trafﬁc light and slow reaction times. The decrease in simulated driving ability
was only observed during the daytime, which is consistent with the tunnel vision that
is associated with amphetamine consumption (Mills et al., 2001; Silber et al., 2005).
Other studies have assessed the effects of dextroamphetamine during sleep
deprivation. Wesensten et al. (2005) investigated the effects of 20 mg dextro-
amphetamine on simple psychomotor tasks during sleep deprivation and found that it
improved psychomotor vigilance speed relative to placebo. The effects of the drug on
cognitive function during sleep deprivation are unclear. Mills et al. (2001) found that
10 mg of dextroamphetamine had no performance-enhancing effect, while Wesensten
et al. (2005) observed improvement on some aspects (e.g. learning to learn on WCST)
and impairment on others (e.g. performance on Stroop test) after administration of
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20 mg dextroamphetamine. Magill et al. (2003) examined the effects of tyrosine
(150 mg/kg), phentermine (37.5 mg), caffeine (300 mg/70 kg), dextroamphetamine
(20 mg) or placebo on cognitive and motor performance in healthy young men during
sleep deprivation. The substances were administered at 15.30 following overnight
sleep deprivation. Performance decrements with sleep deprivation occurred in visual
scanning, running memory, logical reasoning, mathematical processing, the Stroop
test, the time wall test, tracking and visual vigilance. The statistical comparisons of
task performances 1.5 and 5.5 hours after drug administration with performances
at the 13.00 pre-drug baseline session, showed that dextroamphetamine improved
performance at both post-drug sessions for all tasks in which subjects had shown
impairment due to sleep deprivation — except one task. The exception was in logical
reasoning 1.5 hours post-drug administration. However, this effect was signiﬁcantly
improved 5.5 hours after dextroamphetamine administration.
Jones and Holmgren (2005) presented a case series of individuals apprehended
in Sweden for DUID who had abnormally high concentrations of amphetamine in
their blood (> 5.0 mg/l). The commonest signs of drug use reported by the arresting
ofﬁcers were bloodshot and glazed eyes, restlessness, talkativeness, exaggerated
reﬂexes and slurred speech. Unsteady gait and dilated pupils were observed in
some, but not all individuals.
Methamphetamine
In healthy volunteers, Comer et al. (2001) found no effect of 5 or 10 mg
methamphetamine on performance on a battery of tests consisting of a DSST, a
repeated acquisition task, a divided attention task, a rapid information processing
task and an immediate and delayed digit-recall task. Laboratory studies using higher
doses did ﬁnd acute effects on cognitive and psychomotor performance. Johnson
et al. (2000) investigated the cognitive effects induced by d-methamphetamine (13)
(0.21 or 0.42 mg/kg) in healthy volunteers. They found an increase in mean hits and
decreases in mean false hits and mean reaction time on the RVIPT. On the logical
reasoning test, d-methamphetamine signiﬁcantly improved percent correct/time ratio.
There was no effect on FTT, a measure of motor speed. The same research group
(13) There are three different types of methamphetamine (d, d/l and l) and each affects the
central nervous system differently. The most common types are the dextro/levo (d/l) and
dextro (d) types. The most powerful is d -methamphetamine (3–4 times more powerful
than l -methamphetamine).
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studied the effects of d-methamphetamine (15 and 30 mg) in methamphetamine-
dependent individuals and found a dose-dependent increase in attention,
concentration and psychomotor performance (Johnson et al., 2005, 2007).
Silber et al. (2006) assessed the acute effects of 0.42 mg/kg d-methamphetamine
and d,l-methamphetamine on driving-related cognitive functions in healthy
volunteers. Both kinds of methamphetamine improved attention (digit vigilance,
DSST and movement estimation), psychomotor performance (tracking ability) and
perceptual speed (inspection time).
MDMA
Laboratory studies have variously shown negative, positive as well as no effects of
MDMA on driving-related abilities. Cami et al. (2000) found that MDMA (75 mg or
125 mg) produced a mild decrease in responses in the DSST in healthy volunteers.
Only the 125 mg dose induced esophoria in the Maddox wing device. Hernandez-
Pharmacology of methamphetamine
Methamphetamine is a central nervous system stimulant that causes hypertension
and tachycardia with feelings of increased conﬁdence, sociability and energy.
It suppresses appetite and fatigue and leads to insomnia. Following oral use, the
effects usually start within 30 minutes and last for many hours. Later, users may feel
irritable, restless, anxious, depressed and lethargic. Methamphetamine has higher
potency than amphetamine, but in uncontrolled situations the effects are almost
indistinguishable. It is rapidly absorbed after oral administration, and maximum
plasma levels are in the range 0.001–0.005 mg/l. The plasma half-life is about
nine hours. Fatalities directly attributed to methamphetamine are rare. In most fatal
poisonings the blood concentration is above 0.5 mg/l. Analysis of methamphetamine
in urine is confounded because it is a metabolite of certain medicinal products
(e.g. selegiline). Acute intoxication causes serious cardiovascular disturbances
as well as behavioural problems that include agitation, confusion, paranoia,
impulsivity and violence. Chronic use of methamphetamine causes neurochemical
and neuroanatomical changes. Dependence — as shown by increased tolerance —
results in deﬁcits in memory and in decision-making and verbal reasoning. Some of
the symptoms resemble those of paranoid schizophrenia. These effects may outlast
drug use, although often they resolve eventually.
Source: EMCDDA drug proﬁles (http://www.emcdda.europa.eu/publications/drug-proﬁles).
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Lopez et al. (2002) investigated the effects of MDMA (100 mg) on psychomotor
performance in healthy volunteers, but they found no effect on performance on the
DSST, SRT or the Maddox wing device. MDMA (100 mg) given in two successive
doses separated by an interval of 24 hours was studied by Farré et al. (2004). In
the DSST task, both doses slightly decreased the total number of DSST responses,
but these changes were not signiﬁcant. MDMA did not produce signiﬁcant effects on
reaction time. Both doses produced similar levels of esophoria in the Maddox wing
device. In a study in recreational MDMA users, a single dose of MDMA (75 mg)
was administered and cognition, psychomotor performance and driving-related task
performance were assessed (Lamers et al., 2003). MDMA improved psychomotor
performance, such as movement speed and tracking performance in a single task
as well as in a divided attention task. The ability to predict object movement under
divided attention was impaired in the subjects. There was no effect of MDMA on
visual search, planning or retrieval from semantic memory. Ramaekers et al. (2004)
examined MDMA (75 mg) and cognition in recreational MDMA users. A single
dose impaired performance on spatial and verbal working memory tasks 1.5 to
2.5 hours after administration. MDMA showed no effect on behavioural measures of
impulsivity. Smith et al. (2006) conducted neuropsychological assessments in
13 MDMA users, 10 to 15 hours after last use and in a control group. The MDMA
Pharmacology of MDMA (ecstasy)
Ingestion of MDMA causes euphoria, increased sensory awareness and mild
central stimulation. The terms ‘empathogenic’ and ‘entactogenic’ have been coined
to describe the socialising effects of MDMA. Following ingestion, most of the
dose of MDMA is excreted in the urine, unchanged. Following a dose of 75 mg,
the maximum plasma concentration of around 0.13 mg/l is reached within two
hours. The plasma half-life is 6–7 hours. In animals, MDMA causes neurotoxicity,
as evidenced by anatomical changes in axon structure and a persisting reduction
in brain serotonin levels. The signiﬁcance of these ﬁndings to human users is still
unclear, although cognitive impairment is associated with MDMA use. Some of the
pharmacodynamic and toxic effects of MDMA vary, depending on which enantiomer
is used. However, almost all illicit MDMA exists as a racemic mixture. Fatalities
following a dose of 300 mg have been noted, but toxicity depends on many factors,
including individual susceptibility and the circumstances in which MDMA is used.
Source: EMCDDA drug proﬁles (http://www.emcdda.europa.eu/publications/drug-proﬁles).
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users showed impairments on measures of executive function and short-delay free
recall memory. No extrapyramidal motor impairments were detected.
Tests in driving simulators revealed that the consumption of MDMA can decrease
performance. De Waard et al. (2000) conducted driving simulator tests in a group
of young people who had indicated that they regularly use MDMA. They were tested
shortly after the use of MDMA, before going to a party, and then again while sober
on a control night at a comparable time. Under the inﬂuence of MDMA, subjects
drove faster, but only in the built-up area with a speed limit of 50 km/h. Speed
variance increased as well, both in the city and on the motorway. Lateral control and
gap acceptance behaviour was not affected. Crashes occurred during two of the
20 control rides, and four times while under the inﬂuence of MDMA, a 100% increase.
In another study in recreational MDMA users, subjects took a real on-the-road
driving test three to ﬁve hours after use of MDMA (75 mg) (Ramaekers et al., 2004).
MDMA signiﬁcantly decreased SDLP by 2 cm relative to placebo, and decreased
performance during the car-following test. There were no effects on time to speed
adaptation and BRT.
The doses given in the experimental studies on MDMA (75–125 mg) resemble the doses
used by recreational MDMA users (average: 120 mg) (Couper and Logan, 2004b).
Combination of MDMA with other psychoactive substances
Hernandez-Lopez et al. (2002) investigated the effects of MDMA (100 mg) with or
without alcohol (0.8 g/l) on psychomotor performance in healthy volunteers. The
combination of alcohol and MDMA produced a similar impairment to that of alcohol
alone in scores on the DSST, but a signiﬁcant decrease in the number of total and
correct responses compared with placebo and MDMA. MDMA partially reverted
the exophoria induced by alcohol in the Maddox wing test. SRT was signiﬁcantly
increased for the combination of MDMA and alcohol, but not for alcohol alone or
MDMA alone. Brookhuis et al. (2004) asked a group of young participants who
had indicated that they regularly used MDMA to complete test rides in a driving
simulator shortly after having used MDMA, just before going to a party. They were
tested again after having visited the ‘rave’, while they were under the inﬂuence of
MDMA and a number of other drugs, and then again when they were sober, at a
comparable time at night. Separately, a control group of participants was included
in the experiment. Driving performance in terms of lateral and longitudinal vehicle
control was not greatly affected after MDMA use but deteriorated after multiple drug
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use. The most striking result was the apparent decreased sense for risk taking, both
after taking MDMA and after multiple drug use, as was shown by the signiﬁcantly
smaller accepted gaps than in the non-drug condition. Accident involvement or even
causation was increased by 100% and 150% after MDMA use and multiple drug
use, respectively. However, Ramaekers et al. (2004) found that the use of MDMA
(75 mg or 100 mg) can diminish some, but not all, deleterious effects of alcohol
(0.5–0.6‰), while other negative effects of alcohol can be reinforced.
Duration of effects of amphetamines
Effects on cognitive and psychomotor skills have been assessed for up to three
to four hours after administration of amphetamine (Asghar et al., 2003; Barch
and Carter, 2005; de Wit et al., 2000, 2002; Hutchison and Swift, 1999) and
methamphetamine (Johnson et al., 2000, 2005, 2007; Silber et al., 2006). With
MDMA use, the duration of the subjective ‘positive’ effects is less than 24 hours,
but thereafter the ‘crash’ phase starts, with the subject feeling very tired, unable to
combat sleep and even depressed, which can last for several days (Verheyden et al.,
2003). These negative after-effects increase with successive doses, while the positive
subjective effects diminish (Hegadoren et al., 1999). The effects on psychomotor
performance can last for more than ﬁve hours (Lamers et al., 2003). The duration
of the cognitive effects is unclear. Some studies show that the negative effects on
cognitive performance, especially verbal memory, can last for several days (Smith et
al. 2006), while others found that impairments disappear after a few hours (Farré et
al., 2004) or 24 hours after last use (de Waard et al., 2000).
Chronic effects
Experimental studies of the chronic effects of amphetamine use have shown deﬁcits
in decision-making, attention and memory (McKetin and Solowij, 1999; Ornstein
et al., 2000; Rapeli et al., 2005; Rogers et al., 1999). Some of these deﬁcits are
correlated with increasing years of use (Rogers et al., 1999) or increasing severity of
use (McKetin and Solowij, 1999). Rapeli et al. (2005), however, found that attention
deﬁcits of recently detoxiﬁed amphetamine users may be reversible, although recovery
of verbal memory is not complete even after long-term abstinence. The chronic
effects associated with the use of methamphetamine are deﬁcits in memory, attention,
response inhibition and psychomotor speed and an increase in impulsivity (Chang et
al., 2002; Chou et al., 2004; Hoffman et al., 2006; Johanson et al., 2006; Monterosso
et al., 2005; Newton et al., 2004; Salo et al., 2002, 2005; Simon et al., 2000;
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Volkow et al., 2001). Some of these deﬁcits might persist even after a long period of
abstinence (Chang et al., 2002; Hoffman et al., 2006; Johanson et al., 2006; Salo
et al., 2002, 2005; Volkow et al., 2001), while others can be reversed after a short
period of abstinence (Chou et al., 2004).
MDMA users are aware of the consequences of their chronic use and report the
development of tolerance and impaired ability to concentrate (Verheyden et al.,
2003). In experimental studies, the consequences of chronic amphetamine or MDMA
use on cognitive functions include a decrease in executive functioning, attention and
memory and an increased impulsivity. Some of these impairments become more
prominent with increasing severity of use, and might persist up to two years since the
last use of the drug (Gouzoulis-Mayfrank et al., 2000; Mccann et al., 1999; Quednow
et al., 2007; Rizzo et al., 2005; Verdejo et al., 2004; Wareing et al., 2004).
Risks
In Norway, Gustavsen et al. (2006) investigated the concentration-effect relationship
between blood amphetamine concentrations and impairment in a population of real-
life users. They selected 878 cases with amphetamine or methamphetamine as the only
drug present in blood samples from the impaired driver registry at the Norwegian
Institute of Public Health. In each case, the police physician had determined whether the
driver was impaired or not; 27% were judged not impaired, while 73% were judged
impaired. A positive relationship was found between blood amphetamine concentration
and impairment, but it reached a ceiling at concentrations of 270–530 ng/ml.
Accident involvement
Of the four epidemiological studies investigating the accident risk associated with
driving under the inﬂuence of amphetamines, three studies — one in France (Mura
et al., 2003) and the Immortal studies in the Netherlands and Norway (Assum et
al., 2005) — could not calculate the risks because the number of cases positive
for amphetamines was too low. The fourth, a study in Canada, found that driving
under the inﬂuence of amphetamines is associated with an increased accident risk
of 12.8 (OR, 95% CI: 3.0–54.0) (Dussault et al., 2002).
Responsibility analyses
Four epidemiological studies evaluated the risk of being responsible for an accident
while driving under the inﬂuence of amphetamines, including two in Australia. In one
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of these, Drummer et al. (2004) conducted a responsibility analysis in 3 398 fatally
injured drivers. They did not calculate the risks associated with amphetamines
alone, but with a group of substances acting as stimulants, namely amphetamine,
methamphetamine, MDMA, ephedrine, pseudoephedrine, phentermine and cocaine.
There was no signiﬁcant association between stimulants use and crash responsibility.
However, when truckers were considered as a discrete driver type, the OR increased
to 8.8 and was of borderline statistical signiﬁcance (95% CI: 1.0–77.8). In the
other study in Australia, Longo et al. (2000b) also calculated the risks associated
with a group of substances acting as stimulants, but these included amphetamine,
methamphetamine, phentermine, pseudoephedrine, ephedrine and MDEA. They
found that there was no signiﬁcantly increased responsibility risk associated with
driving under the inﬂuence of stimulants alone.
Two studies looked at the responsibility risk associated with amphetamines
only. In Canada, Dussault et al. (2002) found that driving under the inﬂuence of
amphetamines is associated with an inﬁnite risk of being responsible for an accident.
This is probably caused by the fact that only a limited number of fatally injured
drivers tested positive for amphetamines and that all these drivers were judged
responsible for the accident. A responsibility analysis in France found amphetamines
to be associated with an increased risk of being responsible for an accident (3.8 OR,
95% CI: 1.5–9.5) (Laumon et al., 2005). However, after adjustment for confounding
factors such as age, sex, vehicle type and time of crash, the increase in risk was no
longer signiﬁcant (2.0 OR, 95% CI: 0.7–5.3).
The relationship between amphetamine use and the severity of a trafﬁc accident
was examined in one epidemiological study. In the Netherlands, Smink et al. (2005)
analysed blood sample data from drivers involved in crashes from October 1998
through September 1999. The blood samples had been screened for the presence
of alcohol, illicit drugs and medicinal drugs. The strength of the association between
exposure to the different classes of substances and the severity of the accident was
evaluated using logistic regression analysis. The results showed no association
between the use of amphetamines and amphetamine-like substances and the severity
of a trafﬁc accident.
Meta-analysis
There were insufﬁcient data to conduct a meta-analysis on the risk of being involved
in or responsible for an accident while driving under the inﬂuence of amphetamines.
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Conclusion
Experimental studies show that methamphetamine and amphetamine can cause positive
stimulating effects on cognitive and psychomotor functions, especially in fatigued or
sleep-deprived persons. Negative effects are also observed, such as an overall reduced
driving capacity in a simulator during daytime. However, the doses used in these
studies are not representative for the doses actually consumed by users of these drugs.
Experimental studies of MDMA also found both negative and positive effects
on performance. Positive effects include a decrease in SDLP and an increase in
psychomotor speed, while negative effects include an increase in speed and speed
variance and a decrease in the ability to follow a car. Other psychoactive substances
such as alcohol can reinforce the deleterious effects of MDMA, and even cause
some additional negative effects. The use of MDMA can diminish some, but not all,
deleterious effects of alcohol, while other negative effects of alcohol can be reinforced.
The chronic use of amphetamines causes negative effects on cognitive and
psychomotor skills, which last longer than the period of intoxication and are
sometimes correlated with the severity or duration of use.
Epidemiological data on the risks associated with the use of amphetamines are rare.
Results from one out of four available studies on accident involvement indicate that
amphetamines are associated with an increased risk of involvement in an accident.
In the amphetamine studies that investigated responsibility, no signiﬁcant increased
risk of being responsible for an accident was found. A study of drivers involved in
accidents while under the inﬂuence of amphetamines found no association between
the use of the drugs and the severity of the accident.
Cocaine
Acute effects
Only two recent experimental studies were found on the acute effects of cocaine on
performance. Rush et al. (1999) administered a wide range of doses of oral cocaine
(50, 100, 200 and 300 mg) or placebo to nine volunteers with recent histories of
cocaine use. Their performance on DSST was assessed before drug administration
and periodically afterwards for ﬁve hours. Performance was not affected in this
study, although previous studies found performance-enhancing effects with acute
administration. Rush et al. (1999) remarked that the subjects in the previous studies
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reported substantially less cocaine use than the subjects in their own study, who may
have developed tolerance to cocaine’s performance-enhancing effects. Furthermore,
the route of administration was oral in their own study (producing less and a slower
onset of effects) while in one of the previous studies it was intranasal.
A study by Hopper et al. (2004) found no effect of a low dose of cocaine
(0.2 mg/kg) on measures of attention, recall or recognition task performance.
As acute cocaine administration can induce hypercortisolaemia (associated with
symptoms such as mania, depression, poor concentration and hyperactivity), the
researchers also investigated the effects of cortisol on performance. A low dose
of cortisol (0.2 mg/kg) enhanced and a high dose (0.5 mg/kg) impaired vigilance
attention, and a trend was found for the same dose-response proﬁle on twice-heard
words. An opposite trend was observed for recognition: cortisol at a low dose
impaired and at a high dose enhanced recognition of once-heard words, and a very
weak trend was found for recognition of new words. The authors conclude that these
results should be interpreted with caution, given several methodological limitations
(e.g. the low dose of cocaine), but that these ﬁndings suggest that the effects of
cocaine can be inﬂuenced by the induction of hypercortisolaemia.
Combination with other psychoactive substances
No experimental studies on the effects of the combination of cocaine with another
psychoactive substance were found that were published in 1999 or later. Therefore,
a short overview will be given of studies published before 1999.
Pharmacology of cocaine
Cocaine has a similar psychomotor stimulant effect to that of amphetamine and related
compounds. Like amphetamine, it produces euphoria, tachycardia, hypertension
and appetite suppression. Cocaine has a strong reinforcing action, causing a rapid
psychological dependence, an effect even more pronounced in those who smoke
cocaine base. Following a 25 mg dose, blood levels peak in the range 400–700 μg/l
depending on the route of administration. When consumed with alcohol, cocaine also
produces the metabolite cocaethylene. Some unchanged cocaine is found in the urine.
The plasma half-life of cocaine is 0.7–1.5 hours and is dose-dependent. The estimated
minimal lethal dose is 1.2 g, but susceptible individuals have died from as little as
30 mg applied to mucous membranes, whereas addicts may tolerate up to 5 g daily.
Source: EMCDDA drug proﬁles (http://www.emcdda.europa.eu/publications/drug-proﬁles).
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These studies show that cocaine can partially diminish performance impairments
caused by alcohol consumption. The use of a combination of alcohol and cocaine
decreases psychomotor impairment and improves performance on cognitive tests when
compared to the use of alcohol alone (Farré et al., 1993; Foltin et al., 1993). Cocaine
use also reduces the subjective feeling of drunkenness caused by alcohol (Farré et
al., 1993; Foltin et al., 1993). The combined use of cocaine (96 mg cocaine HCl) and
cannabis (2.7% THC) can cause additional performance decrements that are not
caused by either drug alone, such as impaired performance on a repeated acquisition
task (Foltin et al., 1993).
Chronic effects
Chronic use of cocaine can cause deﬁciencies in users, such as difﬁculties in
processing cognitive tasks concerning attention, visuospatial perception, memory,
cognitive ﬂexibility, perceptual-motor speed, problem-solving, abstraction and
executive functioning (Di Sclafani et al., 2002; Goldstein et al., 2004; Kelley et
al., 2005; Lawton-Craddock et al., 2003; Rahman and Clarke, 2005; Smelson et
al., 1999; Toomey et al., 2003). One study found no effects on attention or spatial
memory (Kelley et al., 2005). Chronic cocaine use is also associated with an effect
on behaviour, namely an increase in impulsive behaviour (Moeller et al., 2004).
Chronic use of alcohol or cocaine selectively affects performance on different
neurobehavioural tests in a dose-dependent way (Bolla et al., 2000). However, their
combined use may not cause additional negative effects on the brain, as subjects
addicted to only cocaine demonstrate similar or greater neurocognitive impairments
than those who abuse both alcohol and cocaine (Di Sclafani et al., 2002; Lawton-
Craddock et al., 2003; Robinson et al., 1999).
Risks
Accident risk
Four epidemiological studies on the accident risk associated with driving under the
inﬂuence of cocaine were found. However, three of these studies, one in France
(Mura et al., 2003) and the Immortal studies in the Netherlands and Norway (Assum
et al., 2005), could not calculate the risks because the number of cases positive for
cocaine was too low. A study in Canada found that driving under the inﬂuence of
cocaine is associated with an increased accident risk of 12.2 (OR, 95% CI: 7.2–20.6)
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(Dussault et al., 2002). Driving under the inﬂuence of cocaine alone, a
combination of cocaine and cannabis, a combination of cocaine and alcohol
(BAC > 0.8‰), or a combination of cocaine, cannabis and alcohol (BAC > 0.8‰)
was associated with an increased accident risk of respectively 4.9 (OR, 95% CI:
1.4–17.4), 8.0 (OR, 95% CI: 3.1–20.7), 170.5 (OR, 95% CI: 21.2–1371.2) and
85.3 (OR, 95% CI: 9.5–767.0).
Responsibility analyses
Four accident responsibility analyses were found for driving under the inﬂuence of
cocaine. Drummer et al. (2004), in their responsibility analysis of 3 398 fatally injured
drivers, did not calculate the risks associated with driving under the inﬂuence of
cocaine alone, but a group of substances acting as stimulants, namely amphetamine,
methamphetamine, MDMA, ephedrine, pseudoephedrine, phentermine and cocaine.
There was no signiﬁcant association between stimulant use and crash responsibility,
except for the subset of truckers, in which case the OR increased to 8.8 and was of
borderline statistical signiﬁcance (95% CI: 1.0–77.8). Dussault et al. (2002) investigated
the contribution of alcohol and other drugs in fatal crashes in Québec (Canada).
They found that driving under the inﬂuence of cocaine alone, or in combination with
cannabis and/or alcohol is associated with an inﬁnite risk of being responsible for
an accident. This is probably because only a limited number of fatally injured drivers
tested positive for cocaine and that all these drivers were judged responsible for the
accident. A responsibility analysis in France found that driving under the inﬂuence
of cocaine is associated with an increased risk of being responsible for an accident
(4.4 OR, 95% CI: 1.0–19.0) (Laumon et al., 2005). However, after adjustment for
confounding factors such as age, sex, vehicle type and time of crash, the increase in
risk was no longer signiﬁcant (4.2 OR, 95% CI: 0.9–19.6). Soderstrom et al. (2005)
found that drivers under the inﬂuence of cocaine are signiﬁcantly more likely to be
responsible for a crash than drivers who are not under the inﬂuence of this drug
(2.3 OR, 95% CI: 1.4–4.0).
One epidemiological study investigated the relationship between cocaine use and
the severity of a trafﬁc accident. Smink et al. (2005) examined data from a group of
drivers that were involved in accidents in the Netherlands from October 1998 until
September 1999. All blood samples had been screened for the presence of alcohol,
illicit drugs and medicinal drugs. Logistic regression analysis showed no association
between the use of cocaine and the severity of the accident.
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Meta-analysis
There were insufﬁcient data available to conduct a meta-analysis on the studies of
cocaine use and the risk of being involved in, or responsible for an accident.
Conclusion
Few experimental studies exist on the acute effects of cocaine and these are mostly
restricted by methodological limitations, such as the administration of low doses of
cocaine. The results of the few studies that were found suggest that the effects of
cocaine can be inﬂuenced by the induction of hypercortisolaemia.
Cocaine can partially reverse some negative effects of alcohol, while detrimental
effects of other drugs such as cannabis can be reinforced. The chronic use of
cocaine can lead to cognitive defects, impaired psychomotor performance and
impulsive behaviour.
Epidemiological studies show that cocaine may increase the risk of being involved
in or responsible for an accident. Accident risk is higher when cocaine is used in
combination with another psychoactive substance, such as alcohol and/or cannabis.
Benzodiazepines and other medicines
Benzodiazepines (anxiolytics and hypnotics)
Benzodiazepines are used primarily for rapid relief of anxiety and for muscle
relaxation, sedation and anticonvulsant effects. Chemically, these substances consist
of a benzene ring fused with a diazepine ring, which has a substituted benzene
ring on its ﬁfth position. Most structures resemble the 1,4-benzodiazepine skeleton;
however, there are also 1,5-benzodiazepine derivatives (e.g. clobazam). The ﬁrst
benzene ring is sometimes substituted by a heteroaromatic system (e.g. clotiazepam).
Benzodiazepines bind to the GABAA receptor where they exert their pharmacological
effect. In contrast to the barbiturates, they modulate the effects of the neurotransmitter
GABA. In the absence of GABA, chloride channels do not open in the presence
of benzodiazepines but they do with barbiturates, which may explain the narrow
therapeutic window of the latter. Benzodiazepines tend to be safe in overdose when
taken alone. When combined with other substances, especially alcohol, lethality
is increased. At therapeutic doses, benzodiazepines do not suppress respiration
in healthy individuals. They only exert minor effects on the cardiovascular system.
Adverse effects most frequently encountered are impairment of mental and motor
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functions, drowsiness and light-headedness. The 1,5-benzodiazepine derivatives are
thought to be somewhat less sedating.
Depending on the metabolic pathway, benzodiazepines are divided into three groups:
short-acting: triazolam and midazolam;•
medium-acting: alprazolam, bromazepam, brotizolam, clotiazepam, loprazolam,•
lorazepam, lormetazepam, oxazepam and temazepam;
long-acting: clobazam, clonazepam, clorazepate, cloxazolam, diazepam, ethyl•
loﬂazepate, ﬂunitrazepam, ﬂurazepam, nitrazepam, nordazepam, prazepam
and tetrazepam.
The short-acting benzodiazepines generally do not produce a ‘hangover’ effect if
taken at bedtime. If the drug is stopped after a prolonged period of use, withdrawal
symptoms occur; they can be quite severe, especially with the short- and medium-
acting substances.
The newer benzodiazepine-like drugs (zolpidem, zaleplon and zopiclone) were
thought less likely to lead to dependence, although recent evidence suggests that
there may be no difference with the benzodiazepines.
Effects
Table A10 (Appendix) summarises the results of experimental studies
on benzodiazepines.
Short-acting benzodiazepines and benzodiazepine-like drugs
Danjou et al. (1999) compared the residual effects of administering zaleplon
(10 mg), zolpidem (10 mg) or placebo two to ﬁve hours before awakening. A battery
of tests (including CRT, DSST, CFF and LARS) were conducted after the subjects’
morning awakening. Zaleplon showed no residual effect at any time at any point,
whereas zolpidem’s effects were still apparent up to ﬁve hours after administration.
The effects of zolpidem lasted longer with this night-time administration than in
previous studies using daytime administration, according to the authors.
A comparison of zaleplon (10 or 20 mg), zolpidem (10 or 20 mg), placebo and
triazolam (0.25 mg) revealed no changes in memory or learning after 1.25 hours
and 8.25 hours with zaleplon 10 mg (Troy et al., 2000). At the 1.25 hour mark,
zolpidem 10 mg produced greater psychomotor impairment than the other
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substances. At 8.25 hours, cognitive impairment persisted for zolpidem 20 mg and
triazolam 0.25 mg.
Hindmarch et al. (2001b) administered zolpidem (10 mg) or zaleplon (10 or 20 mg)
at night-time, 5, 3 and 1 hour before awakening at 8.00 a.m., at which time tests were
conducted (including CFF, CRT, DSST and LARS). Zaleplon 10 mg did not produce any
effects, except a small one on the DSST score 1 hour after administration. Zaleplon
20 mg led to signiﬁcant residual effects on memory and performance 1 hour after
administration. Zolpidem had residual effects on DSST and Sternberg memory
scanning up to three hours following administration, and effect on CRT and delayed
free recall of words that lasted up to ﬁve hours after administration. Zolpidem 10 mg
showed more residual effects than zaleplon 20 mg.
In another night-time-administration study, Verster et al. (2002b) examined the
effects of zaleplon (10 or 20 mg) and zolpidem (10 or 20 mg) on driving ability,
memory and psychomotor performance. Driving ability was assessed 4–5 hours
after drug administration. Zaleplon did not affect performance whereas zolpidem
did so in a dose-dependent manner.
Although zaleplon generally does not impair driving, a case report by Stillwell
(2003) shows the contrary. The subject, whose blood concentration of zaleplon
was 0.13 µg/ml, showed symptoms of slow movements and reactions, and poor
coordination and lack of balance. The author concluded that higher-than-therapeutic
blood concentrations of zaleplon have the potential to cause impairment of
psychomotor functions. Logan and Couper (2001) concluded the same for zolpidem.
Whether zolpidem was used alone or in combination with other drugs, the symptoms
generally were the same. Zolpidem levels in subjects’ blood ranged from 0.08 to
1.4 mg/l. Even levels consistent with normal therapeutic concentrations have the
potential to affect driving ability.
Mintzer and Grifﬁths (2007) studied the effects on memory tasks of triazolam
(0.25 or 0.5 mg/70 kg) alone, d-amphetamine sulphate (20 or 30 mg/70 kg) alone,
or their combination. Relative to the sedative measures, d-amphetamine showed
less reversal of triazolam’s effects on the memory measures. The memory measures
ranged in degree of reversal: the most reversal was observed for reaction time
on the n-back working memory task and the least reversal for accuracy on the
Sternberg working memory task.
F
o
r
m
a
t
:
(
1
4
8
.
0
0
x
2
1
0
.
0
0
m
m
)
;
D
a
t
e
:
1
2
0
2
,
2
0
0
8
0
7
:
5
3
:
4
3
;
O
u
t
p
u
t
P
r
o
f
i
l
e
:
S
P
O
T
I
S
O
C
o
a
t
e
d
v
2
(
E
C
I
)
;
I
n
k
S
a
v
e
2
8
0
Drug use, impaired driving and trafﬁc accidents
86
An overview of the pharmacodynamic proﬁle of zaleplon is given by Patat et al.
(2001). In young adults, the recommended dose of zaleplon, 10 mg, produced
minimal or no impairment of psychomotor function and memory performance even
when administered at night as little as one hour before awakening. No impairment
of actual driving was observed when zaleplon 10 mg was administered either
at bedtime or in the middle of the night as little as four hours before awakening.
Zaleplon 20 mg generally produced signiﬁcant impairment of performance and
cognitive functions when these functions were measured at the time of peak plasma
concentration (one hour after dose administration), and no impairment of driving
abilities when measured four hours after a middle-of-the-night administration.
A single oral dose of zolpidem (5, 10 or 20 mg/70 kg) or triazolam (0.125, 0.25 or
0.5 mg/70 kg produced similar dose-related effects on memory for target information
(Mintzer and Grifﬁths, 1999). The results suggested that triazolam, but not zolpidem,
impaired memory for the screen location of picture stimuli.
Greenblatt et al. (2005) compared the effects of triazolam 0.375 mg on the EEG and
the DSST. The changes for the measures are highly correlated.
Vermeeren et al. (2002b) examined the effects of alcohol (0.3 g/l), zaleplon (10 mg)
or zopiclone (7.5 mg). A highway driving test was performed 40 minutes after
administration of alcohol and 10 hours after administration of zaleplon or zopiclone.
Zopiclone and alcohol each produced marked impairment, with the magnitude
of impairment with zopiclone being twice that with alcohol. Zaleplon produced
no impairment.
Medium-acting benzodiazepines
Alprazolam
Mills et al. (2001) studied the effects of stimulants and sedatives on tunnel vision.
The study was with fully rested participants: alprazolam (0.5 mg) clearly impaired
performance while stimulants (dextroamphetamine 10 mg) enhanced performance.
Verster et al. (2002a) examined the effects of alprazolam (1 mg) on driving ability,
memory and psychomotor performance. One hour after intake, the volunteers took
a standardised driving test during which SDLP and standard deviation of speed were
measured. Also, 2.5 hours after administration a laboratory test battery including
a memory scanning test, tracking test and divided attention test was carried
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out. Serious driving impairment was encountered, which was also conﬁrmed by
subjective assessments. Moreover, alprazolam 1 mg seriously impaired performance
on the laboratory test.
In a review of alprazolam studies, Verster and Volkerts (2004b) summarised the
effects of the drug on memory and driving ability. For memory functioning, a clear
dose-impairment correlation was seen.
Leufkens et al. (2007) studied the effects of 1 mg alprazolam extended release (XR)
and 1 mg alprazolam immediate release (IR). Four hours post-dosing, a standardised
driving test was performed, cognitive and psychomotor tests were performed
2.5 and 5.5 hours post-dosing, and memory function was assessed one hour after
administration. Severe impairment of driving performance was noted. Impairment
with the XR formulation was only half of that observed with the IR formulation.
Previously, Bourin et al. (1998) showed that low doses of lorazepam or alprazolam
produced signiﬁcant improvement in cognitive and psychomotor functions in healthy
volunteers. A study by Bentué-Ferrer et al. (2001) in animals found a behavioural
stimulatory effect with alprazolam (0.005 mg/kg) but not with lorazepam, which the
authors supposed was because of the extracellular rise of dopamine in the striatum.
Snyder et al. (2005) found that alprazolam 0.5 mg reduced the speed of attentional
performance. With a dose of 1 mg, impairments in psychomotor functions were
observed in addition to impairments in working memory and learning.
Lorazepam
In a study of the subchronic use of lorazepam or ritanserin, Van Laar et al. (2001)
evaluated subjects’ driving performance, slow-wave sleep and daytime sleepiness.
Lorazepam 1.5 mg, ritanserin 5 mg or placebo was given twice daily for seven
days. Tests included EEG recording, sleep latency test, driving test (SDLP) and
subjective assessments. With lorazepam, marked impairment on the driving test and
daytime sleepiness were observed.
Matthews et al. (2002) studied the effects on memory and behavioural learning of a
single dose of lorazepam 2.5 mg. Marked deﬁcits in delayed free recall, perceptual
priming and written word ﬂuency were recorded, with preservation of digit span.
The results suggest an impairment of the ability to learn behavioural strategies.
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The effects of lorazepam on total and partial retrieval of recently learned material and
feeling-of-knowing rating were studied by Izaute and Bacon (2006). When studying
four-letter nonsense letter strings, the subjects taking lorazepam (0.038 mg/kg)
showed an impairment of episodic short-term memory. The drug also had an effect on
the feeling-of-knowing estimates, but not on their predictive accuracy.
Clarkson et al. (2004) reviewed lorazepam-positive driving cases. When lorazepam
alone caused the impairment, signiﬁcant psychomotor disability was established that
was independent of blood concentration (range: 0.01–0.13 mg/l).
A study by Soo-ampon et al. (2004) on the effects on recall memory of lorazepam
2 mg alone, alcohol 0.6 g/l alone or the two combined showed that word frequency
had a signiﬁcant impact on memory. Low-frequency words were more sensitive to
memory impairment by lorazepam or alcohol than high-frequency ones. However,
subjects’ more accurate recall of the high-frequency words was eliminated when
both lorazepam and alcohol were consumed.
Lormetazepam
Iudice et al. (2002) assessed the effects of lormetazepam (1 mg) on daytime
vigilance, psychomotor performance and simulated driving. For three days, subjects
received lormetazepam or placebo at night, and tests were conducted on the
morning following the last administration. Subjects’ results on neuropsychological
tests, visual reaction times, sleep latency and driving ability showed no deterioration
following placebo or active medication when compared with baseline performance.
Psychomotor performance in young adults given a single dose of lormetazepam
or placebo was assessed using visual SRT and visual CRT, measured before and
after dosing (Fabbrini et al., 2005). Lormetazepam did not affect psychomotor
performance compared with placebo.
Temazepam
Tiplady et al. (2003) tested the difference between alcohol (0.8–1.0 g/l) and
temazepam (20–30 mg) on generating errors in performance tests. Alcohol
generated more error-prone behaviour with less effect on psychomotor speed.
Temazepam had no signiﬁcant effect on accuracy but slowed performance.
Information-processing capacity and long-term memory formation were reduced in
a similar way with both alcohol and temazepam 30 mg.
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Morin et al. (2003) reported few adverse effects of temazepam (7.5 to 30 mg) in
older adults. Those that were observed were in the areas of affective/behavioural/
cognitive function, neuro-sensory function and neuro-automatic function. Tolerance
to these effects developed over time.
Long-acting benzodiazepines
The behavioural and cognitive effects of ﬂunitrazepam and clonazepam were
examined by Dowd et al. (2002). Flunitrazepam (2 mg) affected memory and
attention four hours following intake, while clonazepam (3 mg) affected memory and
attention for 6 hours and reduced psychomotor performance two hours after intake.
Bramness et al. (2006) investigated the relationship between impairment and
ﬂunitrazepam concentrations in the blood of drivers suspected of impairment. The
impaired drivers had higher ﬂunitrazepam concentrations than the drivers who were
not impaired. Paradoxical reactions were observed, but were not related to the
ﬂunitrazepam level.
A study by Rich et al. (2006) evaluated the effect of diazepam 0.19 mg/kg on
retrospective and prospective memory by testing free recall of unrelated word lists
and instructing the participants to request a hidden belonging at the end of the
session. Diazepam impaired performance on all measures.
Between-group comparisons
Bocca et al. (1999) studied the residual effects of zolpidem 10 mg, zopiclone 7.5 mg,
ﬂunitrazepam 1 mg or placebo on driving performance. Doses were given at
11.00 p.m. Zopiclone and ﬂunitrazepam had residual effects in the ﬁrst part of the
morning, while zolpidem was free of any effect. Also, ﬂunitrazepam and zopiclone
affected eye movements adversely.
Vignola et al. (2000) compared people with insomnia not using medications, people
with insomnia using medication (lorazepam, ﬂurazepam, nitrazepam or temazepam)
and good sleepers on neuropsychological tests for memory, attention/concentration
and psychomotor function. Both groups with insomnia performed worse than
good sleepers. Subjects with insomnia who were not taking medications had lower
performance expectancies and rated their own performance more negatively.
Few studies exist on the combined effects of alcohol and benzodiazepines. One
study by Simpson and Rush (2002) showed that triazolam (0.125 or 0.250 mg) and
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temazepam (15 or 30 mg) each produced some impairment, whereas alcohol alone
(0.5 g/l) did not. Triazolam–alcohol and temazepam–alcohol combinations showed
clear impairment, even with low amounts of alcohol.
Partinen et al. (2003) investigated the effects of an after-midnight intake of zolpidem
(10 mg), temazepam (20 mg) or placebo on driving ability in women with non-
organic insomnia. The subjects underwent a driving simulator test 5.5 hours after
intake. No major differences in psychomotor performances between either zolpidem
or temazepam compared to placebo were observed, leading the authors to conclude
that there was an absence of signiﬁcant residual effects. However, differences in
susceptibility to the drugs were seen among the subjects.
The effects of zolpidem 5 mg, zopiclone 3.75 or lormetazepam 1 mg in elderly
people were investigated by Allain et al. (2003) using LMT, CTT, SRT and a
Sternberg test. SRT and CTT results were unaffected by the three drugs, while an
impairment for the LMT with lormetazepam was observed.
Vermeeren (2004) reviewed the effects of 11 hypnotics. Zaleplon 10 or 20 mg,
zolpidem 10 mg, temazepam 20 mg (soft gel capsules), lormetazepam 1 mg
capsules and triazolam 0.125 mg were unlikely to have any residual effects the
morning after administration. Tolerance to these impairment effects upon continued
administration seems to occur, but it may be incomplete and dependent upon dose
and duration of administration.
The acute pharmacological effects of temazepam (15 or 30 mg), diphenhydramine
(50 or 75 mg) and the herbal supplement valerian (400 or 800 mg) were examined
by Glass et al. (2003). Psychomotor effects were assessed with DSST and manual
tracking. Valerian had no effect, while temazepam 30 mg produced the most
psychomotor impairment. Diphenhydramine 75 mg and temazepam 15 mg
produced similar effects on motor performance, and no psychomotor impairment
was detected with diphenhydramine 50 mg.
Staner et al. (2005) evaluated the effects of zolpidem (10 mg), zopiclone (7.5 mg)
or lormetazepam (1 mg) on an EEG and a driving simulation test 9 to 11 hours
after administration. Zopiclone increased the number of collisions and lormetazepam
increased the deviation from speed limit and deviation from absolute speed,
while zolpidem had no effects. EEG recordings showed typical benzodiazepine-
induced alterations.
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The modiﬁcation of visual information processing was studied by Berthelon et al.
(2003). A night-time dose of zolpidem (10 mg), zopiclone (7.5 mg) or ﬂunitrazepam
(1 mg) was given and the effects on collision anticipation capacities were
investigated the next morning. Only ﬂunitrazepam caused subjects to incorrectly
focus their attention during the simulation.
A study by Paul et al. (2003) comparing melatonin 6 mg slow release, zaleplon 10 mg,
zopiclone 7.5 mg and temazepam 15 mg showed that all the substances except
melatonin caused detrimental effects on psychomotor performanceas tested using
the SRT, logical reasoning task, serial subtraction task and multitask. Time to normal
recovery on the SRT for zaleplon, zopiclone and temazepam were 3.25 hours,
6.25 hours and 5.25 hours, respectively.
Risks
Bramness et al. (2002) examined the relationship between benzodiazepine
concentration and impairment in apprehended drivers. Substances tested for
were diazepam, oxazepam, ﬂunitrazepam, nitrazepam, alprazolam, triazolam
and clonazepam. A higher blood concentration of diazepam, oxazepam and
ﬂunitrazepam was found in the impaired subjects compared with the subjects
who were not impaired. There was a clear concentration-related effect of
benzodiazepines on performance.
Accident risk
Four epidemiological studies were found that investigated the risk of being involved
in a trafﬁc accident after having taken a benzodiazepine. A case-control analysis in
Canada found that drivers testing positive for benzodiazepines had a higher risk of
being involved in a trafﬁc accident (OR 4.2, 95% CI: 2.7–6.3) (Dussault et al., 2002).
Testing positive for benzodiazepines alone, a combination of benzodiazepines
and cannabis, or a combination of benzodiazepines, cannabis and alcohol was
associated with an increased accident risk of 2.5 (OR, 95% CI: 1.4–4.3),
21.3 (OR, 95% CI: 5.3–86.0) and 63.9 (OR, 95% CI: 6.6–618.0), respectively. A
combination of benzodiazepines and alcohol (BAC > 0.08%) was associated with
an inﬁnite risk of being involved in a trafﬁc accident, but this is probably due to the
limited number of drivers testing positive for this combination. A comparison of the
prevalence of alcohol, drugs and medicines between 900 injured drivers and
900 control subjects in France found that benzodiazepines alone are associated
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with an increased accident risk of 1.7 (OR, 95% CI: 1.2–2.4) (Mura et al., 2003).
The Immortal study in the Netherlands and in Norway found that benzodiazepines
alone generate an increased accident risk of 3.0 (RR, 95% CI: 1.3–6.8) and
20.6 (OR, 95% CI: 2.1–201.8), respectively (Assum et al., 2005).
One recent pharmacoepidemiological study was found that investigated the
relationship between responsibility for a trafﬁc accident and benzodiazepine
use in the elderly (McGwin et al., 2000). The results showed that the use of
benzodiazepines was not associated with an increased risk of being responsible
for an accident. However, pharmacoepidemiological studies published before
1999 do report that benzodiazepine use is associated with an increased accident
risk (Barbone et al., 1998; Hemmelgarn et al., 1997) and an increased injury risk
(Neutel, 1995, 1998).
Responsibility analyses
Three responsibility analyses were found on benzodiazepines and accident
responsibility. In Australia, a study on alcohol and drug use in 3 398 fatally injured
drivers indicated that drivers testing positive for benzodiazepines did not have
an increased risk of being responsible for an accident (OR 1.3, 95% CI: 0.5–3.3)
(Drummer et al., 2004). Another study in Australia assessed the relationship between
drug prevalence, drug concentration and driver responsibility in 2 500 injured
drivers (Longo et al., 2000b). This study found a signiﬁcant relationship between
use of benzodiazepines alone and responsibility (OR 2.0, 95% CI: 1.1–3.9) as
well as between benzodiazepine concentration and responsibility. The risk of
being responsible for an accident was higher for a combination of alcohol and
benzodiazepines (OR 13.4, 95% CI: 1.8–101.0) than for benzodiazepines alone
or alcohol alone (OR 8.0, 95% CI: 5.3–12.2). There was an inﬁnite risk associated
with use of a combination of benzodiazepines and cannabis because all drivers
testing positive for this combination were judged responsible. A responsibility
analysis in Canada in 482 fatally injured drivers found that drivers testing positive
for benzodiazepines, or for benzodiazepines alone, had no higher risk of being
responsible for an accident (OR 5.8, 95% CI: 0.7–44.4; OR 3.6, 95% CI: 0.5–28.2,
respectively) (Dussault et al., 2002). The combination of benzodiazepines with
either alcohol (BAC > 0.08%) or cannabis or with both substances was associated
with an inﬁnite accident risk, probably because all drivers testing positive for these
combinations, were judged responsible.
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Meta-analysis
A meta-analysis was performed on the data from the case–control studies in France,
the Netherlands and Norway (Assum et al., 2005; Mura et al., 2003). The results
indicate that drivers testing positive for benzodiazepines alone are at an increased
risk of being involved in an accident, as shown by an RR of 2.3 (95% CI: 2.0–2.7)
and an OR of 3.4 (95% CI: 2.5–4.4). A meta-analysis was also performed on the
data from the two responsibility analyses in Australia (Drummer et al., 2004; Longo
et al., 2000b). The combined data showed a increasing but non-signiﬁcant accident
risk (OR 1.5, 95% CI: 0.9–2.4; RR 1.1, 95% CI: 1.0–1.3).
Conclusion
Benzodiazepines are a group of substances that cause impairment ranging
from severe effects to almost no effect. Of the short-acting benzodiazepines and
benzodiazepine-like drugs, zaleplon showed little impairing effects (though some for
20 mg doses), whereas zolpidem and zopiclone, and to some extent triazolam do
produce impairment. Among the intermediate-acting benzodiazepines, alprazolam
and lorazepam cause marked impairment, and less so for lormetazepam and
temazepam. The limited studies using long-acting benzodiazepines showed
impairment for ﬂunitrazepam, clonazepam and diazepam.
From the data collected, it seems there is a correlation between plasma levels and
degree of impairment (less obvious for lorazepam), be it on memory or on psychomotor
performance. However, individual susceptibility and tolerance must still be taken
into account. Combination with alcohol showed clear impairment for temazepam,
lorazepam and triazolam. A few benzodiazepines should generally be regarded as
unlikely to have a residual effect the morning after night-time use: zaleplon 10 mg,
lormetazepam 1 mg and temazepam 20 mg (immediate-release capsules). Zolpidem
10 mg produced no effect 8.25 hours after administration, while zaleplon 20 mg
showed conﬂicting results. It should also be noted that with chronic and subchronic use,
tolerance may develop, partially or completely, to the impairing effects.
Epidemiological studies indicate that drivers have an increased risk of being involved
in a trafﬁc accident after having taken a benzodiazepine, though no distinction was
made between the different kinds of benzodiazepines. Results from responsibility
analyses are contradictory. Only one study (out of the three found) showed that
drivers testing positive for benzodiazepines are at an increased risk of being
responsible for an accident, and that the risk rises with increased concentrations of
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benzodiazepines. But what is clear from all the risk analyses on benzodiazepines
is that the risk of being involved in or responsible for an accident increases when
another psychoactive substance (usually alcohol and/or cannabis) is taken in
combination with a benzodiazepine.
Antihistamines
Antihistamines are drugs used to treat allergic reactions. They work by blocking
the peripheral and central effects of histamines by binding to histamine receptors.
The known histamine receptors include H1, H2, H3 and H4 receptors. Histamines are
released as the result of an allergic response to different types of allergens (e.g. certain
drugs, venoms, peptides), and can lead to vasodilatation, increased permeability
of blood vessels and contraction of smooth muscles (including bronchoconstriction).
Treatment with H1 antihistamines can rapidly resolve these symptoms but can also cause
adverse effects. Depending on the distribution of the drug in the body, the adverse
effects can include sedation, digestive tract troubles and anticholinergic effects. The
antihistamines discussed here are H1-receptor antagonists, although sometimes afﬁnities
for other histamine receptors (sometimes acting as agonists rather than antagonists) or
muscarinergic, adrenergic or serotoninergic receptors as well as cardiac ion channels
(calcium and potassium) occur — hence, the broad range of adverse effects. The H1
receptor is found in neurons, smooth muscle cells, epithelial and endothelial cells and
white blood cells. The H1-receptor antagonists are divided into six different chemical
groups (Table 2). The ﬁrst-generation as well as the second-generation antihistamines
can be categorised into these groups. The second-generation drugs are generally non-
sedating, although exceptions have been shown.
Terfenadine and astemizole were withdrawn worldwide because of serious
cardiovascular adverse events (torsades de pointes) especially when combined with
CYP3A4 inhibitors. With polydrug use, pharmacokinetic interactions are more likely
and may increase the adverse effects (such as sedation) if the metabolisation of the
antihistamine is inhibited.
Effects
It should be noted that allergic rhinitis and allergic diseases in general can cause
sleep disturbances. Baiardini et al. (2006) examined the effects of respiratory
allergies, allergic skin disorders and anti-allergy drugs on sleep. A high prevalence
of sleep disturbance was observed. The cognitive effects of allergic rhinitis and its
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treatment were reviewed by Bender (2005), who noted the deleterious effects on
cognition and performance. The author concluded, however, that it was not clear
whether the improved alertness that results from the drug’s histamine blocking effect
offsets the sedative effect of the medication, or whether there is a combined sedating
effect of the antihistamine and the disease. Impairments in vigilance and cognitive
functioning associated with allergic rhinitis were studied by Wilken et al. (2002),
who also concluded that there is a decrease in speed and efﬁciency across several
cognitive domains. The experimental studies discussed below are summarised in
Table A11 (Appendix).
First-generation antihistamines
Diphenhydramine
Tolerance to the sedative effects of antihistamines was studied by Richardson et al.
(2002). Diphenhydramine 50 mg given twice daily for four days showed almost
Table 2: Overview of the diﬀerent types of antihistamines
Chemical class First-generation antihistamines Second-generation antihistamines
Ethanolamines Carbinoxamine, clemastine,
diphenhydramine,
dimenhydrinate, triprolidine
Ethylenediamines Pyrilamine, tripelennamine
Alkylamines Chlorpheniramine,
brompheniramine
Acrivastine
Piperazines Hydroxyzine, cyclizine,
meclizine, buclizine,
cinnarizine, oxatomide
Cetirizine, levocetirizine
Phenothiazines Promethazine, mequitazine,
oxomemazine, alimemazine
Piperidines Cyproheptadine, pizotifen,
ketotifen, phenindamine
Levocabastine, loratadine,
desloratadine, fexofenadine,
ebastine, terfenadine (†),
astemizole (†)
Phtalazinones Azelastine
(†) Withdrawn from the market in 1998 and 1999.
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complete reversal of the impairment of performance compared with placebo.
Tolerance was complete by the end of three days of administration.
Turner et al. (2006) compared the sedation and memory impairment associated
with a single dose of diphenhydramine (50, 75 or 100 mg) or lorazepam (0.5 or
1.5 mg). The tests included memory recall, DSST and CRT. All doses of
diphenhydramine impaired subjects’ results on the DSST and CRT and caused
subjective sedation. Lorazepam 0.5 mg had no effect on any test, while lorazepam
1.5 mg impaired subjects’ results on the DSST and CRT and caused subjective
sedation. Both diphenhydramine 100 mg and lorazepam 1.5 mg impaired memory
recall. Therefore, sedation is not always associated with impaired memory.
Clemastine
A study by Meltzer et al. (2003) on the safety and efﬁcacy of combined administration
of pseudoephedrine plus paracetamol versus the combination of clemastine 0.68 mg,
pseudoephedrine 60 mg and paracetamol 1 000 mg showed a higher degree of
somnolence with the latter.
Mequitazine
A literature search by Didier et al. (2000) concluded that classiﬁcation based on
the chemical structure alone may be misleading, as in the case of mequitazine,
which shows a low sedation proﬁle even though it is a ﬁrst-generation antihistamine.
Mequitazine 5 mg bid versus dexchlorpheniramine 6 mg, chlorpheniramine 4 mg bid,
brompheniramine 12 mg bid and hydroxyzine 25 mg bid produced less or no greater
sedation than placebo. Mequitazine 5 mg did not produce more CNS side-effects than
the second-generation antihistamines cetirizine, loratadine 10 mg and astemizole 10 mg.
Theunissen et al. (2006b) compared the effects of mequitazine 5, 10 or 15 mg
to cetirizine 10 mg, dexchlorpheniramine 6 mg or placebo on two actual driving
tests (highway-driving and car-following test) and cognitive and psychometric tests
(tracking, divided attention, memory, reasoning and CFF). Cetirizine did not affect
performance on any task, while mequitazine increased SDLP and affected divided
attention and reaction time in a dose-related manner. Divided attention was also
affected as was the reaction time (dose-related). Dexchlorpheniramine impaired
driving performance, as indicated by a signiﬁcant rise in SDLP. It was concluded that
mequitazine was mildly sedating.
F
o
r
m
a
t
:
(
1
4
8
.
0
0
x
2
1
0
.
0
0
m
m
)
;
D
a
t
e
:
1
2
0
2
,
2
0
0
8
0
7
:
5
3
:
4
5
;
O
u
t
p
u
t
P
r
o
f
i
l
e
:
S
P
O
T
I
S
O
C
o
a
t
e
d
v
2
(
E
C
I
)
;
I
n
k
S
a
v
e
2
8
0
Chapter 3: Effects and risks associated with drugs
97
Chlorpheniramine
Mochizuki et al. (2002) used positron emission tomography (PET) to see how
chlorpheniramine 6 mg affects different regions of the brain, compared with
placebo. The alterations observed in cortical and subcortical activity caused an
impairment in spatial cognition.
Chlorpheniramine has major adverse effects on the central nervous system.
According to Serra-Grabulosa et al. (2002), the patient may not even be aware
of this. The authors suggest that because of the nature of the adverse effects, the
prescribing of chlorpheniramine may need to be reviewed. These authors, for
example, found that the use of dexchlorpheniramine 4 mg can lead to auditory
attention impairment, but that there is a lack of awareness of these side-effects by
patients (Serra-Grabulosa et al., 2001).
Cinnarizine
Subjects’ performance after taking cinnarizine 15, 30 or 45 mg was examined by
Nicholson et al. (2002), with promethazine 10 mg used as an active control. The
performance assessment included DSST and vigilance. Cinnarizine 15 mg had no
effects on performance, while cinnarizine 45 mg showed evidence of impairment.
A study of antivertiginous medications by Philipova et al. (2004) found no evidence
of impairment of reaction time after four doses in 24 hours of cinnarizine 20 mg or
dimenhydrinate 40 mg.
Another study of antivertiginous medications by Schneider et al. (2003) found also
no performance effects. This study compared cinnarizine 20 mg plus dimenhydrinate
40 mg with dimenhydrinate 50 mg plus betahistine 12 mg.
Second-generation antihistamines
Desloratadine
Desloratadine is the active metabolite of loratadine. Several studies have examined
its effects on performance and vigilance. Nicholson et al. (2003) concluded that
desloratadine 5 mg is free of daytime sleep latencies, adverse effects on psychomotor
performance and subjective sleepiness. The study was a cross-over design with
promethazine as an active control. Assessments were made one hour before and
from 0.5 to 8 hours post-ingestion. Promethazine impaired tracking, CRT and DSST,
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and increased objective and subjective sleepiness. Desloratadine did not change any
of these parameters.
A safety and efﬁcacy study of desloratadine 5 mg in asthma patients by Berger et
al. (2002) revealed an adverse event rate similar to placebo; Monroe et al. (2003)
concluded the same in a study of patients with chronic idiopathic urticaria.
In a study that simulated ‘real-world’ performance tasks, desloratadine either
completely restored performance to the level of the asymptomatic placebo control
group or improved performance where it had been diminished in subjects with
seasonal allergic rhinitis (Satish and Streufert, 2003; Satish et al., 2004).
Valk et al. (2004) tested, in conditions that simulated cabin pressure at 8 000 feet
(about 2 400 m) altitude, desloratadine 5 mg, diphenhydramine 50 mg and placebo,
all in single doses on different days with 7-day wash-out periods in between.
Measurements included vigilance and tracking, a multi-attribute task battery, the
Stanford sleepiness scale and pulse oximetry. The use of desloratadine 5 mg led to no
detrimental effects on performance associated with ﬂying ability, which was not the
case with diphenhydramine.
In a systematic review, Bousquet et al. (2004) concluded that desloratadine met the
European Academy of Allergology and Clinical Immunology’s criteria for efﬁcacy,
safety and pharmacology of antihistamines. The safety parameters included an
evaluation of cognitive and psychomotor impairment associated with use of the drug.
A review article by Berger (2005) evaluated the CNS safety of desloratadine and
concluded that it caused no signiﬁcant CNS-related adverse events.
A similar conclusion was reached by Limon and Kockler (2003), who reviewed
studies published between 1966 and 2002.
Loratadine
A comparison of the administration of loratadine 10 mg or rupatadine 10 or 20 mg
by Saint-Martin et al. (2004) showed that more somnolence occurred in the subjects
who consumed rupatadine.
Ebastine
Herberg (2000) investigated the effects of ebastine on safety in everyday life and road
trafﬁc. The effects of ebastine 10 and 20 mg were evaluated using computer-aided test
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procedures on days 1, 2 and 7 following administration. Ebastine 10 or 20 mg did not
cause more adverse events than placebo, nor did it impair performance. Ebastine 10,
20 or 30 mg were compared with both placebo and triprolidine 10 mg (active control)
by Hindmarch and Shamsi (2001), who concluded that the effects of ebastine at all
doses were not different from placebo on any of the objective tests. The tests included
CFF, CRT, a simulated car tracking task, the Sternberg test, LARS and subjective
evaluation of sleep.
Levocetirizine
Hair and Scott (2006) reviewed the studies on the pharmacodynamics,
pharmacokinetics, therapeutic efﬁcacy and tolerability of levocetirizine. No signiﬁcant
effect on cognition and psychomotor performance was found with the 5 mg dose.
Tolerability was good, except the incidence of somnolence, which was higher than with
placebo (5.2% versus 1.4%; but no statistical analysis of the difference was reported).
Cetirizine
The effects of different doses of cetirizine (2.5, 5 or 10 mg) on cognitive and
psychomotor functions were evaluated by Shamsi et al. (2001) in comparison with
loratadine (10, 20 or 40 mg) and promethazine 25 mg. The test battery included
CFF, CRT, a compensatory tracking task and assessment of subjective sedation.
Administration of cetirizine 10 mg did not lead to disruptive effects on aspects of
psychomotor and cognitive function.
A comparison of cetirizine 10 mg and rupatadine 10 mg showed no difference in
adverse event rates, including that for somnolence, which was as high as 9.6% for
the subjects who received cetirizine (Martínez-Cócera et al., 2005).
However, a case report by Nordness and Zacharisen (2003) revealed no sedation or
somnolence in a patient taking 50 mg cetirizine a day.
In another study, subjects taking cetirizine 10 mg showed less impairment of
performance on a standardised driving test compared to those taking emedastine
2 or 4 mg bid (Vermeeren et al., 2002a). The driving impairment on the ﬁrst,
fourth and ﬁfth days was signiﬁcant for both doses of emedastine. On the ﬁfth day,
alcohol was given before the test in order to achieve a BAC of 0.5 g/l. Alcohol
combined with cetirizine or emedastine increased impairment on every test. Women
were more impaired than men by both drugs.
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Fexofenadine
Fexofenadine 360 mg, promethazine 30 mg and placebo were evaluated in a
cross-over, double-blind study (Hindmarch et al., 2002). The test battery consisted of
CFF, CRT, compensatory tracking test and a subjective assessment of sedation. The
effects of fexofenadine were not different from those of placebo in any of the tests,
whereas the use of promethazine signiﬁcantly impaired all measures. Even at the
high dose of 360 mg, fexofenadine had no disruptive effects on psychomotor and
cognitive function. In another study, Ridout and Hindmarch (2003) examined the
effects of fexofenadine 60 or 120 mg, promethazine 25 mg and placebo. Here too,
fexofenadine use did not lead to cognitive or psychomotor impairment.
Some studies have shown that fexofenadine has mildly stimulating properties.
Theunissen et al. (2006a) investigated whether this was due to the inhibition of
dopamine reuptake. The subjects in their study, who received fexofenadine 360 mg
or placebo, performed a DSST and a stop signal task. The authors concluded that
fexofenadine use improved performance on the DSST but did not potentiate dopamine
level in the striatum. They suggested that the activating effects of fexofenadine may be
a result of the involvement of H3 receptors and/or GABA receptors.
In a study by Ridout et al. (2003b), the use of fexofenadine 180 mg with or
without alcohol (BAC of 0.3 g/l) had no effect on performance, whereas the use of
hydroxyzine produced signiﬁcant impairment on CFF, RRT and TRT. The combination
of hydroxyzine with alcohol also impaired MRT. The test battery included CFF, RRT,
MRT, TRT and BRT.
According to Mohler et al. (2002), fexofenadine can be safely used in individuals
such as pilots who are involved in skilled activities, without the concern of sedation
at or above the recommended doses.
Mizolastine
Bachert et al. (2001) studied treatment with mizolastine 10 mg, with the conclusion
that the incidence of adverse events was low.
Azelastine
The effects of topical azelastine was studied by Golden et al. (2000), who did not
ﬁnd that azelastine causes daytime somnolence.
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Within-group comparisons
A review article on the adverse reaction proﬁles of second-generation antihistamines
by Lange and Bachert (2004) evaluated sedative potential as well as cardiotoxicity,
hepatotoxicity and teratogenity. Cetirizine, desloratadine, ebastine, fexofenadine,
levocetirizine, loratadine and mizolastine were included in the review. Cetirizine,
levocetirizine and mizolastine were associated with the highest incidence of sedative
adverse reactions, whereas desloratadine, ebastine and fexofenadine exhibit few
sedative effects.
A placebo-controlled comparison of fexofenadine 120 mg, cetirizine 10 mg and
hydroxyzine 30 mg (as positive control) showed no signiﬁcant impairment associated
with fexofenadine use relative to placebo, whereas cetirizine use showed a trend
towards increased sleepiness (Tashiro et al., 2004). Fexofenadine was less impairing
than cetirizine on some tasks. Measurements included the Stanford sleepiness
scale (subjective sleepiness) and objective psychomotor tests (SRT, CRT and visual
discrimination tests).
A study by Takahashi et al. (2004) evaluated the effects of bepotastine 10 mg bid,
cetirizine 10 mg, fexofenadine 60 mg bid and olopatadine 5 mg bid on wheal-and
ﬂare-response, sedation and psychomotor performance. The visual analogue scale
was used to test for sedation and a word processor test was used to test psychomotor
activity. Olopatadine, fexofenadine and cetirizine showed a signiﬁcant sedative effect
in this order, while bepotastine showed the least. Olopatadine affected psychomotor
performance more markedly, followed by fexofenadine and cetirizine.
Passalacqua and Canonica (2005) reviewed comparative studies of levocetirizine
and desloratadine. Neither drug was been shown to alter memory, divert attention,
decrease alertness or impair performance.
A study of cetirizine 10 mg versus loratadine 10 mg showed less somnolence in
patients taking loratadine and better motivation during the day (Salmun et al., 2000).
Inter-drug differences in sedation caused by antihistamines is discussed by Shamsi
and Hindmarch (2000). They used proportional impairment ratios for objective
evidence (PIR-O) for ranking the antihistamines, calculating an impairment index
for each antihistamine and comparing it with the impairment index obtained for all
antihistamines. Fexofenadine, ebastine and astemizole ranked the highest in terms of
no impairment, while promethazine ranked the lowest.
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A prescription-event monitoring study showed an overall low incidence of sedation
for four second-generation antihistamines (cetirizine, fexofenadine, loratadine and
acrivastine) (Mann et al., 2000). The authors suggest that people working in safety-
critical jobs who need antihistamines be given fexofenadine or loratadine.
A letter by Ramaekers and Vermeeren (2000) states that ebastine, fexofenadine,
loratadine, and terfenadine do not have any effects on driving performance when
given at the recommended doses, but have at least measurable effects with doses
that are twice as high. They also noted that these higher doses are often used by
patients with seasonal allergic rhinitis and urticaria.
Layton et al. (2006) conducted a prescription-event monitoring study and
concluded that the rates of drowsiness and sedation are low for desloratadine
and levocetirizine. However, patients prescribed levocetirizine are more likely to
experience drowsiness and sedation in the ﬁrst month of observation.
Between-generation comparisons
In a review designed to help physicians select the ‘optimal’ oral antihistamine for
their patients, Meltzer (2005) found no impairment associated with fexofenadine
even at high doses, impairment only at high doses with use of desloratadine or
loratadine and impairment at every dose with cetirizine use. A strong sedating
effect was found for clemastine and diphenhydramine, while brompheniramine,
chlorpheniramine and cetirizine (at a high dose) produced a moderate effect.
Desloratadine and loratadine were not associated with sedating effects, except with
high doses, which showed small effects. Fexofenadine was free of sedative effects at
any dose.
Fexofenadine 120 mg, compared to hydroxyzine 30 mg had no inﬂuence on BRT
when driving and using a mobile phone, while hydroxyzine did slow down BRT
(Tashiro et al., 2005).
An evaluation of the effects of fexofenadine 180 mg, diphenhydramine 50 mg
and placebo on the test of variables of attention (TOVA) found no signiﬁcant effect
associated with fexofenadine, which was in contrast to the results for diphenhydramine
(Mansﬁeld et al., 2003). Bower et al. (2003), who evaluated fexofenadine for safe use
by aviation personnel, found that the psychomotor effects following a single dose of
the drug were no different than with placebo administration.
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An evaluation of the acute effects of fexofenadine 120 mg, olopatadine 10 mg
and d-chlorpheniramine versus placebo on psychomotor function found no effects
of fexofenadine on any of the parameters, whereas d-chlorpheniramine and
olopatadine had sedating effects on psychomotor performance (Kamei et al., 2003).
An analysis of the differential cognitive effects of ebastine 10 mg or chlorpheniramine
2 or 6 mg versus placebo revealed no cognitive impairment with use of ebastine 10 mg
(Tagawa et al., 2002). Chlorpheniramine, however, even at the lower dose of 2 mg,
produced cognitive function impairment; there was a clear dose-response relationship.
In a comparison of diphenhydramine 50 mg, loratadine 10 mg and placebo,
diphenhydramine was found to produce substantial adverse effects on divided
attention, working memory, vigilance, and speed (Kay, 2000; Kay and Quig,
2001). There was no difference between loratadine and placebo. Although testing
on days 3 and 5 showed some equilibration between the active treatment groups,
diphenhydramine generated more errors on the divided attention test. The authors
concluded that individuals may not be aware of their reduced level of functioning. A
study of desloratadine 5 mg versus diphenhydramine 50 mg by Wilken et al. (2003)
showed that desloratadine improved ragweed-induced allergic rhinitis symptoms
without adversely affecting performance.
Barbanoj et al. (2006) investigated the combined effects of antihistamines with
alcohol on seven psychomotor performance tests (e.g. CFF and reaction time).
The greatest impairment was seen with the combination of hydroxyzine 25 mg
and alcohol 0.8 g/l. When rupatadine 10 mg plus alcohol was administered, the
impairment was not greater than with alcohol alone. Alcohol plus cetirizine 10 mg
or rupatadine 20 mg produced more impairment than alcohol alone, albeit smaller
than with hydroxyzine. Subjects taking hydroxyzine or cetirizine were not aware of
the increased impairment.
A study of tolerance development after repeated doses of mequitazine 10 mg,
cetirizine 10 mg or controlled-release dexchlorpheniramine 6 mg revealed a
wearing off of the driving impairment after eight days (Theunissen et al., 2006b).
Cetirizine did not cause any effect from the start of the study.
Levocetirizine 5 mg in contrast to diphenhydramine 50 mg does not signiﬁcantly
affect driving performance (Verster et al., 2003b). Subjects underwent a
standardised driving test, and SDLP was analysed. In another study, the same
authors found no inﬂuence of levocetirizine 5 mg on memory, attention or tracking
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performance after acute or subchronic administration (Verster et al., 2003a).
Diphenhydramine 50 mg did, however, signiﬁcantly affect divided attention and
tracking after acute administration.
Vuurman et al. (2004) examined the effects of desloratadine 5 mg, diphenhydramine
50 mg and placebo on a standard driving test two hours post-dosing. No
signiﬁcant effect of desloratadine on SDLP was noted (while this was not the case
for diphenhydramine) and BRT was signiﬁcantly faster following desloratadine
administration. Desloratadine did not impair driving performance.
A meta-analysis by Bender et al. (2003) of diphenhydramine and second-generation
antihistamines studies did not ﬁnd consistent diphenhydramine-induced sedation.
They concluded that a clear and consistent distinction between sedating and non-
sedating antihistamines does not exist.
Weiler et al. (2000) compared the effects on driving of fexofenadine 60 mg,
diphenhydramine 50 mg and alcohol 1 g/l (BAC) versus placebo. Driving
performance was assessed with a 1-hour driving simulation. Fexofenadine and
placebo had equal effects, while diphenhydramine had an even greater impact on
driving performance than alcohol.
An analysis by Verster and Volkerts (2004a) shows signiﬁcant impairment associated
with the use of ﬁrst-generation antihistamines, even with repeat administration.
Second-generation antihistamines may also impair driving performance, but
the magnitude and extent depends on dose, the subject’s sex, and time between
testing and administration. The second generation antihistamines fexofenadine and
levocetirizine produce no driving impairment.
Hindmarch et al. (2001a) compared the effects of levocetirizine 5 mg, cetirizine 10 mg,
loratadine 10 mg, promethazine 30 mg and placebo on tests that included CFF, CRT, a
continuous tracking task and subjective rating scales for sedation (LARS). Levocetirizine
and cetirizine were found to have no effect, even after repeated doses, on psychomotor
and cognitive functions.
A review of the evidence for impairment by Moskowitz and Wilkinson (2004) states
that ﬁrst-generation antihistamines produce objective performance impairment,
as well as subjective symptoms of sedation. This may also be the case with some
of the second-generation drugs in some individuals. Within each group, there are
substances that lead to less sedation and driving-related performance impairment.
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Risks
Accident risk
No recent epidemiological studies were found that speciﬁcally investigated the
accident risk associated with antihistamines. Some studies, however, assessed the
possible association between antihistamines and injuries in general. Finkle et al.
(2002) showed that the percentage of injuries attributable to diphenhydramine was
55% (compared with before use and with loratadine use). Hanrahan and Paramore
(2003) found an elevated acute injury risk after exposure to sedating antihistamines
(OR = 2.93).
Responsibility analyses
One responsibility analysis was found that calculated the risk of being responsible
for a trafﬁc accident while under the inﬂuence of psychoactive drugs, including
sedating antihistamines, but also TCA, phenothiazine antipsychotics, phenytoin and
carbamazepine (Drummer et al., 2004). The results showed that driving under the
inﬂuence of these psychoactive drugs alone is associated with an increased risk of
being responsible for a trafﬁc accident (3.8 OR, 95% CI: 1.3–11).
Conclusion
Among the ﬁrst-generation antihistamines, mequitazine seems to be associated
with less sedation than the other substances in this group. Diphenhydramine and
chlorpheniramine clearly show impairment of psychomotor performance. Clemastine
has proven sedating effects. Tolerance to the effects seems to be the case with
repeated use of diphenhydramine, mequitazine and dexchlorpheniramine.
Among the drugs of the second generation, fexofenadine, even at high doses, is not
associated with impairment, as is also the case with ebastine. Desloratadine and
loratadine are free of any disruptive effects on psychomotor performance, nor do
they lead to sedation. Cetirizine use can result in a certain degree of impairment,
although the studies show contradictory results. Levocetirizine shows a proﬁle similar
to that of desloratadine. Alcohol can have an additive effect on antihistamines’
sedation and psychomotor impairments. Fexofenadine does not potentiate the effects
of alcohol and vice versa.
The antihistamines that do not cause impairment should be preferred for prescription
to drivers. Based on the studies discussed above, it seems that fexofenadine,
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desloratadine and ebastine are the safest options to be used. Also, topical azelastine
does not appear to have an effect on vigilance.
More epidemiological research is needed on the risks of being involved in or
responsible for a trafﬁc accident that are associated with antihistamine use.
Antidepressants
Antidepressants are substances commonly prescribed for mood disorders,
anxiety and sometimes pain. These substances commonly inhibit the reuptake of
norepinephrine, and/or serotonin and/or to a minor extent dopamine. There are
ﬁrst- and second-generation antidepressants and an atypical group (Table 3). The
second-generation drugs are associated with fewer adverse effects compared to the
ﬁrst generation, mainly because of greater selectivity. Adverse effects encountered
in the ﬁrst generation are anticholinergic effects (dry mouth, gastric distress, blurred
vision and urinary retention), cardiovascular effects (palpitations, hypotension,
tachycardia and arrhythmia), sedation (with the serotoninergic compounds), while
second-generation selective serotonin reuptake inhibitors (SSRIs) are more prone to
causing gastrointestinal disturbances and sexual dysfunction.
Acute effects
Table A12 (Appendix) summarises the experimental studies discussed below.
First generation
Few studies have been conducted on the use of TCAs alone after 1999. However,
previous studies show a clear impairment associated with these substances.
According to the ICADTS classiﬁcation (14), TCAs cause minor or moderate effects,
except for trimipramine, amitriptyline, doxepin, dosulepine and amoxapine, which
can produce severe adverse effects and are potentially dangerous.
A study by Podewils and Lyketsos (2002) revealed that TCA use is not related to
cognitive deﬁcits, nor does it appear to signiﬁcantly comprise memory (measured by
MMSE) over a substantial timespan.
Veldhuijzen et al. (2006a) studied the effects of a nocturnal dose of amitriptyline
25 mg on actual driving. At the start of the therapy a signiﬁcant increase in SDLP
(14) http://www.icadts.org/reports/medicinaldrugs1.pdf and http://www.icadts.nl/reports/
medicinaldrugs2.pdf for the list of drugs.
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was noted, higher than with a BAC of 0.5 g/l. Also, reaction times increased
signiﬁcantly. In contrast, after two weeks of treatment, no differences were found
compared to placebo, suggesting tolerance.
Second generation
SSRIs
A review by Dumont et al. (2005) showed that low doses of an SSRI in healthy
volunteers stimulate attention and memory, while high doses tend to impair visual/
auditory visuomotor systems and subjective performance, but show acceleration in
motor function. The CFF test showed the most pronounced effect.
Fluoxetine 20–60 mg has been shown to have no effects on cognitive performance
on the visual verbal learning test, concept shifting task, letter-digit substitution test
and a Stroop colour-word test after nine weeks of treatment (Strik et al., 2006).
Table 3: Overview of the diﬀerent kinds of antidepressants
Class Mechanism of action Examples
First generation
(TCA)
Noradrenergic Nortriptyline, desipramine, protriptyline,
maprotiline, amoxapine
Serotoninergic Amitriptyline, clomipramine, doxepin,
imipramine, trimipramine, dosulepine,
melitracen
Second generation SSRI Paroxetine, sertraline, citalopram,
escitalopram, ﬂuvoxamine, ﬂuoxetine
NRI Reboxetine, atomoxetine
SNRI Venlafaxine, milnacipran, duloxetine
Atypical Trazodone, nefazodone, bupropion,
mianserin/mirtazapine, tianeptine/amineptine
MAO inhibitors Selegiline (MAOI-B), phenelzine (MAOI-A),
tranylcypromine (MAOI-A), moclobemide
(RIMA)
Abbreviations: SSRI, selective serotonin-reuptake inhibitor; SNRI, serotonin/norepinephrine-reuptake
inhibitor; NRI, norepinephrine-reuptake inhibitor; MAOI, monoamine oxidase inhibitor; RIMA, reversible
inhibitor of MAOI-A.
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SSRIs do not always show an improvement of memory in healthy subjects. Rose et al.
(2006) studied the effects of escitalopram 10 mg and found no effects on cognitive
or haemodynamic functions. However, Wadsworth et al. (2005) found SSRI use to be
associated with memory impairment.
Additional dopamine reuptake inhibition can attenuate vigilance impairment (Schmitt
et al., 2002). Sertraline 50–100 mg was compared with paroxetine 40–60 mg using
a vigilance test and a Stroop test. Paroxetine, but not sertraline, impaired vigilance.
Neither drug resulted in impairment on the other tests. Sertraline is known to block
dopamine reuptake.
Sertraline 50–75 mg was shown by Constant et al. (2005) to have beneﬁcial effects
on psychomotor slowing and on attentional and executive functions, even after
one week of treatment, whereas a study by Devanand et al. (2003) found little
improvement of cognitive function with sertraline 50–200 mg.
Acute intravenous administration of citalopram 10 mg was associated with increased
memory consolidation on an auditory verbal learning test (Harmer et al., 2002).
A study of ﬂuoxetine 20–60 mg and paroxetine 20–40 mg showed no
deterioration of cognition; in fact, most of the tested cognitive functions were
improved (Cassano et al., 2002).
Abrupt discontinuation of an SSRI can result in a syndrome of adverse effects.
According to Hindmarch et al. (2000a), only discontinuation of paroxetine, and no
other SSRI, leads to a deterioration in various aspects of health and functioning.
The effects of depression and antidepressant therapy on driving performance
were evaluated in the Immortal study (Schmitt et al., 2004). Results showed an
improvement on the SDLP test during SSRI use (6–52 weeks). However, performance
was still signiﬁcantly worse than that of the healthy controls. As for cognitive
function, there was no signiﬁcant difference in performance between healthy
individuals and those taking antidepressants, except for the reduction of the CFF
threshold in the subjects taking antidepressants.
SNRIs
Venlafaxine had no signiﬁcant effect on SDLP and failed to impair psychomotor
performance in a study by O’Hanlon et al. (1998). However, serious withdrawal symptoms
may occur within hours of cessation or reduction of the usual dose and may affect motor
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and coordination skills to such a degree that patients should be explicitly urged either to
adhere to a strict medication routine or not to drive a car (Campagne, 2005).
Milnacipran use was evaluated in young and elderly volunteers by Hindmarch et al.
(2000b). Milnacipran 25 or 50 mg had no performance effects in young people,
but signiﬁcantly raised CFF scores in the elderly. Amitriptyline, in contrast, lowered
CFF threshold, lengthened CRT and increased the errors in compensatory tracking.
Poirier et al. (2004) tested the effect of milnacipran on memory and vigilance
(CFF, CRT). Milnacipran was shown to be free of any disruptive effects on cognitive
function in young and elderly volunteers. In the latter group it seemed to improve
performance on the CFF. Repeated administration of milnacipran 50 mg bid had
no effects on cognitive function (Richet et al., 2004). The authors concluded from
the results on laboratory tests and a ‘real’ on-road driving test that milnacipran
50 mg bid does not affect the psychomotor functions required for driving. The drug
did not accentuate the negative effects of alcohol.
Within-generation comparisons
Fluoxetine 10–40 mg versus reboxetine 4–8 mg showed no difference in reversal of
memory impairment (Gallassi et al., 2006). Therapy with either substance led to a
signiﬁcant but incomplete improvement of memory impairment.
A comparison between SSRIs (sertraline, paroxetine, citalopram) and SNRIs
(venlafaxine) shows an impaired driving performance (on SDLP and CFF) for both
classes of antidepressants (Wingen et al., 2006b). However, the authors remarked
that this impairment is probably due to residual depressive symptoms.
Comparison between generations
Driving performance
The effects on driving performance with use of TCAs and SSRIs are summarised in a
review by Ramaekers (2003a). SDLP during a one-hour on-the-road driving test was
assessed. Sedating antidepressants (TCAs and mianserin) led to a change in SDLP
similar to that with a BAC of 0.8 g/l. Nocturnal doses of sedating antidepressants
(dothiepin, mianserin and mirtazapine) did not produce residual driving impairment
the next morning. Non-sedating antidepressants (moclobemide, ﬂuoxetine,
paroxetine, venlafaxine and nefazodone) did not affect SDLP; however, when they
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were co-administered with a benzodiazepine (with an incompatible pharmacokinetic
proﬁle), the SDLP rose to unacceptable levels.
Brunnauer et al. (2006) found that in terms of ﬁtness to drive, SSRIs and mirtazapine
have an advantage over TCAs and the SNRI venlafaxine.
Ridout et al. (2003a) found that paroxetine 20 mg has no effect on BRT and
improves CFF and the RRT component of the CRT, while mirtazapine 15 or 30 mg
taken at night leads to impaired results on laboratory performance tests.
Cognitive performance
Physical and cognitive symptoms are frequently reported by patients whose major
depressive disorder has responded to long-term antidepressant therapy. Fava et al.
(2006) concluded that these symptoms are both side-effects of the antidepressant
therapy and the residual depressive symptoms. In patients with depression, Kalb et
al. (2006) found increased reaction times and reduced error rates compared with
healthy controls. The antidepressant doses correlated negatively with reaction time
but positively with the error rates.
A continuous performance test (CPT) was used by Koetsier et al. (2002) to evaluate the
attentional performance of in-patients with depression before and after four weeks
of taking imipramine (blood level 200–300 µg/l) and ﬂuvoxamine (150–200 µg/l).
CPT performance was improved with both drugs as was the clinical state. However, a
clear relationship between the altered CPT and the changes on the clinical scales was
absent. A clear difference was seen between desipramine 125–200 mg and ﬂuoxetine
20 mg on memory impairment (Levkovitz et al., 2002). Fluoxetine led to a greater
improvement in memory performance compared to desipramine.
A comparison of the effects of ﬂuvoxamine 100 mg and dothiepine 100 mg on
sleep and daytime sleepiness after a single administration showed an alteration of
night-time sleep with both drugs (Wilson et al., 2000). More daytime sleepiness was
observed with dothiepine use. Fluvoxamine decreased and dothiepine increased
total sleep time.
Katona et al. (1999) compared reboxetine 4–6 mg with imipramine 50–100 mg
administration and found no somnolence in the subjects taking reboxetine.
According to a review by Peretti et al. (2000) of SSRIs and TCAs, TCAs with
anticholinergic and antihistaminic properties have a greater risk of affecting
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memory and psychomotor function. CFF was elevated for ﬂuoxetine and sertraline,
while TCAs decreased the CFF threshold. Paroxetine produced no impairment of
performance compared to placebo, while this was not the case with amitriptyline.
BRT is not impaired with use of SSRIs but it is with use of TCAs.
Cognitive dysfunction commonly occurs in older persons and sometimes this is caused
by major depression. Nebes et al. (2003) examined the persistence of cognitive
dysfunction after treatment with paroxetine or nortryptiline (information on the doses
was not given). Neither antidepressant led to changes in cognitive function, although
the subjects showed good clinical outcomes for their depression. However, Doraiswamy
et al. (2003) found an improvement of cognitive function and an improvement of
the symptoms of the depression with use of sertraline 50 mg, ﬂuoxetine 20 mg or
nortryptiline 25 mg. Venlafaxine (37.5 mg bid) compared to dothiepine (25 mg in the
morning plus 75 mg in the evening) does not lead to disruptive effects on cognitive
function in elderly patients with depression (Trick et al., 2004). The tests included
CFF, a short-term memory test and a questionnaire assessing cognitive failure. Butters
et al. (2000) also found an improvement in speciﬁc cognitive domains following
antidepressant treatment in elderly subjects, but normal levels of performance were not
always reached, particularly in memory and executive functions. The antidepressants
used were paroxetine or nortryptiline (dosing information was not given).
In a study by Wingen et al. (2006a), use of escitalopram 10–20 mg did not affect
immediate or delayed verbal memory score, while treatment with mirtazapine
30–45 mg led to impairment. The authors suggested that the effects seen with
mirtazapine might be due to the antihistaminic effect of the substance.
Compared with nortryptiline 25–100 mg, sertraline 50–100 mg had a more positive
effect on verbal learning and recall as well as on visual tracking, coding and motor
performance (Coffey et al. 2002). The tests included a shopping list task (recall),
DSST and MMSE.
Atypical antidepressants
Ridout and Hindmarch (2001) compared the use of tianeptine 12.5 or 37.5 mg
(an antidepressant promoting the reuptake of serotonin and related to the TCAs) with
mianserin 30 mg and placebo on subjects’ performance on the CRT, CFF, BRT and
self-assessed ratings of sedation (LARS). Tianeptine proved to be free of any effects,
while mianserin use was associated with changes on all of the parameters.
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Two studies on Hypericum perforatum (St. John’s wort) found no effects on cognitive
or psychomotor function. Timoshanko et al. (2001) administered 900–1 800 mg of
the herb and observed only dose-related impairment on the DSST and no effects
on CRT and CFF, while the positive control amitriptyline 25 mg impaired subjects’
overall performance. Siepmann et al. (2002) found no effect of St. John’s wort
extract 255–285 mg on cognitive function.
The use of moclobemide 150 mg bid does not appear to affect cognitive function
(Siepmann et al., 2004). The tests included CFF, CRT and memory.
Risks
Accident involvement
Two epidemiological studies were found that investigated the accident risk
associated with antidepressant use. The Immortal study in the Netherlands attempted
to evaluate the accident risk associated with TCA use; however, there were too
few TCA-positive samples to be able to calculate the risk (Assum et al., 2005).
A case-control study in France found that 1.8% of injured drivers tested positive
for antidepressants, while only 1.1% of control subjects tested positive (Mura et
al., 2003). The authors did not calculate accident risk in their study, but our own
calculations using their data found that the risk was not signiﬁcantly increased for
these prevalence rates in cases and controls.
Responsibility analyses
One responsibility analysis was found that calculated the risk of being responsible for a
trafﬁc accident while under the inﬂuence of psychoactive drugs, including TCAs, but also
sedating antihistamines, phenothiazine antipsychotics, phenytoin and carbamazepine
(Drummer et al., 2004). The results showed that driving under the inﬂuence of these
psychoactive drugs alone is associated with an increased risk of being responsible for a
trafﬁc accident (3.8 OR, 95% CI: 1.3–11) (Drummer et al., 2004).
One pharmacoepidemiological study was found that investigated the relationship
between responsibility for a trafﬁc accident and antidepressant use in the elderly
(McGwin et al., 2000). The use of antidepressants was not associated with an
increase in the risk of being responsible for an accident. Pharmacoepidemiological
studies that were published before 1999 came to similar conclusions: the use of
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antidepressants was not associated with an increased risk of hospitalisation (Neutel,
1995) or for a trafﬁc accident (Barbone et al., 1998).
Conclusion
Moclobemide, tianeptine, the SNRIs venlafaxine and milnacipran and the SSRI
escitalopram seem to cause no major impairment of cognition or psychomotor skills.
Withdrawal symptoms with venlafaxine or paroxetine can cause serious impairment.
Mirtazapine use leads to clear impairment of memory, but subjects who took the
drug before bedtime did not fail a driving test the next morning. TCAs, compared
with the more recent antidepressants, show more impairment of cognition and
psychomotor skills. However, tolerance to the cognitive and psychomotor effects
of TCA seems to develop with prolonged use. Nevertheless, caution should be
advised when prescribing these older substances, since previous studies clearly
demonstrate an impairing effect. The results of the SSRI studies are not always
consistent. Sertraline use was associated with improvement of psychomotor function.
For most SSRIs, cognitive function was either unchanged or improved. The effects
of antidepressants on memory and cognition can be difﬁcult to interpret since
depression itself can have detrimental effects on these functions. Resolution of the
depression can often also result in resolution of depression-related cognitive deﬁcits.
The epidemiological data on the risks associated with antidepressant use do not
indicate an increased risk of being involved in or responsible for an accident.
However, very few data were available.
Other synthetic drugs
Gamma-hydroxybutyrate (GHB)
Gamma-hydroxybutyrate (GHB) is a normal component of the mammalian central
nervous system. In the 1960s, synthetic GHB began to be used as an anaesthetic. In
the early 1990s, it was sold in health food stores and marketed as a treatment for
anxiety, insomnia and drug and alcohol abuse and for use by athletes and body
builders. The United States Food and Drug Administration (FDA) removed GHB from
the market in 1990 following reports of GHB-related coma and seizures (Freese et
al., 2002). GHB (Xyrem™) has recently been approved in Europe for the treatment
of narcolepsy (15).
(15) http://www.marketwire.com/press-release/ucb-bxs-ucb.br-721758.html
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Acute effects
Four experimental studies were found on the acute effects of GHB.
Ferrara et al. (1999) examined the subjective, cognitive and motor effects in humans
following administration of typical therapeutic doses. Oral doses of 12.5 and
25 mg/kg had no effect on attention, vigilance, alertness, short-term memory or
psychomotor skills based on the tests used. The only adverse effects noted were
slight dizziness and dullness, and these effects disappeared within 60 minutes.
Haller et al. (2004) administered 50 mg/kg GHB to 8 healthy adults, 0.6 g/l ethanol
in two doses or both drugs in a double-blind, placebo-controlled, four-arm crossover
study. Changes in cognitive performance were assessed using a computerised
test battery. GHB impaired speciﬁc cognitive tasks: speed of attention, quality of
episodic memory and speed of memory. Although decrements in speed of response
were identiﬁed, the accuracy of those responses was not impaired. Additive but not
synergistic effects of GHB and ethanol on cognitive impairment were identiﬁed.
Carter et al. (2006) investigated the psychomotor and cognitive effects of
supratherapeutic doses of GHB (2–18 g/70 kg) and compared them to those of
triazolam (0.5 and 1 mg/70 kg) and pentobarbital (200 and 400 mg/70 kg).
GHB produced effects similar to triazolam and pentobarbital; however, memory
impairment after GHB use was less than that after use of triazolam or pentobarbital.
The within-subject dose-effect function for sedation was steeper for GHB than for
triazolam or pentobarbital. Also, at higher doses, GHB was associated with greater
sedation and more variability between subjects.
Abanades et al. (2006) administered increasing doses of oral sodium GHB (40, 50,
60 and 72 mg/kg) to eight volunteers. The mean peak GHB plasma concentrations
were 79.1, 83.1, 113.5 and 130.1 mg/l for the doses of 40, 50, 60 and 72 mg/kg,
respectively. GHB showed a mixed stimulant-sedative pattern, with initially increased
scores in subjective feelings of euphoria, ‘high’ and liking followed by mild-moderate
symptoms of sedation with impairment of performance and balance. GHB produced
a slight deterioration of psychomotor performance that was apparently dose-
dependent with a peak effect at 30 minutes after administration for lower doses,
and at 1.5 hours post-administration for the 72 mg/kg dose. A decrease was seen
in DSST total responses and DSST correct responses, while there was an increase in
DSST errors at the same time. Doses of 60 and 72 mg/kg were associated with an
impairment of the balance task with a peak effect at one hour, post-administration.
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At all administered doses, GHB induced exophoria, a typical effect for sedatives, as
measured by the Maddox wing device.
A few case reports were found on driving under the inﬂuence of GHB.
Couper and Logan (2001) describe 13 subjects arrested for impaired driving
in the United States whose blood samples were tested positive for GHB. GHB
concentrations ranged from 26 to 155 mg/l (mean 87 mg/l, median 95 mg/l).
In eight cases, GHB was the only drug detected, and signs of impairment were
consistent with those of a CNS depressant, including erratic driving (weaving,
swerving and ignoring road signs), confusion, incoherent speech, unresponsiveness,
lack of balance, unsteady coordination, poor performance on ﬁeld sobriety tests
and varying states of wakefulness. The authors concluded that given the ability
of GHB to induce sleep and unconsciousness, these cases show that recreational
use of the drug has the potential to impair driving ability. The same authors later
described a case report of a 38-year old man who was arrested seven times over
an eight-month period for driving under the inﬂuence of GHB (Couper and Logan,
2004a). Blood GHB concentrations ranged from 44 to 184 mg/l (mean 100 mg/l,
median 73 mg/l). The overall signs of impairment included erratic driving (severe
lane travel, collisions and near-collisions), slurred speech, disorientation, slowness
to react, shaking, agitation, inability to focus, poor coordination and balance, poor
performance in ﬁeld sobriety tests, somnolence and unconsciousness. On only one
occasion were other drugs present in the subject’s blood (thiopental and diazepam)
that may also have contributed to the observed driving impairment.
Bosman and Lusthof (2003) described forensic cases involving the use of GHB in the
Netherlands, including 13 cases of driving under its inﬂuence. GHB concentrations
in subjects’ blood ranged from 51 to 195 mg/l and in urine from 100 to 2000 mg/l.
High concentrations of GHB corresponded with extreme sleepiness or temporary loss
of consciousness. GHB was considered to have caused driving impairment in all cases.
No studies were found on the chronic effects or risks associated with the use of GHB.
Conclusion
The limited data that were found for GHB suggest that the range of GHB doses that
are typically consumed by users (25–75 mg/kg) (Abanades et al., 2006) can cause
dose-dependent cognitive and psychomotor impairments. The results from case
reports also indicate impairments following GHB use by drivers, including extreme
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sleepiness, poor coordination and balance and even unconsciousness. No risk
studies were found.
Ketamine
Ketamine is a synthetic sedative compound that acts as a CNS depressant and
produces a rapid-acting dissociative effect.
Acute effects
Several experimental studies were found that assessed the acute effects of ketamine.
Curran and Morgan (2000) investigated the cognitive effects of ketamine in
recreational users on the night of drug use and three days later. Twenty volunteers
who reported having taken ketamine were compared with 19 volunteers who
reported no consumption of ketamine on the relevant night (day 0). All 39
participants took a battery of tests for memory functions and attention. Doses taken
before testing varied from 0.0624 g to 0.5 g with a mean dose of 0.14 g (±0.16 g).
The ketamine users were profoundly impaired on virtually all objective assessments
of cognitive function, compared to the controls on the day they took the drug. On
most objective measures, ketamine users performed at much higher levels on day
three than day 0. However, on certain measures, group differences were still highly
signiﬁcant on day three, namely on the tasks that assessed semantic memory.
Hetem et al. (2000) gave 26 healthy volunteers a 60-minute infusion of ketamine
(0.5 mg/kg/hour) or placebo. Subjects carried out episodic memory tasks involving
words presented before and during infusion. Memory performance was assessed
using recognition and free recall tasks. Ketamine impaired performance in free
recall and recognition of words presented during, but not before, infusion. Ketamine
thus decreased episodic memory performance by impairing the encoding but not the
retrieval processes.
Krystal et al. (2000) reported the results of two studies designed to examine the
effects of ketamine on WCST performance. In the ﬁrst study, 15 healthy subjects
completed the WCST on two occasions separated by one week. In the second study,
22 healthy subjects completed the WCST and other assessments after administration
of ketamine (intravenous bolus 0.26 mg/kg followed by infusion of 0.65 mg/kg/
hour) or placebo during two test days separated by approximately one week. In
the ﬁrst study, subjects reduced the number of total and perseverative errors with a
single repetition of the WCST. In the second study, ketamine signiﬁcantly increased
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the number of total errors and the number and percent of perseverative errors on the
ﬁrst but not the second test day. Similarly, it reduced the number of category criteria
met on the ﬁrst but not on the second test day. Ketamine also increased distractibility
and impaired recall.
Guillermain et al. (2001) investigated the effects of a subanaesthetic dose of
ketamine (0.5 mg/kg over 60 minutes) on information processing using a two-
choice visual reaction time task. The results showed that ketamine slowed down
CRT and that there was an additive pattern of effects of signal intensity, stimulus-
response mapping and foreperiod duration on both mean reaction time and
reaction time variance.
Honey et al. (2003) investigated the effects of ketamine on executive processes
during a working memory task. Eleven healthy volunteers received a different
intravenous infusion on each of three occasions: placebo, a low ketamine dose
(target plasma concentration of 50 ng/ml) and a high ketamine dose (target plasma
concentration 100 ng/ml). Impairments were seen only at the higher dose of
ketamine and restricted to a subgroup of the verbal working memory tasks. While
visuospatial working memory and simple maintenance processes during verbal
working memory showed no evidence of impairment, the higher dose ketamine
produced a signiﬁcant impairment in the manipulation of information within
working memory.
Morgan et al. (2004b) found that ketamine (infusions of two doses of 0.4 or
0.8 mg/kg) produced a dose-dependent impairment of episodic and working memory
and a slowing of semantic processing in healthy volunteers. Ketamine also impaired
recognition memory and procedural learning. Attention, perceptual priming and
executive functioning were not affected. The same researchers report in another
study that the infusions at 0.4 or 0.8 mg/kg acutely impaired response inhibition and
episodic memory in healthy volunteers, while semantic memory was not affected; no
residual effects were observed three days after administration (Morgan et al., 2004a).
Rowland et al. (2005) investigated the cognitive effects of a subanaesthetic dose
of ketamine (a loading dose of 0.27 mg/kg over 10 minutes and a maintenance
dose of 0.00225 mg/kg/minute for the remaining extent of the experiment) in
healthy volunteers. Ketamine impaired learning of spatial and verbal information,
but retrieval of information prior to drug administration was preserved. The drug
did not signiﬁcantly impair attention, verbal ﬂuency or verbal working memory task
performance. Spatial working memory was slightly impaired.
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Passie et al. (2005) investigated the effects of different subanaesthetic doses of
S-ketamine (a bolus of 5 mg over ﬁve minutes for the low- and the high-dose
conditions, followed by infusion with 0.003 mg/kg/minute for the low dose and
0.005 mg/kg/minute for the high dose) on neuropsychological tests in healthy male
volunteers. Results indicated that both doses produce only nonsigniﬁcant impairment
on most of the tasks. Tasks involving divided and sustained attention showed
signiﬁcant impairment in a dose-dependent manner.
Lofwall et al. (2006) administered single intramuscular injections of ketamine
(0.2 mg/kg or 0.4 mg/kg) in healthy volunteers. Ketamine selectively impaired free
recall while sparing recognition memory, source memory and metamemory. It also
disrupted encoding while sparing retrieval processes, impaired working memory
performance while sparing attention, and slowed DSST performance while sparing
accuracy. Subjective and psychomotor effects were dose-dependent, and present at
a dose (0.2 mg/kg) that did not produce signiﬁcant memory impairment. Whereas
impairment on most of the psychomotor measures dissipated within two hours of
injection, performance on the CLT and subjective feelings of alertness, drug liking-
disliking and drug strength persisted 2.5 hours after injection.
Morgan et al. (2006a) examined whether there were gender differences in response
to ketamine in humans, and found that men showed greater impairment in memory
after ketamine administration than women. No other gender differences in cognitive
measures were found.
Combination with other psychoactive substances
Krystal et al. (2005) investigated the effects of administering ketamine (one-minute
infusion of 0.23 mg/kg followed by a one-hour infusion of 0.5 mg/kg) combined
with amphetamine (one-minute infusion of 0.25 mg/kg) in healthy volunteers. They
found that amphetamine attenuated the impairment of working memory produced
by ketamine and that amphetamine and ketamine had additive effects on thought
disorder, arousal and euphoria.
Nicotine is known to enhance attention and information processing. Cho et al.
(2005) investigated whether nicotine attenuates the deﬁcits in cortical information
processing and cognitive functions produced by ketamine (bolus 0.26 mg/kg
followed by infusion 0.65 mg/kg/hour). The results indicated that nicotine can
attenuate ketamine-induced deﬁcits in information processing and attention.
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Chronic effects
Curran and Monaghan (2001) investigated whether the persisting memory impairment
three days after ingestion of ketamine in recreational users that was assessed by
Curran and Morgan (2000) reﬂects chronic effects. They assessed the effects of
ketamine in frequent and infrequent users on the day of ketamine use and three
days later. On day three, the frequent users showed signiﬁcant impairments on tasks
assessing episodic and semantic memory compared with the infrequent users. The
authors concluded that frequent use of ketamine produces long-lasting impairments
in episodic memory and aspects of retrieval from semantic memory. These ﬁndings
were conﬁrmed in later studies (Morgan et al., 2004d, 2006b). During a three-
year longitudinal investigation of the cognitive and subjective effects of ketamine in
recreational users who have substantially reduced their use of the drug, Morgan et
al. (2004c) found that semantic memory impairments associated with recreational
ketamine were reversible upon marked reduction of use. However, impairments to
episodic memory and possibly attentional functioning appeared long-lasting.
No epidemiological studies were found on the risk of being involved in or
responsible for an accident associated with the use of ketamine.
Conclusion
Experimental studies using single subanaesthetic intravenous or intramuscular doses
of ketamine indicate that some cognitive and psychomotor functions are affected for
up to 2.5 hours, while other functions, such as semantic memory, are not affected.
Some of these defects are dose-dependent and can be attenuated by, for example,
amphetamine or nicotine. Recreational use of ketamine can cause cognitive defects,
of which some are reversible and others long-lasting.
No studies were found on accident risks associated with the use of ketamine.
Phencyclidine (PCP)
Phencyclidine (PCP) was ﬁrst developed for use as an intravenous anaesthesia
agent, but was withdrawn from clinical trials because of the occurrence of severe
emergence delirium. It was subsequently abused as a recreational drug.
Acute effects
No experimental studies on the acute effects of PCP in humans were found that were
published in 1999 or later. Studies that were published before 1999 showed that a
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single dose of PCP, in subanaesthetic doses (<20 mg), can induce severe impairment
of cognitive and psychomotor functions lasting up to 14 hours in healthy volunteers
(Baselt, 2001).
No studies were found on the chronic effects or risks associated with the use of PCP.
Conclusion
Experimental studies show that single subanaesthetic doses of PCP can cause severe
cognitive and psychomotor impairment in healthy volunteers. There is a need for
more experimental studies on the acute effects of PCP alone or in combination
with other psychoactive substances, and on the chronic effects and accident risks
associated with the use of PCP.
Ephedrine
Ephedrine is a naturally occurring stimulant drug similar in structure to
amphetamine. It is commonly used as a stimulant, appetite suppressant,
decongestant and to treat hypotension associated with regional anaesthesia (Baselt,
2001). Ephedrine is a key precursor of methamphetamine, and is used as a cutting
agent in amphetamine powder and in other illicit tablets.
Acute effects
Beversdorf et al. (1999) compared the effects of 40 mg of propranolol (a
β-adrenergic antagonist), 25 mg of ephedrine (a β-adrenergic agonist) or placebo
on problem-solving in healthy volunteers. On the task that appeared to rely most
heavily on cognitive ﬂexibility (anagrams), subjects who were most able to solve
these problems demonstrated signiﬁcantly shorter solution times after propranolol
use than after ephedrine. There was a trend towards shorter solution times for
ephedrine compared with placebo, but this was not statistically signiﬁcant.
Choi et al. (2006) compared the performance of healthy volunteers on tasks
assessing cognitive ﬂexibility, problem-solving and verbal and spatial memory
tasks after receiving 0.1 mg of clonidine (an α2-agonist), 25 mg of ephedrine or
placebo. Ephedrine use led to impairment of verbal memory and a non-signiﬁcant
improvement of spatial memory.
No recent studies were found on the effects of ephedrine in combination with
another psychoactive substance. Previously, Alkana et al. (1977) found that
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ephedrine (50 mg) use may partially counteract the adverse effects of
alcohol (0.8 g/l).
No studies were found on the chronic effects of ephedrine.
Risks
No studies were found on the risks associated with the use of ephedrine alone.
However, two responsibility analyses were found for the risks associated with
the use of stimulants, including ephedrine. Drummer et al. (2004) conducted a
responsibility analysis in 3 398 fatally injured drivers. They calculated the risks
associated with a group of substances acting as stimulants, namely amphetamine,
methamphetamine, MDMA, ephedrine, pseudoephedrine, phentermine and
cocaine. There was no signiﬁcant association between use of stimulants and crash
responsibility. However, when truckers were considered as a discrete driver type, the
OR increased to 8.8 and was of borderline statistical signiﬁcance (95% CI: 1.0–77.8).
Longo et al. (2000b) also calculated the risks associated with a group of substances
acting as stimulants, including amphetamine, methamphetamine, phentermine,
pseudoephedrine, ephedrine and MDEA. There was no signiﬁcantly increased
responsibility risk associated with driving under the inﬂuence of stimulants alone.
Conclusion
Experimental studies suggest that a dose of 25 mg of ephedrine has no signiﬁcant
inﬂuence on performance in healthy volunteers. A dose of 50 mg, however, can
partially reverse adverse effects of depressants such as alcohol. No epidemiological
studies were found on the accident risk associated with ephedrine alone, but studies
investigating the risks associated with stimulants indicate no increase in risk of being
responsible for an accident.
Phentermine
Phentermine, like ephedrine, is a stimulant drug similar in structure to amphetamine.
Its principal indication is as a treatment for obesity, while the primary manifestation
of drug use is central stimulation (Baselt, 2001).
Acute effects
Magill et al. (2003) investigated the effects of tyrosine (150 mg/kg), phentermine
(37.5 mg), caffeine (300 mg/70 kg), dextroamphetamine (20 mg) or placebo
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on cognitive and motor performance deﬁcits in healthy young men during sleep
deprivation. The substances were administered at 15.30 following overnight sleep
deprivation. Performance decrements as a result of sleep deprivation occurred
in visual scanning, running memory, logical reasoning, mathematical processing,
the Stroop test, the time wall test, tracking and visual vigilance. The statistical
comparisons of task performances 1.5 and 5.5 hours after drug administration with
baseline performances at 13.00 showed that phentermine improved performance
at both time points for all tasks that had been affected by sleep deprivation. Results
with phentermine and dextroamphetamine were similar.
No recent studies were found on the effects of phentermine in subjects who are
not sleep-deprived, but studies that were published before 1999 indicated that
phentermine has the capacity to improve cognitive and motor performance in healthy
volunteers under laboratory conditions (Brauer et al., 1996; Volkerts et al., 1997).
No studies were found on the chronic effects of phentermine.
Risks
There were no studies found that examined the accident risks associated with
phentermine, speciﬁcally. However, two responsibility analyses were found that
investigated the risk of being responsible for an accident while driving under the
inﬂuence of a stimulant in general (Drummer et al., 2004; Longo et al., 2000b).
Neither study found a signiﬁcant association between the use of stimulants and
crash responsibility.
Conclusion
Experimental studies show that a dose of 20–38 mg of phentermine can improve
cognitive and psychomotor performance in volunteers following sleep deprivation.
No studies were found on the chronic effects or on the accident risk associated with
the use of phentermine alone, but studies investigating the risks associated with
stimulants indicate no increase in risk of being responsible for an accident.
Conclusion
According to experimental studies, most of the illicit drugs discussed in this report
can affect driving performance. Cannabis may impair some of the cognitive and
psychomotor skills required to drive. Most of these effects increase in a dose-
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dependent way. A cannabis user is aware of the impairment, but can only partially
compensate for the decrements. Amphetamine and methamphetamine may cause
positive stimulating effects on cognitive and psychomotor functions, especially in
fatigued or sleep-deprived individuals; however, negative effects are also observed
with the use of these drugs, including an overall decreased driving capacity seen in
driving simulator tests that approximate daytime conditions. Experimental studies on
MDMA also found both negative and positive effects on performance. Numerous
studies on the opiates suggest that heroin use might lead to severe impairment, while
there is much less impairment with use of methadone and little impairment with
buprenorphine use; however, these results were highly dependent on the dose given
and subjects’ drug use history.
The few studies that were found on the effects of cocaine suggest that low doses
appear not to affect performance or even to improve it, but chronic use causes
various deﬁciencies in performance and an increase in compulsive behaviour.
Synthetic drugs such as GHB, ketamine and PCP (in subanaesthetic doses) can
reduce cognitive and psychomotor performance. Ephedrine and phentermine were
found not to affect performance and sometimes they even improved it.
Experimental studies on the effects of consuming both alcohol and illicit drugs on
performance found that the combination of some illicit drugs (for instance, cannabis)
with alcohol can cause impairment in addition to that caused by either substance
alone, while other illicit drugs (for example, cocaine) may partially reverse the
impairment caused by alcohol. MDMA diminishes some but not all deleterious effects
of alcohol, while other negative effects of alcohol may be reinforced. Generally,
the chronic use of illicit drugs such as cannabis, amphetamines, cocaine or heroin
is associated with cognitive and/or psychomotor impairment, and may lead to
impaired driving performance, even when the subject is no longer intoxicated.
One limitation to many of the experimental studies on illicit drugs is that the
doses administered are not always representative of doses that might in reality be
consumed by drug users. For heroin, no recent experimental studies have been
conducted using realistic doses. This is also the case for studies on cocaine. In the
few experimental studies that exist on cocaine’s acute effects, the study limitations
include the administration of low doses and oral administration (which produces
fewer effects at a slower onset).
The results of experimental studies on therapeutic drugs show obvious impairment
for some, such as some of the ﬁrst-generation antihistamines, benzodiazepines and
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tricyclic antidepressants. Nevertheless, in every therapeutic class, some substances
have been associated with little or no impairment, and these should preferably be
prescribed to drivers.
Some benzodiazepines and related drugs should generally be regarded as
unlikely to have a residual effect in the morning. These include zaleplon 10 mg,
lormetazepam 1 mg and temazepam 20 mg (immediate-release capsules). It
should also be noted that with chronic and subchronic use, tolerance may develop,
partially or completely, to the impairing effects that have been observed for some
benzodiazepines. Based on the studies on antihistamines, it seems that fexofenadine,
desloratadine and ebastine (which are second-generation antihistamines of the class
piperidines) are the least impairing options. Fexofenadine in particular, in contrast
to the other drugs, does not potentiate the effects of alcohol or vice versa. Also, the
use of topical azelastine (second generation, class phtalazinones) does not appear
to affect vigilance.
Experimental data on antidepressants show that tricyclic antidepressants
(ﬁrst generation), when compared with the more recent second-generation
antidepressants, lead to greater impairment of cognition and psychomotor skills,
though tolerance does seem to develop. Nevertheless, caution is advised when
prescribing these older substances to drivers, since previous studies clearly
demonstrate an impairing effect. As for the second generation, the results from
various studies are not always consistent, partly because the drugs’ effects on
memory and cognition can be difﬁcult to interpret since depression often leads to
cognitive deﬁcits.
Epidemiological studies also suggest that driving ability is impaired by many illicit
drugs. Increased accident risk and/or risk of being responsible for an accident were
found for cannabis, amphetamines, heroin and cocaine, and many of these risks
increase when the drug is consumed with another psychoactive substance, such
as alcohol. Epidemiological data on the accident risks associated with therapeutic
drugs are rare. For benzodiazepines, however, some studies clearly indicate an
increased accident risk and an increased risk of being responsible for an accident.
These are useful ﬁndings but they come with various limitations. The DRUID project
is therefore promising, as this European consortium will conduct reference studies on
the effects of alcohol, illicit drugs and psychoactive medicines on driving ability, and
it will also calculate detection and risk thresholds for several illicit and licit drugs.
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Overall conclusion
The use of illicit drugs in the EU as reported by the EMCDDA has, as a whole,
increased since the late 1990s. It is perhaps not surprising then that the prevalence
estimates of drivers under the inﬂuence of drugs on EU roads seem to have greatly
increased during the same period. Comparisons are extremely difﬁcult to make
because of the considerable changes in statistics collection between then and
now, but both experimental and epidemiological studies show that, while alcohol
is still the number one substance endangering lives on European roads, drug and
medicine use among drivers is a problem that needs to be addressed. The range
of psychoactive substances available for illicit use is widening, and the latest
studies which look for evidence of their use in drivers are indeed ﬁnding it. Drivers
are being discovered with a range of drugs in various subsets of the motoring
population, whether while being tested randomly, upon suspicion, in hospital or after
a fatal accident.
This report aims to add to the knowledge accumulated in the 1999 literature
review (EMCDDA, 1999), but it bears repeating that, while the EMCDDA strives
for comparable statistics on the drug situation in Europe, there is no indication of
the comparability of the statistics analysed here. To give a simple example, cases
‘positive’ for a drug registered at above 1 ng/ml cannot be equated with ‘positives’
registered at above 3 ng/ml. According to new guidelines for research into drugs
and driving (NIDA, 2007), comparisons of such cases should take into account the
different study designs, biological matrices tested, cut-off levels, etc.
Research covered in this report can be broadly split into two types, experimental
and epidemiological. Each type has its advantages and disadvantages. Experimental
research consists of performance, driving simulator and/or real on-the-road tests.
These studies avoid unknown external factors and allow the doses to be controlled,
but often cannot simulate the doses or environment actually experienced by drug
users on the roads. In contrast, the types of epidemiological studies are manifold,
from daytime random roadside surveys which may show a prevalence of 1% through
to questionnaire surveys of young chronic drug users that may indicate a prevalence
of 85%. These results can be used to calculate the statistical risks of involvement
in and responsibility for an accident. Sample sizes can be quite small for various
reasons, and different study samples cannot be added for the reasons described
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above. Nevertheless, given the inherent characteristics of each type of study, a good
estimate of the impact will be obtained by combining the results of both.
Cannabis is the most prevalent illicit drug detected in drivers and benzodiazepines
are the most prevalent therapeutic drug group. In studies that tested for both among
drivers involved in accidents (fatal or non-fatal), benzodiazepines were sometimes
even more prevalent than cannabis. However, where drivers were tested only on
suspicion, cannabis was the most prevalent. Even in questionnaire surveys of drivers,
they report having driven under the inﬂuence of drugs — again, mainly cannabis.
Most illicit drugs can have an effect on varying aspects of driving performance.
Some dose-dependent impairment has been shown, but only for a few substances,
so increased effects at higher doses, or diminished effects at lower doses, should not
always be assumed. Cannabis, GHB, ketamine and PCP can reduce cognitive and
psychomotor performance, while low doses of amphetamine or methamphetamine
may improve cognitive and psychomotor performance but could also reduce
driving capacity during the day, due to tunnel vision. Experimental studies with
low or medium doses of MDMA showed no impairment, or even improvement, of
psychomotor function, but some decrease in memory functions. Similarly, of the few
studies on cocaine since 1999, low doses appear not to affect performance and
may even improve it, but chronic use causes various deﬁciencies in performance
and an increase in compulsive behaviour. Numerous studies on opiates suggest
the possibility of severe impairment with heroin use, while those in substitution
treatment programmes experience much less impairment with methadone and little
with buprenorphine use, but it should be kept in mind that these results were highly
dependent on the dose given and type of subjects tested, as well as their history.
Other therapeutic substances also showed considerable differences in the effects
by group. Benzodiazepines generally have impairing effects, with some types
(whether long-, medium- or short-acting) causing severe impairment and others
unlikely to have residual effects in the morning. First-generation antihistamines are
generally more sedating than second-generation ones, though there are exceptions
in both groups. Tricyclic antidepressants show more impairment than the more
recent types, though the results of experimental studies on the effects of SSRIs
are not always consistent. In every therapeutic class, some substances have been
associated with little or no impairment, and it should preferably be these that are
prescribed to patients who wish to drive. With most medicinal drugs, tolerance also
has a signiﬁcant effect, as does the indication that is being treated (such as pain
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or depression). However, in some cases, although a drug may cause measurable
impairment of some functions, it may nevertheless improve the patient’s overall
ability to drive.
New studies have been published since the end of 2006 that are not discussed
in detail in this report, and the DRUID project aims to deliver more authoritative
results in 2010, but it is already clear that driving under the inﬂuence of illicit
or medicinal drugs is not uncommon and can cause a substantial risk to trafﬁc
safety. Nevertheless, at this early stage, policy responses already implemented are
encountering numerous challenges to their effectiveness.
Prevention programmes that address drugs and driving are in place in the form of
training in driving schools as well as various public safety campaigns, though these
may not always be effectively targeted. In prescribing psychoactive medications,
whether for traditional pain management, antidepressant use or substitution treatment,
the challenge is to prescribe enough to have the correct effect but not enough to
lose driving skills or ability, something that could seriously affect the patient’s quality
of life. Roadside detection mechanisms, whether trafﬁc police with special training,
or testing of drivers’ biological samples, continue to suffer accuracy concerns, with
even the newer technological advances not being considered reliable enough by an
international testing project to be recommended for use in EU countries (16).
To deliver a clear public message, both scientists and policymakers must attempt to
ﬁnd a cut-off level of blood concentration for each drug, similar to the commonly
understood blood alcohol concentration (BAC). This would give a simple legal
threshold to indicate at what stage impairment becomes dangerous for users or for
those around them. Yet while the BAC ﬁgure has become generally accepted after
decades of research, Member States have refused/resisted attempts by the EU to
harmonise it (similarly, the issue of testing at random or only on suspicion, even for
excess alcohol, still sharply divides them).
In addition, it is difﬁcult to apply the BAC parallel to other psychoactive substances
because of the vastly different pharmacological natures of the range of substances
involved, the limitations of experimental and epidemiological research in trying to
determine such a cut-off level, the ethical considerations involved in its enforcement,
and the question of combining or separating drug abuse control and road safety
measures. Speciﬁcally, it is unacceptable to some that a driver be punished for
(16) Rosita project (http://www.rosita.org).
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driving with an amount of drug that has no relevant effect on driving, while it is
equally unacceptable to others to condone illicit drug use by stating that up to a
certain threshold, it will not be punished. This can be seen in the various country
legislations, some of which will use a positive blood sample to convict only for
a driving offence, while others will use that sample, taken for proving a driving
offence, to prosecute for a drug use offence. On top of all this complexity comes
the ﬁnding that a considerable number of drivers have been found to have multiple
drugs, including alcohol, in their blood, some combinations of which have been
proven to have synergistic effects.
Studying the relationships between drug use, impaired driving and trafﬁc accidents
is a remarkably complex subject, and this simple review does not pretend to give any
deﬁnitive solutions; as with many research projects, sometimes the answers found
only give rise to more questions. Nevertheless, the EMCDDA aims to give a more
accurate delimitation of the problem to date in this fast-moving area of research, to
assist policymakers to choose more effective solutions for their countries, as we wait
for DRUID to report in a few years’ time.
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Abbreviations
11-OH-THC 11-hydroxy-Δ9-tetrahydrocannabinol
BAC Blood alcohol concentration
bid Bis in die (twice a day)
BRT Brake reaction time
BVRT Benton visual retention test
Certiﬁed Conception and evaluation of roadside testing instruments to
formalise impairment evidence in drivers
CFF Critical ﬂicker fusion
CI Conﬁdence interval
CLT Circular lights task
CRT Choice reaction time
CTT Critical tracking test
DG-TREN Directorate-General for Energy and Transport
DRUID Driving under the inﬂuence of drugs, alcohol and medicines
DSST Digit symbol substitution test
DUID Driving under the inﬂuence of drugs
EEG Electroencephalogram
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
FTT Finger tapping test
GHB Gamma-hydroxybutyrate
HCl Hydrogen chloride
ICADTS The International Council on Alcohol, Drugs and Trafﬁc Safety
Immortal Impaired motorists, methods of roadside testing
and assessment for licensing
LARS Line analogue rating scale
LMT Learning memory task
MAOI Monoamine oxidase inhibitor
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MBDB N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine
MDA 3,4-methylenedioxyamphetamine
MDEA 3,4-methylenedioxyethylamphetamine
MDMA 3,4-methylenedioxymethylamphetamine
MMSE Mini-mental state exam
MRT Motor reaction time
NRI Selective norepinephrine (noradrenaline)-reuptake inhibitor
OR Odds ratio
PASAT Paced auditory serial addition task
PIR-O Proportional impairment ratios for objective evidence
RIMA Reversible inhibitor of MAOI-A
Rosita Roadside testing assessment
RR Relative risk
RRT Recognition reaction time
RVIPT Rapid visual information processing task
SDLP Standard deviation of lateral position
SFTA ‘Société Française de Toxicologie Analytique’: French Society
of Analytical Toxicologists
SNRI Serotonin/norepinephrine-reuptake inhibitor
SRT Simple reaction time
SSRI Selective serotonin-reuptake inhibitor
TCA Tricyclic antidepressants
THC Δ9-tetrahydrocannabinol
THC-COOH 11-nor-Δ9-THC-9-carboxylic acid
TIAFT The International Association of Forensic Toxicologists
TMT Trail making test
TRT Total reaction time
WAIS Wechsler adult intelligence scale
WCST Wisconsin card sorting task
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Table A4: Prevalence of drugs, medicines and/or alcohol in drivers involved in a traﬃc
accident
France Greece
Pépin et al.
(1999)
Pépin et al.
(2003)
Laumon et al.
(2005)
Maravelias
(2003)
Year 1999 2001 2001–2003 1995–2002
Sample size 164 3 751 10 748 2 712
Sample Blood Blood Blood Blood (A),
urine (D)
Remarks Severe or fatal
accident
Fatal accident Fatal accident
Alcohol >0.5‰ 37.2%
Drugs 17.0% (1) 7.9% 5.1% (2)
Drugs and alcohol >0.5‰ 19.5% 4.2%
Amphetamine 0.6% 1.7% 0.5% 1.0% (3)
Cocaine 0.0% 0.8% 0.2%
Cannabis 15.9% 13.7% 7.0% 4.0%
Benzodiazepines 4.0%
Opiates 3.1% 3.5% 0.9% 3.7%
(1) Only one drug present, no combinations with another drug or alcohol.
(2) Only drugs present, no combinations with alcohol.
(3) Also includes cocaine.
Abbreviations: A, alcohol; D, drugs.
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Table A6: Prevalence of drugs and/or medicines in drivers suspected of driving
under the inﬂuence of alcohol
Germany United Kingdom
Rentsch et al. (2002) Römhild et al. (2005) Oﬃcer (2003)
Year 2000–2001 2002 1996–2000
Sample size 673 1 199 102
Sample Serum Serum Biological samples
Remarks Young drivers involved
in a traﬃc accident
Hannover, Göttingen,
Maagdeburg, Halle and
Leipzig
Scotland
Drugs 7.8% 33.0%
Combination of drugs 8.8%
Amphetamine 10.2% 1.3%
Cannabis 23.0% 5.3% 25.0% (1)
Benzodiazepines 1.7% (2)
Cocaine 4.6% 0.0%
Opiates – morphine 0.2%
(1) Also includes benzodiadpeines.
(2) See cannabis.
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Table A10: Results of experimental studies on benzodiazepines
Substance Study Tests Doses Eﬀect
Zaleplon (Za)
Zolpidem (Z)
Danjou et al.
(1999)
CRT, DSST, CFF Za = 10 mg
Z = 10 mg
Z eﬀects visible next
morning
Zaleplon
Zolpidem
Triazolam (Tr)
Troy et al.
(2000)
Memory
Learning
Za = 10 or 20 mg
Z = 10 or 20 mg
Tr = 0.25 mg
Cognitive impairment
with Z and Tr after 8.25
hours after administration
Zolpidem
Zaleplon
Hindmarch et al.
(2001b)
CFF
CRT
DSST
Z = 10 mg
Za = 10 or 20 mg
Z had more residual
eﬀects than Za 20 mg
Zolpidem
Zaleplon
Verster et al.
(2002b)
Memory
Psychomotor
performance
Z = 10 or 20 mg
Za = 10 or 20 mg
Z aﬀected performance
in dose-dependent
manner
Zaleplon
Zolpidem
Stillwell (2003)
Logan and Couper
(2001)
Driving cases Driving impairment
Triazolam
Amphetamine
Mintzer and Griﬃths
(2007)
Memory tasks Tr = 0.25 or
0.5 mg/70 kg
D = 20 or
30 mg/70 kg
Amphetamine did
not reverse eﬀects of
triazolam
Zaleplon review Patat et al. (2001) Za = 10 or 20 mg No eﬀect with zaleplon
10 mg
Triazolam
Zolpidem
Mintzer and Griﬃths
(1999)
Memory Tr = 0.125, 0.25 or
0.5 mg/70 kg
Z = 5, 10 or
20 mg/70 kg
Impairment for triazolam
Triazolam Greenblatt et al.
(2005)
DSST–EEG
correlation
Tr = 0.375 mg High degree of
correlation
Zaleplon
Zopiclone (Zo)
Alcohol
Vermeeren et al.
(2002b)
Highway driving
test
Za = 10 mg
Zo = 7.5 mg
BAC = 0.3 g/l
No impairment for
zaleplon
Alprazolam (A)
Dextroamphetamine
(Dex)
Mills et al. (2001) A = 0.5 mg
Dex = 10 mg
A impaired performance,
Dex enhanced except
with fatigue
Alprazolam Verster et al.
(2002a)
SDLP A = 1 mg Serious driving
impairment
Alprazolam Verster and Volkerts
(2004b)
Memory Dose-dependent
impairment
Alprazolam XR Leufkens et al.
(2007)
Standardised
driving test
Memory
Psychomotor tests
A = 1 mg Severe driving
impairment
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Table A10 continued
Substance Study Tests Doses Eﬀect
Alprazolam Bentué-Ferrer et al.
(2001)
Behaviour A = 0.005 mg/kg Stimulatory eﬀect
Alprazolam Snyder et al.
(2005)
Attention
Psychomotor function
A = 0.5 or 1 mg 0.5 mg reduced
attention, 1 mg
reduced psychomotor
performance and
attention
Lorazepam (Lor)
Ritanserin (Ri)
Van Laar et al.
(2001)
SDLP Lor = 1.5 mg bid
Ri = 5 mg
Lor showed marked
driving impairment
Lorazepam Matthews et al.
(2002)
Memory Lor = 2.5 mg Impairment to learn
behavioural strategies
Lorazepam Izaute and Bacon
(2006)
Memory Lor = 0.038 mg/kg Impairment
Lorazepam Clarkson et al.
(2004)
Driving cases Driving impairment
Lorazepam
Alcohol
Soo-ampon et al.
(2004)
Recall memory Lor = 2 mg
BAC = 0.6 g/l
Impairment for both
substances
Lormetazepam
(Lorm)
Iudice et al.
(2002)
Daytime vigilance
Driving simulation
Lorm = 1 mg No eﬀect next morning
Lormetazepam Fabbrini et al.
(2005)
SRT
CRT
Lorm had no eﬀect
Temazepam (Te)
Alcohol
Tiplady et al.
(2003)
Te = 20 or 30 mg
BAC = 0.8–1.0 g/l
Te slowed performance,
alcohol generated more
errors
Temazepam Morin et al.
(2003)
Te = 7.5 or 30 mg Few eﬀects and tolerance
Flunitrazepam (Flu)
Clonazepam (Cl)
Dowd et al.
(2002)
Behaviour and
cognitive
Flu = 2 mg
Cl = 3 mg
Flu had an eﬀect up to 4
hours after intake, Cl for
6 hours
Flunitrazepam Bramness et al.
(2006)
Blood level-impairment
degree correlation
Clear correlation
Diazepam Rich et al. (2006) Memory Di = 0.19 mg/kg Impairment
Zolpidem
Zopiclone
Flunitrazepam
Bocca et al.
(1999)
Z = 10 mg
Zo = 7.5 mg
Flu = 1 mg
Residual eﬀects in
morning for Zo en Flu
Lorazepam
Flurazepam
Nitrazepam
Temazepam
Vignola et al.
(2000)
Memory
Attention
Psychomotor function
Unmedicated insomniacs
performed worse than
medicated ones
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Table A10 continued
Substance Study Tests Doses Eﬀect
Temazepam
Triazolam
Alcohol
Simpson and Rush
(2002)
Te = 15 or 30 mg
Tr = 0.125 or
0.25 mg
BAC = 0.5 g/l
Te and Tr alone had
some impairment,
combined with alcohol
= worse
Zolpidem
Temazepam
Partinen et al.
(2003)
Z = 10 mg
Te = 20 mg
No diﬀerence between
drugs and placebo
Zolpidem
Zopiclone
Lormetazepam
Allain et al. (2003) LMT
CTT
SRT
Sternberg test
Z = 5 mg
Zo = 3.75 mg
Lorm = 1 mg
Lorm gave impairment
LMT
11 benzodiazepines Vermeeren (2004) Za = 10 or 20 mg
Te = 20 mg
Lor = 1 mg
Tr = 0.125 mg
4 benzodiazepines were
unlikely to have residual
eﬀects
Temazepam
Diphenhydramine (Di)
Valerian (Val)
Glass et al. (2003) DSST
Manual tracking
Te = 15 or 30 mg
Dip = 50 or 75 mg
Val = 400 or 800 mg
No impairment with Val
and Di 50 mg
Zolpidem
Zopiclone
Lormetazepam
Staner et al. (2005) Driving simulation
EEG
Z = 10 mg
Zo = 7.5 mg
Lorm = 1 mg
Zolpidem had no eﬀect
Zopiclone
Zolpidem
Flunitrazepam
Berthelon et al.
(2003)
Collision anticipation Zo = 7.5 mg
Z = 10 mg
Flu = 1 mg
Flunitrazepam had a
negative eﬀect
Melatonin (Mel)
Zaleplon
Zopiclone
Temazepam
Paul et al. (2003) Serial reaction time
Logical reasoning
Mel = 6 mg
Za = 10 mg
Zo = 7.5 mg
Te = 15 mg
Melatonin shows no
impairment
Dose-dependent
driving impairment
benzodiazepines
Bramness et al.
(2002)
Apprehended drivers Clear drug concentration
eﬀect
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Table A11: Results of experimental studies on antihistamines
Substance Author Tests Doses Eﬀect
Diphenhydramine Richardson et al.
(2002)
50 mg bid Impairment
Diphenhydramine Turner et al.
(2006)
Memory, CRT, DSST 50, 75, 100 mg Impairment
Clemastine Meltzer et al.
(2003)
0.68 mg Somnolence
Mequitazine Didier et al.
(2000)
5 mg bid Less somnolence than 1st
generation, not more than
2nd generation
Mequitazine Theunissen et al.
(2006b)
SDLP 5, 10, 15 mg Dose-related increase
Chlorpheniramine Mochizuki et al.
(2002)
PET scan
Chlorpheniramine Serra-Grabulosa
et al. (2001)
Auditory attention 4 mg Impairment
Cinnarizine Nicholson et al.
(2002)
DSST 15, 30, 45 mg No
Cinnarizine Philipova et al.
(2004)
DSST 20 mg No
Cinnarizine Schneider et al.
(2003)
DSST 20 mg No
Desloratadine Nicholson et al.
(2003)
CRT, DSST 5 mg No
Desloratadine Berger et al.
(2002)
5 mg No
Desloratadine Monroe et al.
(2003)
No
Desloratadine Satish and Streufert
(2003); Satish et
al. (2004)
No
Desloratadine Valck et al. (2004) No
Desloratadine Bousquet et al.
(2004)
No
Desloratadine Berger (2005) 5 mg No
Desloratadine Limon and Kockler
(2003)
No
Loratadine Saint-Martin et al.
(2004)
10 mg Less somnolence
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Table A11 continued
Substance Author Tests Doses Eﬀect
Ebastine Herberg (2000) 10/20/30 mg No
Ebastine Hindmarch and
Shamsi (2001)
CFF, CRT, simulated
car tracking task
No
Levocetirizine Hair and Scott
(2006)
5 mg Somnolence
Cetirizine Shamsi et al.
(2001)
CFF, CRT, tracking
task
2.5, 5, 10 mg No
Cetirizine Martínez-Cócera et
al. (2005)
10 mg Somnolence
Cetirizine Nordness and
Zacharisen (2003)
50 mg No
Cetirizine Vermeeren et al.
(2002a)
Standardised driving
test
10 mg Less impairment
Fexofenadine Hindmarch et al.
(2002)
CFF, CRT, tracking
task
360 mg No
Fexofenadine Ridout and
Hindmarch (2003)
60–120 mg No
Fexofenadine Theunissen et al.
(2006a)
360 mg No
Fexofenadine Ridout et al.
(2003b)
180 mg No
Fexofenadine Mohler et al.
(2002)
DSST No
Mizolastine Bachert et al.
(2001)
10 mg Low
Azelastine Golden et al.
(2000)
No
Review second
generation
Lange and Bachert
(2004)
Desloratadine, ebastine,
fexofenadine: no eﬀect
Fexofenadine (F) versus
cetirizine (C)
Tashiro et al.
(2004)
CRT, SRT F = 120 mg
C = 20 mg
F less impairing than C
Bepotastine (B) versus
cetirizine, fexofenadine
and olopatadine (O)
Takahashi et al.
(2004)
Sedation,
psychomotor
performance
B =10 mg bid
C = 10 mg
F = 60 mg bid
O = 5 mg bid
O most impairing and B least
impairing
Levocetirizine versus
desloratadine
Passalacqua and
Canonica (2005)
Memory, attention,
alertness
No
Cetirizine versus
loratadine (Lo)
Salmun et al.
(2000)
C = 10 mg
Lo = 10 mg
Lo less somnolence
F
o
r
m
a
t
:
(
1
4
8
.
0
0
x
2
1
0
.
0
0
m
m
)
;
D
a
t
e
:
1
2
0
2
,
2
0
0
8
0
7
:
5
3
:
5
6
;
O
u
t
p
u
t
P
r
o
f
i
l
e
:
S
P
O
T
I
S
O
C
o
a
t
e
d
v
2
(
E
C
I
)
;
I
n
k
S
a
v
e
2
8
0
Appendix
151
Table A11 continued
Substance Author Tests Doses Eﬀect
Inter-drug diﬀerences Shamsi and
Hindmarch (2000)
Fexofenadine and
ebastine least eﬀect
Prescription-event
monitoring
Mann et al. (2000) Fexofenadine and loratadine
least eﬀect
Letter Ramaekers and
Vermeeren (2000)
Fexofenadine, ebastine
and loratadine no eﬀect
Desloratadine and
levocetirizine
Layton et al.
(2006)
Less sedation with
desloratadine
Review Meltzer (2005) Fexofenadine, loratadine,
and desloratadine no eﬀect
Fexofenadine versus
hydroxyzine
Tashiro et al.
(2005)
BRT F = 120 mg
H = 30 mg
F no eﬀect
Fexofenadine Mansﬁeld et al.
(2003)
180 mg No
Fexofenadine Bower et al.
(2003)
No
Fexofenadine versus
olopatadine and
chlorpheniramine
Kamei et al.
(2003)
Sedation F = 120 mg
O = 10 mg
F no eﬀect
Ebastine (E) versus
chlorpheniramine
Tagawa et al.
(2002)
Cognitive impairment E = 10 mg E no eﬀect
Loratadine versus
diphenhydramine (Di)
Kay (2000); Kay
and Quig (2001)
Divided attention Lo = 10 mg
Di = 50 mg
L no eﬀect
Desloratadine (D) versus
diphenhydramine
Wilken et al.
(2003)
D = 5 mg
Di = 50 mg
D no eﬀect
Potentiation of alcohol Barbanoj et al.
(2006)
Hydroxyzine 30 mg
> cetirizine 10 mg =
olopatadine 20 mg >
olopatadine 10 mg (non)
Tolerance to cetirizine,
mequitazine, and
dexchlorpheniramine
Theunissen et al.
(2006b)
Driving impairment M = 10 mg
C = 10 mg
Cl = 6 mg
Tolerance after 8 days
Levocetirizine (L) versus
diphenhydramine
Verster et al.
(2003b)
Memory, attention,
tracking, SDLP
L = 5 mg
Di = 50 mg
L no eﬀect
Desloratadine versus
diphenhydramine
Vuurman et al.
(2004)
SDLP D = 5 mg
Di = 50 mg
D no eﬀect
Diphenhydramine versus
second-generation
antihistamines: a review
Bender et al.
(2003)
No clear eﬀect of
diphenhydramine
Fexofenadine versus
diphenhydramine and
alcohol
Weiler et al.
(2000)
F = 60 mg
Di = 50 mg
Di greater eﬀect than
alcohol
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Table A11 continued
Substance Author Tests Doses Eﬀect
Review Verster and Volkerts
(2004a)
F and L no eﬀect
Levocetirizine versus
cetirizine, loratadine,
promethazine (P)
Hindmarch et al.
(2001a)
CFF, CRT, continuous
tracking task
L = 5 mg
C = 10 mg
Lo = 10 mg
P = 30 mg
L no eﬀect
Review Moskowitz and
Wilkinson (2004)
Eﬀect depends on substance,
generation, individual
Abbreviation: bid, bis in die (twice daily).
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Table A12: Results of experimental studies on performance eﬀects associated with use
of antidepressants
Substance Study Tests Doses Eﬀect
TCA (general) Podewils and
Lyketsos (2002)
MMSE No
Amitryptiline Veldhuijzen et al.
(2006a)
SDLP 25 mg Acute: impairment
Chronic: tolerance
SSRI (general) Dumont et al.
(2005)
Diﬀerent tests
CFF
Low dose
High dose
Stimulation
Impairment
Fluoxetine Strik et al.
(2006)
Stroop
Visual verbal test
Letter digit
substitution
20–60 mg No
Escitalopram Rose et al. (2006) 10 mg No
SSRI (general) Wadsworth et al.
(2005)
Impairment
Sertraline
Paroxetine
Schmitt et al.
(2002)
Vigilance
Stroop
50–100 mg
40–60 mg
No
Sertraline Constant et al.
(2005)
Psychomotor
slowing/executive
function
50–75 mg Positive eﬀect
Sertraline Devanand et al.
(2003)
Psychomotor
slowing and
executive function
50–200 mg No
Citalopram Harmer et al.
(2002)
memory 10 mg IV Positive eﬀect
Fluoxetine (Fl) versus
paroxetine (Pa)
Cassano et al.
(2002)
Cognitive function Fl = 10–40 mg
Pa = 20–60 mg
No
Paroxetine Hindmarch et al.
(2000a)
Withdrawal Impairment
Venlafaxine O’Hanlon et al.
(1998)
CFF, CTT,
divided attention,
Macworth
37.5–75 mg No
Venlafaxine Campagne
(2005)
Withdrawal Impairment
Milnacipran Hindmarch et al.
(2000b)
CFF 50+25 mg No (young)
Positive eﬀect (old)
Milnacipran Poirier et al.
(2004)
CFF 50 mg bid No
Milnacipran Richet et al.
(2004)
50 mg bid No eﬀect and no potentiation
of alcohol
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Table A12 continued
Substance Study Tests Doses Eﬀect
Fluoxetine versus
reboxetine (R)
Gallassi et al.
(2006)
Fl = 10–40 mg
R = 4–8 mg
Improvement
SSRI versus SNRI Wingen et al.
(2006b)
Impairment
All Antidepressants
(AD)
Ramaekers
(2003a)
SDLP Sedating AD = impairment
Non-sedating AD = no eﬀect
SSRI, mirtazapine better than
TCA, SNRI
All Antidepressants
(AD)
Brunnauer et al.
(2006)
Fitness to drive Sedating AD = impairment
Non-sedating AD = no eﬀect
SSRI, mirtazapine better than
TCA, SNRI
Paroxetine versus
mirtazapine (M)
Ridout et al.
(2003a)
BRT, CFF, CRT Pa = 20 mg
M = 15–30 mg
No eﬀect for paroxetine
Fluvoxamine versus
imipramine
Koetsier et al.
(2002)
CPT Both improvement
Fluoxetine (Fl) versus
desipramine (De)
Levkovitz et al.
(2002)
Memory Fl = 20 mg
De = 125–200mg
Improvement Fl greater than De
Fluvoxamine (Fluv)
versus dothiepine
(Do)
Wilson et al.
(2000)
Sleep Fluv = 100 mg
Do = 100 mg
Fluv decreased
Do increased
Reboxetine versus
imipramine (I)
Katona et al.
(1999)
Somnolence R = 4–6 mg
I = 50–100 mg
R no eﬀect
TCA and SSRI Peretti et al.
(2000)
CFF threshold
BRT
TCA decreased CFF, BRT
impaired
Paroxetine versus
nortryptiline
Nebes et al.
(2003)
Cognitive function
in elderly
No change
Sertraline (S),
ﬂuoxetine and
nortryptiline (N)
Doraiswamy et al.
(2003)
Cognitive function S = 50 mg
Fl = 20 mg
N = 25 mg
Improvement
Venlafaxine (V),
dothiepine
Trick et al.
(2004)
Cognitive function:
CFF
V = 37.5 mg bid
Do = 25+75 mg
No disruptive eﬀect
Paroxetine and
nortryptiline
Butters et al.
(2000)
Memory and
executive function
Improvement
Escitalopram (Es)
versus mirtazapine
Wingen et al.
(2006a)
Delayed verbal
memory score
Es = 10–20 mg
M = 30–45 mg
Es no inﬂuence
Sertraline versus
nortryptiline
Coﬀey et al.
(2002)
Shopping list task,
DSST, MMSE
S = 50–100 mg
N = 25–100 mg
S more positive eﬀect
Tianeptine (T) versus
mianserin (Mi)
Ridout and
Hindmarch
(2001)
CRT, CFF, BRT T = 12.5–37.5 mg
Mi = 30 mg
T no eﬀect
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Table A12 continued
Substance Study Tests Doses Eﬀect
Hypericum Timoshanko et al.
(2001)
Siepmann et al.
(2002)
DSST 900–1800 mg
extr: 255–285 mg
Impairment
No
Moclobemide Siepmann et al.
(2004)
CFF, CRT, memory 150 mg bid No
Abbreviation: bid, bis in die (twice daily).
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